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                                             Abstract 
Ligand-observed NMR spectroscopy is frequently employed in early-stage drug discovery, often as an initial 
screen to narrow the field of potential drug-like molecules. However, its use is limited to this early stage. 
More information regarding binding mode can be extracted from these experiments via quantification, and 
this should help extend the remit of these experiments beyond simple screening functions. 
 
Initially, it was shown that the amount of signal that could be produced from an STD NMR experiment 
could be dramatically increased by careful consideration of the selective saturation pulse. By systematically 
shortening the Gaussian pulse and positioning it at specific offset positions, it was shown that these dramatic 
increases in signal are genuine and need not result in false positives. 
 
Quantitative STD NMR spectroscopy as applied to Hsp90 and a series of small fragment ligands provided 
evidence to suggest that the precise inter-atomic distances between a protein and ligand within a crystal 
structure correlate with both initial rates of STD build up, and T1-adjusted STD values. This precise 
correlation has implications for chemotype clustering and initial binding mode selection, something which 
should be useful in the absence of a crystal structure. 
 
Taking the same quantitative principles and applying to LOGSY experiments elucidated another, discrete 
property of protein-OLJDQGELQGLQJ([DPLQLQJWKHµ/2*6<GLIIHUHQFH¶VLJQDOIRUSURWRQVRIDOLJDQGDOORZV
us to see what protons are in close proximity to conserved, bound water at the protein-ligand binding 
interface. This is fundamentally different to the information gained from STD experiments. 
 
Applying the insights to a protein of a different nature, Ras, it was shown that quantitative STD can be 
applied to proteins of both different size and structure. Furthermore, more evidence was acquired to suggest 
that conserved, bound water in the binding site really is responsible for generating LOGSY signal. In the 
absence of these molecules, as in Ras, proximity of a proton to an exchangeable tends to dominate. In 
addition we were able to show that these quantitative methods can be used together to help eliminate 
incorrect computationally generated docking poses.  
 
The work presented in this thesis provides evidence for the advantages of STD and LOGSY NMR 
spectroscopy in fragment-based drug discovery. The information that can be extracted from relatively 
simple ligand-observed NMR experiments should be used to provide more evidence at an earlier stage of 
the drug discovery process, hopefully reducing late-stage attrition and helping us get to the therapeutic drug 

































1.1  A basic introduction to NMR spectroscopy 
 
NMR spectroscopy probes the fundamental property of nuclear spin. µNMR active¶ 
nuclei - with a spin ½ - include naturally abundant nuclei such as 1H and 31P, as well 
as more rare isotopes such as 15N and 13C. This is fortunate since these are the nuclei 
that comprise the vast majority of biochemically interesting atoms in molecules of 
interest, from small organic molecules through to large macromolecular protein 
complexes. 
 
These nuclei are NMR active because when placed within an external magnetic field 
WKHVSLQRIWKHQXFOHXVLQGXFHVDPDJQHWLFPRPHQWȝ7KLVPDJQHWLFPRPHQWDOLJQV
in the magnetic field either with or against the field, and precesses with a frequency 
related to the strength of this applied external field (B0). A magnet of strength 14.1 T 
causes hydrogen nuclei (protons) to precess ± or resonate - with a frequency of 
approximately 600 MHz. 
 
However despite all protons resonating with approximately the same frequency, there 
are small differences in the frequencies of different proton environments. This is due 
to differences in the local environment around each proton nucleus. Different 
individual proton resonances dictate that each type of proton appears at a different 
µFKHPLFDOVKLIW¶DQGWKLVLVREVHUYHGRQDW\SLFDO'1H NMR spectrum, as illustrated 




A chemical shift describes the extent of de-shielding that a particular nucleus 
undergoes, which is dependent on the electronegativity of neighboring atoms. For 
example, a proton directly bonded to an electronegative atom such as nitrogen 
experiences a significantly de-shielded electron cloud, and appears with a higher 
chemical shift value, relative to the reference. In contrast, non-electronegative atoms 
surround protons of methyl groups - that is non-electron withdrawing atoms - 
resulting in minimal de-shielding of its nucleus, and a lower chemical shift, relative to 
the reference. 
 
In simple, small organic molecules there are several different proton environments, 
whereas in proteins there will be several thousand different proton environments. For 
structural studies of larger proteins this spectral overlap necessitates extending NMR 
Figure 1.1: 1D 1H proton NMR spectrum of a typical small molecule with 
different proton groups.  
Introduction 
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experiments into 2 and 3 dimensions, isotopic labeling, and deuteration of proteins. 
However, these issues are circumvented by the approach of study taken in this thesis. 
 
 
1.1.2 Nuclear Overhauser Effect 
The Nuclear Overhauser Effect (NOE) is a fundamental concept in NMR 
spectroscopy that rests at the heart of ligand-observed NMR experiments that 
comprise this chapter. The NOE is the transfer of spin polarisation (or magnetisation) 
from one nuclear spin population (S) to that of another population (I) via cross-
relaxation, assuming I is the spin that is measured and S is the spin whose resonance 
is saturated (Anderson and Freeman, 1962, Neuhaus and Williamson, 1989). For an 
NOE to be observed atoms must be close enough together in space that they are 
dipole-dipole coupled appreciably, rather than being spin-spin coupled. 
 
 
The NOE occurs through space rather than through bonds. As a result the NOE can 
inform upon which atoms are within close proximity of each other. For an NOE to be 
observed protons must be within 6 Å of each other in space. The intensity of an NOE 
is related to distance as shown by equation 1. 
    ܱܰܧ ן ଵ௥ల         (Equation 1) 
 
Intensity is proportional to the inverse of the inter-proton distance, raised to the sixth 
power. This is a major boon for certain NMR experiments, as it allows us to examine 






The NOE possesses DµVLJQ¶WKDWLVHLWKHUSRVLWLYHRUQHJDWLYHDQGUHODWHVWRWXPEOLQJ
time. This is shown in figure 1.2. The size and sign of the NOE depends on the 
tumbling time of the protein as well the distance between nuclei. As correlation time 
increases (i.e. tumbling rate decreases) the NOEs tend towards -100% as omega tau 
increases. The NOE can appear non-existent at null points in circumstances when 
omega-tau = 1.  
 
However limitations do still remain. Spin diffusion by cross relaxation across multiple 
spins in a large molecule can affect every spin until steady state, something which is 
needs to be taken into account. 
 
 
Through the Nuclear Overhauser Effect SpectroscopY (NOESY) experiment, the 
limit of the NOE enables secondary and tertiary structure of proteins to be 




determined, when used in conjunction with other structural experiments including 
TOtal Correlation SpectroscopY (TOCSY) and COrrelation SpectroscopY (COSY).  
 
1.2  The STD Experiment 
Saturation transfer difference NMR (STD NMR) is a powerful ligand-observed NMR 
experiment that identifies when ligands bind to a protein (Mayer and Meyer, 1999, 
Mayer and Meyer, 2001, Meyer and Peters, 2003). It was developed by Mayer and 
Meyer in 1999 and was proposed as a method for screening compound libraries in 
order to identify binding activity to proteins. STD NMR is presented as a simple and 
easy way in which the ligand binding epitope may be observed, by associating greater 
STD signals with parts of the ligand that bind. Central tenets of the method are 
illustrated with a sample of N-acetylglucosamine (GlcNAc) binding to wheat germ 
agglutinin, a protein-ligand setup that not coincidentally forms the basis of 
investigations reported in chapter 2.  
 
 
The technique works via selective saturation of nuclei in a protein, followed by 





1.2.1  Basics of STD NMR 
 
The experiment is composed of two parts, and the spectra from the on resonance 
experiment is subtracted from the off resonance spectrum, hence a difference 
spectrum. To begin with an off resonance spectrum is acquired. This involves 
proceeding through the pulse sequence in Figure 1.3 with both a selective shaped 
pulse and an ordinary 90° hard pulse. In the off resonance experiment, selective 
saturation is deliberately placed well away from any proton resonance in the system, 
at say -30 ppm. The net result of the off resonance experiment is a simple 1D 1H 
NMR spectrum of the ligands in the system (As they are present in a large excess), as 
Figure 1.3: 1H STD NMR pulse sequence highlighting the shaped excitation 
pulse that drives saturation of the protein. Pulse sequence components 
responsible for spin-locking ± in order to reduce protein background signal ± 
and water suppression are also shown 
Figure 1.4: (A) The off resonance experiment acquires a 1D spectrum of the 
ligand, whereas (B) the on resonance spectrum gives a 1D spectrum of the ligand 
with small attenuations of peaks of the ligand involved at the binding interface. 
Subtraction of spectra from each other provides the STD difference spectrum (C). 
A B C 
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acquired via the square-wave hard pulse, and shown in fig. 1.4A.  
Following this, as part of the on resonance experiment, the selective saturation is 
placed within the upfield region of the protein chemical shift envelope. This causes 
NMR excitation of methyl groups within the protein, which is subsequently 
transferred through the protein by spin-diffusion and onto any ligand at the binding 
interface. In combination with the off-resonance spectrum acquired with a hard pulse, 
this negative NOE transfer manifests itself as a small reduction in the intensity of 
peaks belonging to the bound ligand (fig. 1.4B). This attenuation is small, but 
subtraction of on resonance spectra from corresponding off spectra provides the 
XVHIXOµ67'GLIIHUHQFH¶VSHFWUXPILJ&6LJQDOVRIQRQ-binding ligands will give 
WKH VDPH VSHFWUXP ZLWK ERWK µRQ¶ DQG µRII¶ UHVRQDQFH SXOVHV VXFK WKDW DIWer 
VXEWUDFWLRQDOOVLJQDOVDUHFDQFHOOHGRXWDQGWKHUHLVQRµGLIIHUHQFH¶VLJQDO 
 
1.2.2  Nature of the selective pulse 
Selective pulses in STD NMR are typically applied as a Gaussian pulse train, and 
must be positioned very carefully so as to avoid accidental excitation of protein and/or 
ligand where appropriate. Rectangular hard pulses are rarely employed for selective 
excitation due to possessing an unfavourable excitation profile including unwanted 
side bands that are responsible for unwanted excitation of signals beyond the desired 
width. The Gaussian envelope is given by: 
    ܵሺݐሻ ൌ ሾെܽሺݐ െ ݐ଴ሻଶሿ  (Equation 2) 
 
S is the intensity of the pulse, a is the pulse duration (and hence pulse width), t is the 
time and t0 is the centre of the pulse envelope. Fourier transform of the Gaussian 
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envelope gives a Gaussian function that reduces side bands, and this makes Gaussian 
pulses favourable over other types of pulse.  
 
At the same time as wanting to reduce accidental excitation beyond specified limits, 
obtaining maximum signal from a single is also an important consideration in order to 
avoid experimental inefficiencies. Both factors must be taken into account when 
choosing pulse type, pulse length, and position of application(Cutting et al., 2007). 
This concept forms the basis of chapter 2. 
 
1.2.3  The advantages of STD NMR 
 
STD has a number of advantages over the protein-observed NMR experiments 
discussed thus far. One of the main advantages is the reduced requirement for large 
quantities of protein and ligand. In addition, there is no need for any isotopic 
enrichment of any kind (15N or 13C), something that is extremely costly when 
producing large quantities of protein target. Another advantage is the ease and 
versatility of the experiment, which can be acquired in a few minutes compared to the 
timescales required for protein-observed experiments. Furthermore, if one wanted to 
extend the STD experiment to two dimensions, that is now easily possible(Wagstaff et 
al., 2010). 
 
In terms of experimental setup the limit on protein target size is also lifted. Whereas 
protein-observed experiments may wish to keep a cap on protein size (to below, say, 
30 kDa(Barile and Pellecchia, 2014)) in order to aid resolution and assignment (due to 
relaxation dependent line broadening), with STD larger protein size is positively 
Introduction 
 24 
encouraged in order to aid efficient spin diffusion through the protein. However as a 
result the protein should not be below 10 kDa(Meyer and Peters, 2003). Furthermore, 
STD is an extremely versatile technique and is applicable to investigations involving 
membrane proteins and other large macromolecules such as virus coat proteins.  
 
 
1.2.4  Group epitope mapping (GEM) 
 
The tentative ability to establish binding mode from simple 1D STD data is a 
promising avenue, and forms the basis of investigations in chapter 3, wherein I shall 
go into much more detail. In simple terms; the regions of the ligand in closer 
proximity to the protein receptor tend to receive more saturation than more distant 
parts of the ligand, and this can be used to infer binding mode(Mayer and Meyer, 
2001). However this is not routinely carried out with confidence and there is dramatic 
scope to improve its implementation. Of course, there are caveats too.  
 
1.2.5  Ligands binding too weakly or tightly 
 
Ligands binding to a protein target can be considered as an association between 
protein [P] and ligand [L], given as follows: 
             ܲ ൅ ܮ ֖ ܲܮ     (Equation 3) 
kon and koff are the rate constants for the association and dissociation events 
respectively. As per textbook theory, the dissociation constant may then be described 
as:  ܭ஽ ൌ ሾ௉ሿሾ௅ሿሾ௉௅ሿ ൌ ௞೚೑೑௞೚೙     (Equation 4) 
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Assuming a diffusion-controlled on rate of 107 s-1 M-1, koff can be calculated for fixed 
dissociation constants i.e. KD 1 mM = 10,000 s-1, ȝ0 V-1 and 1 nM = 0.01 s-1.  
 
However kon is not constant, and can vary between 104 and 1011 s-1 leading to large 
variations in koff. Off rates generally tend to be larger for small ligands, something 
that has implications for NMR binding experiments. 
 
Fast exchange on the chemical shift time scale is defined as ݇௢௙௙ ൐ ߱, intermediate 
exchange as ݇௢௙௙ ൌ ߱, and slow exchange as ݇௢௙௙ ൏ ߱. Fast exchange in NMR is 
therefore associated with chemical shift differences between the bound and unbound 
states. In fast exchange, the rate of exchange (Hz) is greater than the chemical shift 
difference (Hz). 
 
At faster ݇௢௙௙ values signals appear at the chemical shift value corresponding to the 
weighted average of the chemical shifts of the signals from the bound and free ligand. 
 
A drawback of ligand-observed NMR techniques STD is the lower limit on binding 
affinity. Slow exchange between bound and unbound states of a ligand ± the case 
when KD GURSV EHORZ  ȝ0 HYLGHQWO\ GULYHQ E\ VORZ koff values ± means that 
saturation is not effectively transferred to the free ligand state in solution. This false 
negative scenario is a limitation of the experiment and precludes STD NMR from 
being useful much further beyond fragment ligand screening stage in the drug 
discovery process. 
In STD experiments it is the ligand that is observed. As with all ligand-observed 
VFUHHQLQJH[SHULPHQWVµIDVWH[FKDQJH¶EHWZHHQOLJDQGDQGUHFHSWRr is assumed, and 
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considered necessary for the experiment to be useful. To this end, experiments are 
carried out with at least a 10 times excess of ligand over protein. 
 
It is estimated that for an STD experiment to be useful(Mayer and Meyer, 1999) the 
KD must be 10-8 < KD <10-3 M. Weak binders leave more than half of receptor sites 
unoccupied, which causes STD signal to be too weak. On the other hand, strong 
binders spend too great a proportion of time in the bound state, resulting in a 
decreased exchange rate constant. This causes free ligand magnetisation to relax back 
to equilibrium quicker than the receptor is able to bind to new ligand to saturate. 
Consequently the population of free saturated ligand is too low, and the STD signal 
disappears.     
 
The KD of fragments to be investigated in this thesis are validated fragment hits and 
are known binders. Where dissociation constants are unknown, either the equivalent 
values as calculated by Tm analysis or the IC50 values are known. 
Figure 1.5: A schematic of the FBDD process. As fragment hits are elaborated upon 
there is an increase in both mass and potency (Figure adapted from(Scott et al., 2012)) 
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As fragment hits are elaborated upon according to input from both structural biology 
and medicinal chemistry, there is usually a simultaneous increase in both mass and 
potency(Scott et al., 2012). This is to be expected, but it does mean that quantitative 
STD NMR ceases to be useful from a fairly early stage of the fragment-based drug 
discovery (FBDD) process. 
 
This early screening stage is important enough such that any reforms using pre-
existing techniques are a massive advantage. Perhaps if we can be more informed 
about our fragment hits from an earlier stage in the FBDD process before moving 
forward ± without having to spend too much extra time or money ± the chances of 
late-stage attrition are surely reduced.  
 
1.2:KDWLVPHDQWE\µTXDQWLWDWLYH¶105" 
)RU WKHSXUSRVHVRI WKLV WKHVLV µTXDQWLWDWLYH¶ UHIHUVYDULRXVDVSHFWVRIELRPROHFXODU
NMR spectroscopy. In FKDSWHUZH UHIHU WKH µTXDQWLILFDWLRQ¶RI67'DPSOLILFDWLRQ
factors based on peak heights and intensities of one-dimensional STD NMR spectra. 
,QFKDSWHUDQGµTXDQWLWDWLYH¶UHIHUVWRWKLVVDPHSULQFLSOHEXWZLWKWKHH[WHQVLRQ
of calculating initial rates of STD build up from this data, and the act of dividing 




0DWUL[¶ &25&(0$-ST) algorithms. This program is able to predict the expected 
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STD intensities for a given protein-ligand complex. In order to do this, it requires 
myriad inputs including PDBs of the protein, ligand, and bound protein-ligand 
structures, knowledge of the ligand T1 values, information on the protein/ligand 
correlation times, as well as the concentrations of the NMR sample. Given this 
requirement for so much data pre-analysis, and how difficult the program is to use, 
this analysis had no involvement with CORCEMA-ST analysis, and we preferred to 
focus on a simpler, non-computational, more pragmatic approach to quantitative STD 
analysis. (Jayalakshmi and Krishna, 2004, Krishna and Jayalakshmi, 2006) 
 
Quantitative STD may also refer to a method very closely related to this analysis, that 
of calculation of protein-ligand binding affinities via STD initial growth rates. Here, 
the dissociation constant is determined by single-ligand titration experiments. 
Competition experiments with a ligand of known affinity allows indirect 
determination of KD (Angulo et al., 2010). 
$WWKLVMXQFWXUHLWPXVWEHVWUHVVHGWKDWµTXDQWLWDWLYH67'¶LQWKLVWKHVLVUHIHUVQRWWR





1.3  Water-Ligand Observed via Gradient SpectroscopY (WaterLOGSY) 
Water-Ligand Observed via Gradient SpectroscopY (WaterLOGSY) is an alternative 
ligand-observed NMR screening technique. It was developed around the turn of the 
millennium by Dalvit et al(Dalvit et al., 2001, Dalvit et al., 2000) as another primary 
method for screening compound libraries for compounds that bind to proteins.  
 
Their method built upon the previous observation that water molecules were often 
found to be conserved in several x-ray structures at the protein-ligand 
interface(Poornima and Dean, 1995). Water molecules in protein cavities were 
determined to possess residence times between a few ns to several hundred ȝV(Dalvit 
et al., 2001, Otting and Wuethrich, 1989), a long time relative to the effective 
correlation time where intermolecular water-proton NOEs change sign, but short 
compared to the chemical shift timescale where a separate resonance for bound water 
would be observed (ms). This led to the development of saturating the protein in a 
protein-ligand complex, via selective saturation of the water signal, thereby retaining 
the sign of the starting magnetisation.    
 
 
Instead of selectively saturating the protein, bulk water is targeted, and magnetisation 
is transferred from protein to ligand. For free ligands in solution magnetisation is also 
transferred directly via the bulk water. The relay processes involved in magnetisation 








Selectively excited bound water at the binding interface, followed by NOE mixing, 
allows for effective magnetisation transfer to the protein whilst conserving the 
negative sign of the NOE. The other mechanism of magnetisation transfer (which also 
conserves the sign of the NOE) via the protein is mediated by chemical exchange with 
labile protons such as those of carboxyl, amino, hydroxyl and other groups(Liepinsh 
and Otting, 1996, Dalvit et al., 2001). Both these processes act together to transfer 
magnetisation from bulk water to protein and subsequently to the bound ligand.  
 
On the other hand, free ligand that only interacts with bulk water experiences a 
positive NOE from the water, and this is due to these water molecules experiencing a 
much faster tumbling time. A ligand bound to the protein takes on the tumbling 
correlation time of the protein, which is significantly slower. Opposite sign NOEs 
cause NMR signals of opposite sign, and this in turn allows us to distinguish between 
those ligands that bind, and those that do not. 
Figure 1.6: The WaterLOGSY principle. The ligand is shown in both free and 
bound states, with the protein possessing cavities in the binding site. Solid 
arrows represent excitation of bulk water molecules (circles) with the various 
magnetisation transfer pathways illustrated as curves lines. Figure taken from 
(Dalvit et al., 2001) 
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1.4  Fragment-based drug discovery 
 
Fragment-based drug discovery (FBDD) describes the creation of a drug compound 
via building up from small, weakly binding molecules and successive modifications 
to improve potency and ligand efficiency. Small molecular weight fragments that bind 
weakly, but form high quality interactions with a protein target, are selected to 
optimise into larger, more potent molecules(Jencks, 1981, Scott et al., 2012). Initial 
fragment molecules tend to conform to the Rule of Three(Congreve et al., 2003), a 
standard rule of thumb for determining optimal fragment ligand properties: a 
PROHFXODU ZHLJKW RI OHVV WKDQ  'D D FDOFXODWHG ORJ3 RI   WKUHH RU IHZHU
hydrogen bond donors, and up to three hydrogen bond acceptors.   
 
Using an appropriate fragment library, compounds are screened using one of several 
biophysical techniques to detect weak non-covalent interactions, after which fragment 
µHODERUDWLRQ¶ RFFXUV LQ ZKLFK YDOLGDWHG KLWV XQGHUJR F\FOHV RI V\QWKHVLV LQWR ODUJHU
compounds with input from structural biology, medicinal chemistry and 
computational chemistry. This eventually produces a potent compound.  
 
1.4.1  Other Techniques in FBDD 
 
Several biophysical techniques are used by FBDD users during the early stages of 
development. X-ray crystallography is the generally considered to be the most 
powerful primary screening technique by FBDD practitioners. This generates three-
dimensional structures of protein-ligand complexes at atomic resolution. These 
structures are considered very important for validating hits, as well as for establishing 
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initial binding modes. However this is dependent on access to synchrotrons, as well as 
high quality crystals, which may not always be possible.   
 
Native mass spectrometry (MS) is extremely versatile. Protein/fragment mixtures 
undergo electrospray ionization (ESI) and fragment binding can be observed as a 
corresponding increase in the mass of the target. This way, fragments can be screened 
in large cocktails, and a gauge on affinity gained from the relative abundance of 
different protein-ligand species(Vivat Hannah et al., 2010). However the requirement 
for relatively large amount of target limits the utility of this technique.  
 
Another technique is surface plasmon resonance (SPR), in which the protein target is 
covalently bound to the gold surface of an SPR chip, and solutions of individual 
ligands are then passed over it. If a fragment binds to the target, an increase in mass is 
detected, and from the resulting association/dissociation curve the binding kinetics 
and affinity can be calculated(Navratilova and Hopkins, 2010). This provides 
information for kon and koff, rather than simply KD and so might be more suited for 
follow up studies rather than initial screening. 
 
Typically a range of techniques is employed in order to ensure results are validated. 
There is a distinct lack of correlation between fragment hits obtained via different 
techniques, in fact it is possible to run a fragment screen using two different methods 






1.4.2  Other NMR Techniques in FBDD 
The principal NMR method employed in FBDD ± other than ligand-observed 
experiments ± is chemical shift perturbation mapping (CSP). Here, two 2D 
Heteronuclear single quantum coherence spectroscopy (HSQC) experiments are run 
in the absence and presence of a ligand. In a 15N HSQC spectrum each peak is 
representative of an amide proton, thus representing a particular amino acid. Any shift 
of a particular amide proton upon ligand binding is indicative of ligand binding. In 
contrast to ligand-observed NMR, this is very much protein-observed. The method 
relies on chemical shifts of amide peaks of the protein target being acutely sensitive to 
changes in local environment.  
 
It also depends upon isotopic enrichment of protein (15N) since the natural abundance 
of this spin ½, NMR-active nucleus, is only 0.368%. This process can be tricky and 
costly, and is a clear limitation. 
 
CSPs can be used as an initial screen on a library of ligands in order to identify 
binders but is more likely to be employed as a secondary method in order to give 
more information. Both the interface and the kinetics of binding can be identified by 
titration of increasing quantities of ligand(Medek et al., 2000). Given fast exchange 
between protein and ligand, incrementally increasing the ligand concentration 
produces a trajectory of CSPs for certain amide peaks, these can then be fitted to 






1.4.3  The fruits of FBDD 
 
In 2011 a phase 3 randomised clinical trial of 675 patients with untreated metastatic 
melanoma taking the drug vemurafenib ± who possessed the BRAF V600E mutation 
± showed improved rates of overall survival (OS) and progression-free survival (PFS) 
over the previous standard therapy, dacarbazine(Chapman et al., 2011). Later that 
year the FDA approved the drug, and it became the first drug to be approved that had 
been produced with fragment-based principles. 
 
The discovery of vemurafenib began with an initial screen of 20,000 compounds 
between 150 and 350 Daltons binding to various kinases by in vitro phosphorylation 
measurement. Of these, 238 compounds were found to bind to three kinases and 
subsequently > 100 bound crystal structures were solved(Tsai et al., 2008). Using a 
structure-guided approach the potent, selective inhibitor was subsequently found to 
inhibit BRAF V600E with an IC50 of 13 nM.  
 
Whilst this significant milestone for FBDD was passed in 2011, the future holds the 
prospect of much greater reward. In phase 3 trials currently is the BACE inhibitor 
MK- DQG D WULDO LQYROYLQJ  SDWLHQWV ZLWK $O]KHLPHU¶V GLVHDVH VHW WR EH
completed in 2018. In phase 2 trials are many FBDD-derived compounds for a variety 
of disease indications (including multiple myeloma, non-+RGJNLQ¶VO\PSKRPDQRQ-
small cell lung cancer, and gastrointestinal stromal tumour), among them are 
compounds that inhibit: CDKs 1, 2, 4 and 5(Wyatt et al., 2008), VEGF(Albert et al., 




1.5  The story of AT13387  
 
1.5.1  FBDD as applied to Hsp90 
Of most relevance to the studies presented in this thesis is the discovery of Hsp90 
inhibitor AT13387. Hsp90 has proven to be perfectly suited to fragment-based 
approaches in the past(Barker et al., 2009), and several compounds are now in the 
FOLQLF +RZHYHU LW¶V WKH DSSURDFK WDNHQ E\ $VWH[ WKDW LV WKH PRVW LQWHUHVWLQJ DQG
forms the launchpad for my investigations. 
 
1.5.2  The Astex approach 
A combination of NMR and x-ray crystallography was applied to Hsp90(Murray et 
al., 2010). Hsp90 is a molecular chaperone involved in the stabilisation and function 
of other proteins in the cell(Bukau et al., 2006). Several of the proteins stabilized by 
Hsp90 are implicated in cancer progression(Workman et al., 2007), hence the clear 
attraction of Hsp90 as a target for chemotherapeutic agents. Typical Hsp90 function 
depends on the conversion of ATP to ADP via the N-terminal ATPase domain(Pearl 
and Prodromou, 2006). This nucleotide-binding site has been fully characterised 
crystallographically(Prodromou et al., 1997) and inhibition of this site has been 
shown to cause the down-regulation of the proteins that bind to Hsp90(Vilenchik et 
al., 2004).  
 
1600 compounds were screened against the N-terminal domain of Hsp90. Fragments 
were screened in cocktails of four using the WaterLOGSY experiment, and any 
FRFNWDLOVWKDWFRQWDLQHGDIUDJPHQWWKDWVKRZHGHLWKHUDµPHGLXP¶RUµVWURQJ¶SRVLWLYH
LOGSY signal were taken and examined further in competition mode. Adding ADP 
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to the mixture, which under the experimental conditions binds weakly to Hsp90, 
enabled this. Any reduction in the LOGSY signal of ADP is indicative of 
displacement by a fragment in the mixture, allowing definitive identification of a 
fragment that binds in the nucleotide-binding site, also eliminating any false positives. 
Adding 5 mM Mg2+ to the mixture increases the affinity of ADP for the binding site, 
and so doing this acts as a second competition experiment, giving further information 
on the affinity of the fragment for the site. Extremely weak binders are 
displaced(Murray et al., 2010). 
 
125 compounds progressed from NMR to x-ray crystallographic screening, using both 
co-crystallisation and soaking experiments. Of these compounds, 26 were capable of 
providing crystal structures and isothermal titration calorimetry was then used to 
determine their dissociation constants. Four key examples are shown in figure 1.7. 
 
Of particular note are fragments 1 and 3, both of which feature heavily in this thesis. 
Crystallographic analysis of the 26 ligand-protein complex structures sheds light on 








1.5.2.1  Optimising the interactions of fragment 1 ± The aminopyrimidine route 
The binding interactions between Hsp90 and fragment 1 ± as in fig. 1.8 - were shown 
to be sub-optimal by virtue of the bond twisting between the two aromatic rings as 
well as the poor filling of the proximal lipophilic pocket (made up of the side chains 
Met98, Leu107, Phe138, Val150 and Val 186). Both of these were areas that would 
clearly need to be addressed in any subsequent fragment elaboration in order to 
improve the hydrophobic fit. 
 
Optimisation of fragment 1 began with virtual screening of close analogues, which 
resulted in the identification of compound 5, a simple chloro analogue (as in figure 
1.9), which gave an improvement in affinity of 100 times as measured by ITC. From 
this it was then deemed worthy to synthesize analogues of compound 5 by 
substituting groups at positions R2 and R6 of the phenyl ring in an attempt to both 
stabilize the twist in the bond observed in fig. 1.8 as well as fill the proximal 
lipophilic pocket. These changes are shown in figure 1.9. 
Figure 1.8: Analysis of the binding mode of aminopyrimidine fragments to Hsp90. A) the 
crystal structure of Hsp90 and compound 1 shown with key hydrogen bonds to conserved 






The result was compounds 6-9. Compound 9 clearly has the greatest ligand efficiency 
whilst all four compounds possess dissociation constants lower than 0.1 µM. 
Compound 9 was selected as the molecule for the next iteration, with alterations at 
positions 4 and 5, in order to introduce more lipophilic interactions with the protein as 
well as aid solubility. 
 
The resulting compounds are shown below in figure 1.10, with compound 14 showing 
the most promise in terms of the combination of IC50, LE (ligand efficiency: see 




Figure 1.9: Compounds 1, 5, and a list of analogues of compound 5 (at positions 2 and 
6) and their associated potencies  










Figure 1.11: Crystallographic overlays of compound 1 (orange) and compound 14 




1.5.2.2  Optimising the interactions of fragment 3 ± The phenol route 
Starting with compound 3 as a scaffold, several changes at position 1 led to the 
synthesis of chloro, ethyl and isopropyl and tert-butyl analogues (15-18). Compounds 
18 and 17 exhibited a reduction in KD by a factor of 100, as shown in fig. 1.12.  
 
Next it was decided to shift the 4-OH group to a 2-OH group position due to the fact 
that the binding natural product (radicicol) possesses hydroxyl groups at both 
positions, and its 2-OH group forms a hydrogen bond with the Asp 93 side chain. 
Figure 1.12: Optimisation of the phenol series using compound 3 as a base (pictured) 
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Compounds 19 and 20 based on the 2-OH formula were synthesized but a large 
reduction in potency was observed compared to compounds 17 and 18.    
 
After this compound 18 ± with a KD RIȝ0± had its diethylamide group replaced 
with a number of other amides, and compounds 21- 26 were synthesized. This was 
done in order to stabilize the twisted torsion angle between the phenyl ring and 
carbonyl group (which is essential for indirect hydrogen bonding with Asp93, as in 
fig. 1.13).  
 
Of the new tertiary amides compound 24 was the most promising, exhibiting an 
increase in affinity of several hundred-times, to a KD RI  ȝ0 7KUHH QHZ
compounds 27 ± 29 were synthesized on the basis of altering compounds 21, 24 and 
26 respectively by substituting tert-butyl group to an isopropyl group. This change 
increased affinity for all three compounds, reduced lipophilicity, and provided better 
filling of the pocket as dictated in fig 1.13C.  
 
Figure 1.13: Compound 3 bound to Hsp90. A) Hydrogen bonds to two conserved water 
molecules. B) Compound 3 superimposed with radicicol, illustrating the importance of the 
additional hydroxyl group in radicicol, which makes a direct hydrogen bond with Asp93 as 
well as a conserved water molecules, hinting that conversion of the phenol to a resorcinol 
may be beneficial. C) As with the aminopyrimidine series better filling of the proximal 
lipophilic pocket was also required, and this was achieved by replacing the methoxy group 
with other larger substituents     
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The final change was to incorporate the extra hydroxyl group that is present in the 
Hsp90 binding natural product, Radicicol(Schulte et al., 1998).  This change to the 
fragment WRDGGWKH¶2+ is shown in the final two fragments in fig 1.12. This 2,4-
OH configuration led to compounds 30 and 31 from compounds 27 and 28 
respectively. The extra hydroxyl group at position 2 gave increases in affinity to 0.011 
ȝ0 DQG  ȝ0 IURP  ȝ0 DQG  ȝ0 UHVSHFWLvely. Compound 31 in 
particular gave excellent improvements in ligand efficiency and cell activity, and the 
three overall group changes from fragment 3 are highlighted in figure 1.14.  
 
 
1.5.2.3  In summary 
Following this FBDD campaign two compounds are determined to be lead 
compounds, via a process that can be deemed the most efficient fragment to lead 
campaigns ever reported(Verdonk and Rees, 2008). Optimisation of small molecular 
weight fragments in two lead campaigns - from both aminopyrimidines and phenols ± 
allowed for the optimisation of lead compounds around 300 Da in mass. This is 
suggested to be optimal as it allows for further tuning, as functional groups may now 
Figure 1.14: Conversion of compound 3 to compound 31 via modification at the 
WKUHHJURXSVLQGLFDWHG7KHVHFKDQJHVUHVXOWLQDOHDGPROHFXOHWKDW¶VRYHU
1,000,000 times more potent than the starting phenol.  
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be added to the compound that improve non-potency related properties, without the 
IHDUWKDWWKHFRPSRXQGZRXOGHGJHRXWRIµGUXJ-OLNHVSDFH¶ 
A clinical candidate for Hsp90 ± AT13387 ± was subsequently developed as an 
extension to this FBDD process(Woodhead et al., 2010) that ultimately built on the 
resorcinol lead. This compound is now in phase II trials for a range of different 
cancers. 
 
Important FBDD concepts are beautifully illustrated here. Firstly, small fragments 
that bind very weakly ± at KDs greater than  ȝ0 ± are perfect starting points. 
Fragment 3 of the phenol series possessed a KD of 790 ȝ0 DQG LQ PDQ\ GUXJ
screening programmes would be dismissed instantly. FBDD however takes into 
consideration more than potency, and a compound that binds extremely weakly could 
easily offer high quality interactions that act as an attractive structural scaffold that 
may have otherwise been missed but is now available for modification. Another key 
point in this example is the use of ligand efficiency as a metric: 
 ܮܧ ൌ  ି୼ୋு஺஼ ൌ  ିோ் ୪୬ሺ௄೏ሻு஺஼      (Equation 5) 
 
LE, ligand efficiency; HAC, heavy atom count; ǻ*JLEEVIUHHHQHUJ\.D, dissociation constant 
 
Ligand efficiency, as in the example of the discovery of AT13387, is used to monitor 
the potency of compounds during lead identification and to assess whether or not any 
increase in potency is worth it in terms of heavy atoms added. Ligand efficiency is 





As part of my investigations I shall be taking some of the fragments in this Hsp90 
story mentioned thus far, and will use both protein and ligands to probe the 
parameters of the STD experiment.  
 
1.6  Aims and overview 
Ligand-observed NMR is the term given for NMR experiments between a protein 
target and a ligand in which the signals of the ligand are the only ones that matter. 
This category comprises a number of experiments, of which two we focus on in this 
investigation: STD and LOGSY. If these ligand-observed NMR experiments can be 
expanded to provide more information on protein ligand binding than simply giving a 
µ\HV¶RUµQR¶DQVZHUIRUDKLW- such as unambiguously defining the binding epitope, 
describing a binding site interaction, or combining with computational models to 
eliminate incorrect solutions - the remit of these relatively simple experiments is 
improved forever. This would extend the applicability of ligand-observed NMR from 
being a pure NMR discipline into one in which non-specialists may routinely employ, 















Chapter 2  
 
Optimising selective 
excitation pulses to 
maximize saturation 

















2.1  Introduction 
Saturation transfer difference NMR (STD NMR) is a powerful ligand-observed NMR 
experiment used for identifying small ligand molecules that interact with a particular 
protein (Biet and Peters, 2001, Mayer and Meyer, 1999, Mayer and Meyer, 2001, 
Meyer and Peters, 2003). This chapter focuses on optimising the basic STD 
experiment via modification of the selective Gaussian pulse, in order to achieve 
significantly enhanced signal and consequently STD amplification factors. The work 
described in this chapter was published in 2014 as a journal article(Ley et al., 2014) 
(see appendix item A). 
2.1.1  The STD Experiment 
67'105 LV DSRSXODU SRZHUIXO H[SHULPHQW ,W¶V H[WHQVLYHO\XVHG LQ LQGXVWU\ DQG
academia to screen and identify small-molecule ligands that bind to target 
biomolecules in drug discovery contexts (Jhoti et al., 2007, Lepre et al., 2004, Moore 
et al., 2004, Pellecchia et al., 2008, Sillerud and Larson, 2006, Stockman and Dalvit, 
2002, Wishart, 2005). In more recent times, STD NMR has been used to help cast 
light upon investigations into the binding mode of samples containing a single ligand 
and protein as a secondary screen (Begley et al., 2010a, DiCara et al., 2007, Kemper 
et al., 2010a, Wagstaff et al., 2010). In light of these contexts, it is important to obtain 
results that optimise all avenues to achieve maximum signal.   
Figure 2.1:  1H STD NMR pulse sequence highlighting the shaped excitation pulse that 
drives saturation of the protein. Pulse sequence components responsible for spin-locking 
± in order to reduce protein background signal ± and water suppression are also shown 
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1H STD NMR experiments begin with selective saturation of the protein by virtue of a 
specific, shaped excitation pulse, illustrated in fig. 2.1 
 
The shaped pulse is placed within the spectral envelope of the protein ± typically 
between 0 ppm and -1 ppm ± and saturates the protein 1H via excitation of upfield 
methyl protons and subsequent efficient spin diffusion through the protein.  
 
Protons of any ligand involved in an interaction with the protein also experience this 
saturation via intermolecular NOE transfer at the binding interface, so long as 
magnetisation transfer occurs before the ligand dissociates from the protein. This is 
measured in a 1H NMR ligand spectrum as the difference between two datasets: one 
ZKHUH WKHSURWHLQ LV VDWXUDWHG µRQ¶ UHVRQDQFHRU I) and another when the protein is 
QRWVDWXUDWHGµRII¶UHVRQDQFHRU I0). The STD difference spectrum ISTD is defined as 
(I-I0). Any signal in an STD difference spectrum is indicative of a bound ligand, and 
LV VXIILFLHQW IRU TXDOLWDWLYHO\ VWDWLQJ µ\HV¶ RU µQR¶ DV WR ZKHWKHU RU QRW D IUDJPHQW
molecule binds.  
 
2.1.2  Typical conditions for STD NMR 
In order to ensure that selective saturation targets only methyl resonances of the 
SURWHLQ DQG DYRLGV LQGLUHFWO\ VDWXUDWLQJ WKH OLJDQG GLUHFWO\ WKH SRVLWLRQ RI µRQ¶
resonance saturation is typically chosen to be between 0 ppm and -1 ppm, whilst the 
SRVLWLRQRI µRII¶ UHVRQDQFHVDWXUDWLRQ LV VSHFLILFDOOy placed distant from both ligand 




For experimental setups involving large proteins, virus-OLNHSDUWLFOHVRUFHOOVWKHµRII¶
resonance saturation position must be much further downfield or upfield, say ± 300 
ppm. This is in order to prevent accidental excitation of the protein, a scenario made 
possible by the large protein molecular weight(Rademacher et al., 2008).  
 
The protein is typically saturated by the repetition of a shaped excitation pulse that is 
usually between 20 to 50 ms in length and for a total duration of between 1 to 10 
seconds. The pulse is shaped in nature (for example Gaussian(Freeman, 1998) or E-
burp(Cutting et al., 2007)) in order to limit its excitation profile beyond certain 
bounds and prevent accidental excitation of the ligand. Gaussian and E-burp pulses 
are preferred to hard pulses in STD NMR due to the near absence of side lobes and 
low excitation at large offset positions from the pulse(Cutting et al., 2007, Freeman, 
1998, Meyer and Peters, 2003).  
 
It is crucial that selective pulses are applied to sufficiently saturate the protein as 
optimally as possible, whilst preventing accidental excitation of the ligand protons. In 
this chapter, we examine the process of rationally placing selective Gaussian pulses of 
differing length at different offset positions so as to maximize STD signal whilst 
minimising accidental excitation of the ligand. 
 
2.1.3  Our Model System ± WGA/GlcNAc 
STD Optimisation 
 49 
This chapter focuses on a model system: wheat-germ agglutinin (WGA) and N-acetyl-
D-glucosamine. This protein-ligand system was selected due to its availability and 
ubiquity. It also provides a simple methyl peak to follow as the largest signal and 
most upfield resonance. 
WGA is a lectin found in the seeds of Triticum vulgaris. It specifically binds 
GlcNAc as well as N-acetylneuraminic acid and is known to inhibit fungal growth 
via an interaction with fungal cell wall components(Mirelman et al., 1975). WGA 
forms a 36 kDa homodimer with a two-fold symmetry axis(Wright, 1980, Wright, 
Figure 2.2: The GlcNAc ligand with methyl group highlighted. Alongside is a 
typical STD spectrum with the large peak representing that of the methyl group. 
Figure 2.3: Two of the four unique binding sites of WGA with bound ligand. GlcNAc 
can be seen positioned with the methyl group orientated towards the protein. Figures 
taken from PDB 2UVO(Schwefel et al., 2010)  
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1989, Harata et al., 1995). Each polypeptide chain forms four domains of 43 residues 
each (A-D). There exist eight functional carbohydrate-binding sites per WGA dimer, 
hence four unique sites per monomer unit. A binding site for GlcNAc is formed via a 
cluster of three conserved aromatic residues of which the second stacks against the 
sugar ring(Wright and Kellogg, 1996). Polar residues from adjacent domains then 
compliment this binding.  
 
Binding sites are not identical and the sites involving domains A and D possess an 
inherently lower affinity for GlcNAc than binding sites involving B and C 
domains(Wright and Kellogg, 1996). As a result of this heterogeneity in binding 
affinity it is impossible to quantify the effects of GlcNAc binding by NMR, however 
it is worth noting that in all instances of binding the methyl group is usually orientated 
towards the protein, which explains the disproportionately large STD signal for the 




2.2  Materials and Methods  
2.2.1  Sample production and preparation 
Wheat-germ agglutinin (WGA) protein from Triticum vulgaris and N-acetyl-D-
glucosamine (GlcNAc) were purchased from Sigma-Aldrich. Samples were prepared 
DVȝ0:*$DQGP0*OF1$FLQGHXWHULXPR[LGHDQGS+FRUUHFWHGWRLQD
buffer of 10 mM sodium phosphate and 10 mM sodium chloride. This ensured a 
ligand-to-protein ratio of 50:1 for all experiments.  
  
In addition 1 mM Raffinose pentahydrate was added in excess to a sample containing 
WGA and GlcNAc as a negative STD control experiment for the spectra shown in fig. 
2.4.  
 
Excitation profiles constructed as shown in figs. 2.9 and 2.10 were generated from a 
sample of 100% deuterium oxide (D2O), and ligand-only negative control 
experiments in figs. 2.11 and 2.12 were prepared in identical manner as usual STD 
samples, simply without the protein.  
 
2.2.2  NMR experiments 
All experiments were run at 283 K using a Bruker AV3 600 MHz NMR spectrometer 
equipped with a QCI-F cryoprobe. A standard Bruker STD sequence was used and 
water suppression was achieved using a standard Bruker 3-9-19 WATERGATE 
sequence. Datasets were processed and analysed with Bruker Topspin 3.2 and 1H 




Shaped pulses were generated and optimised using Bruker Shape Tool. STD NMR 
datasets were obtained over  LQWHUOHDYHG VFDQV  µRQ¶ VFDQV DQG  µRII¶
VFDQV IRU     RU  PV *DXVVLDQ VKDSHG SXOVHV ZLWK YDULDEOH µRQ¶
VDWXUDWLRQSRVLWLRQVEXWZLWKµRII¶VDWXUDWLRQFRQVWDQWO\VHWWR-30 ppm.  
 
The resonance for the methyl GlcNAc protons was measured for absolute intensity 
using MestReNova (Mnova) and used to calculate STD amplification factors (STDAF) 
from the STD difference spectra ሾܫௌ்஽ ൌ ሺܫ െ ܫ଴ሻሿ and the control spectra ሺܫ଴ሻ as has 
been previously described using the equation(Meyer and Peters, 2003):  
 ܵܶܦ஺ி ൌ ቀூೄ೅ವூబ ቁ ൈ ܮ݅݃ܽ݊݀ܧݔܿ݁ݏݏ     (Equation 6) 
 
Practical excitation profiles ± using both single shaped pulses as well as Gaussian 
trains - for the various Gaussian pulses are designed to show the excitation limits for 
the various length pulses used. Although spectrometer software enables us to evaluate 
shaped pulses for excitation and width, we deemed it prudent to determine these 
ourselves. Profiles for single shaped pulses were acquired for 2.5, 5, 10, 25 and 50 ms 
Gaussian pulses (fig. 2.9) whereas excitation profiles for pulse trains were acquired 
for 2.5 and 5 ms Gaussian pulses (fig. 2.10). Pulse trains used were the same as those 
used to produce standard STD NMR data. The usual approach for providing 
saturation for STD is to loop the selective pulse without an inter-pulse delay. A 2 
second saturation period uses 400 5 ms pulses or 800 2.5 ms pulses. Measuring the 
residual 1H resonance (HDO) in deuterium oxide provides a single resonance to 
measure with a narrow half peak height below 0.003 ppm (2 Hz). Sweeping the 
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carrier frequency in a pulse-acquire experiment containing the shaped pulse of interest 
and measuring the resulting intensity produced the excitation profiles. 
 
The negative control experiment shown in figs. 2.11 and 2.12 is designed to measure 
virtual STD amplification factors for the GlcNAc methyl resonance in the absence of 
SURWHLQ DW D UDQJH RI µRQ¶-resonance offset positions, such that any accidental 
excitation will clearly manifest itself as a non-zero STDAF value. µ,¶ DQG µ,0¶
experiments should in theory produce the same result in the absence of protein. Since 
ISTD = (I ± I0), the difference spectrum should be blank and produce an STDAF value of 
zero. However, if a difference spectrum is obtained then this must be because ISTD > 0. 
If I  I0, and there is no protein present, then there must be accidental excitation of the 
ligand. 
 
In combination, both negative controls should allow identification of offset values at 
which we can definitively say we have caused accidental excitation. It should also 
help identify the maximum allowable percentage excitation at which a false-positive 











2.3  Results  
2.3.1  Standard STD NMR spectrum for WGA/GlcNAc/Raffinose  
 
The bedrock of all analysis within this chapter centres on the binding of GlcNAc to 
WGA, and the monitoring of this process via STD NMR. Below shows a typical STD 


















Figure 2.4: 1H STD NMR difference (a) and control (b) spectra obtained over 
256 scans with a 10 ms Gaussian pulse for WGA/GlcNAc/Raffinose. The 
GlcNAc 1H methyl resonance is highlighted by the arrows 
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In fig. 2.4 the signal relating to the methyl protons of GlcNAc is clearly evident at 1.8 
ppm relative to DSS. The protons of the methyl group clearly appear with the greatest 
intensity in the STD spectrum, and these provide the perfect signal to monitor the 
effects of changing both the Gaussian pulse OHQJWK DQG µRQ¶ VDWXUDWLRQ SRVLWLRQ E\















































 Figure 2.5: 1+67'105VSHFWUDRI:*$*OF1$FRYHUDUDQJHRIµRQ¶
saturation offset positions for a 2.5 ms Gaussian pulse. Expanded STDdiff 




Figure 2.6: 1H STD NMR spectra of WGA/GlcNAc RYHUDUDQJHRIµRQ¶
saturation offset positions for a 5 ms Gaussian pulse. Expanded STDdiff 





saturation offset positions for a 10 ms Gaussian pulse. Expanded STDdiff 
datasets are shown in (a) and datasets scaled to the STDcontrol are shown in (b) 
STD Optimisation 
 59 
The various spectra in figs. 2.5-LOOXVWUDWHWKHHIIHFWRIDOWHULQJWKHµRQ¶UHVRQDQFH
position with respect to the upfield GlcNAc resonance  - as well as altering the 
Gaussian pulse length ± on STD amplification factor. Taking the absolute intensity ± 
or peak height - for the GlcNAc resonance allows calculation of the STD 
amplification factor at each variation. All the data extracted from these spectra is 
summarized neatly below in fig. 2.8. 
 
Shortening the length of the Gaussian pulse in fig. 2.8 clearly suggests that a 2.5 ms 
Gaussian pulse placed at -1.8 ppm (1080 Hz) upfield from the ligand resonance seems 
to provide the optimum STD signal. This gives an amplification factor seven times 
greater than the equivalent 5 ms Gaussian pulse, and nineteen times greater than an 







































µRQ¶ saturation position as an of fset from the GlcNAc CH3 resonance / ppm
Figure 2.8: GlcNAc methyl 1H STD amplification factors in the presence of 
:*$IRUDQGPV*DXVVLDQSXOVHVRYHUDUDQJHRIµRQ¶VDWXUDWLRQ
SRLQWV7KHµRQ¶UHVRQDQFHSRVLWLRQLVVKRZVDVDSSPRIIVHW0+]1H) 
from the ligand resonance; i.e. an offset of -1.8 ppm is at 0 ppm.  
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Gaussian pulse exceed the 5 ms and 10 ms counterparts across the entirety of the 
UDQJHRIµRQ¶UHVRQDQFHVDWXUDWLRQpositions. 
2.3.3  Practical NMR Gaussian excitation profiles  
Figure 2.9: Excitation profiles for a single Gaussian pulse of variable length. The profiles 
were created by delivering a single Gaussian pulse at one of the fixed saturation times, at 
14.1 T (600 MHz 1H). Each profile was acquired by measuring the intensity of the 1HDO 
resonance in deuterium oxide (D2O) with a 0.1 ppm resolution between data points over a 
±5 ppm offset window. 
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The excitation profiles generated in fig. 2.9 illustrate that shorter length Gaussian 
pulses have a broader range of excitation, with the 2.5 ms pulse exciting over a 
significantly wider range. As fig. 2.9 shows, the 2.5 ms Gaussian pulse excites up to 
~2.5 ppm upfield and downfield from the position of application. To verify these 
UHVXOWVLW¶VSUXGHnt to also examine the intensity of the water signal across a range of 




















Figure 2.10: Excitation profiles for 2.5 ms (solid line) and 5 ms (dotted 
line) Gaussian pulses delivered as a train of pulses ± for 2 seconds in total 
- at 14.1 T (600 MHz 1H). Each profile was acquired by measuring the 
intensity of the 1HDO resonance in deuterium oxide (D2O) with a 0.1 ppm 
resolution between data points over a ±4 ppm offset window. 
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The excitation profiles generated in fig. 2.9 illustrate the same principle as those in 
fig. 2.10. The same expected result ± that a shortening of the Gaussian pulse length 
creates a wider excitation profile ± is clearly observed. In addition, fig. 2.10 shows 
that a profile obtained from a 2 second train of pulses is significantly different to that 
obtained from a single Gaussian pulse. Again, the pulse train profiles confirm that a 2 
ppm offset is sufficient for a 5 ms Gaussian pulse, but that a 2.5 ms pulse should be 
placed at least 2.5 ppm from the nearest ligand resonance. 
 
2.3.4  Negative controls: STD experiments in the absence of protein 
The final experiments examine a full STD experiment on an identical experimental 
setup as figs. 2.5-2.8 but in the absence of protein. Any STD amplification factor in 
this control experiment must be indicative of direct excitation of the ligand by the 2.5 






















Figure 2.11: Calculated STD NMR amplification factors acquired using a 
2.5 ms Gaussian pulVHRYHUDUDQJHRIµRQ¶VDWXUDWLRQSRLQWVIRUP0
GlcNAc as a control in the absence of WGA protein 
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The STD amplification factor values fall to zero when the 2.5 ms pulse is placed at 
offsets greater than or equal to 1.8 ppm. This result corroborates that of fig. 2.10 in 
which the 1.8 ppm position provides a valley in the excitation profile in between two 
offsets of 1.4 and 2 ppm. 
 
This result is illustrated more elegantly below in fig. 2.12. The relative intensities of 
the methyl CH3 signal from STD spectra that generated the data in fig. 2.11 are shown 
as spectral overlays below.  
 
As can be clearly seen, STD signal caused by direct excitation of the ligand falls away 
dramatically at offsets of 1.8 ppm or greater.  
 
Figure 2.12: 1H NMR difference spectra of the GlcNAc CH3 resonance generated 
ZLWKGLIIHUHQWµRQ¶VDWXUDWLRQRIIVHWVIRUDPV*DXVVLDQSXOVHWRLGHQWLI\
SHUWXUEDWLRQRIWKHOLJDQGUHVRQDQFH2IIVHWRIWKHµRQ¶VDWXUDWLRQSXOVHLV
indicated by the ppm values shown  
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2.4  Discussion  
2.4.1  Initial observations of altering the length and position of the Gaussian 
pulse 
Spectra such as that exhibited in fig. 2.4 are representative of all data acquired and 
processed in this chapter, and involved in creation of subsequent spectra. 
Qualitatively, figures 2.5 ± 2.7 show that the STD signal to noise ratio increases as the 
pulse length shortens, for all offset positions. The STD signal to noise ratio of the 
GlcNAc peak also increases as the offset position is gradually moved closer towards 
the ligand, for all Gaussian pulse lengths. 
 
These results are best illustrated in fig. 2.8 that shows how the 2.5 ms Gaussian pulse 
placed at -1.8 ppm upfield (1080 Hz) from the ligand resonance provides the 
maximum STD signal, with an amplification factor seven times greater than a 5 ms 
pulse, and 19 times greater than a 10 ms pulse at the same offset position. These 
results are generally unsurprising, as it has been previously noted that STD spectra 
display a dependence on the power level of the shaped pulse(Cutting et al., 2007).  
,W¶V FOHDU WKDW WKH67' signal acquired using the 2.5 ms pulse surpass that acquired 
ZLWK WKH  PV DQG  PV SXOVHV RYHU WKH ZKROH µRQ¶-resonance range, but more 
intriguing is how the measured amplification factors with the 2.5 ms pulse increase 
dramatically as it is applied at offset positions less than 2.8 ppm (1680 Hz) upfield 
from the GlcNAc methyl resonance.  
 
The increase that is observed with the 2.5 ms pulse - at very close offset positions - 
upon first glance may instantly be attributed to accidental excitation of the ligand in 
either the bound or unbound state. This would clearly be undesirable and can be tested 
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in two ways: obtaining practical NMR Gaussian excitation profiles, and acquiring 
virtual STD spectra for GlcNAc in the absence of protein. Any direct excitation 
would clearly manifest itself here. 
 
2.4.2  Practical NMR Gaussian excitation profiles as a negative control  
The excitation profiles produced with a Gaussian pulse train confirm that an offset of 
2 ppm is sufficient for a 5 ms Gaussian pulse but that a 2.5 ms pulse should be placed 
at least 2.5 ppm from the nearest ligand resonance in order to prevent accidental 
excitation. The appearance of these profiles are markedly different to those produced 
using a single pulse. 
 
The profile created with a single 2.5 ms Gaussian pulse reaches an outer limit of 
approximately 2.2 ppm in both directions, which tallies with that created with a pulse 
train. Similarly the limit of the 5 ms pulse in both directions is ~1.4 ppm achieved 
with both pulse types. On this basis the profiles are comparable, but the profiles 
created with a pulse train show that the smooth Gaussian distribution obtained using a 
single pulse hides a multitude of differences. The 2.5 ms pulse train provides the 
profile with significant sidebands at offsets of 0.6, 1.4 and 2 ppm. Sidebands caused 
by pulse combs are well-known phenomena and are due to perturbation of magnetic 
trajectories between on and off resonance positions(Freeman, 1998).       
 
2.4.3  STD experiments in the absence of protein  
In the absence of protein, calculated STD amplification factors > 1 are evidently 
present, proving that accidental excitation of the ligand directly is possible. This is 
perhaps not surprising at an offset of 0 ppm. This calculated STD amplification factor 
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value falls sharply across the range we calculated with a 2.5 ms Gaussian pulse, and 
reaches a value of zero by the time the offset is moved beyond 1.8 ppm. Figure 12 
displays the STD spectral data used in calculation of fig. 2.11 as overlays. As can be 
seen, there are only three offset positions that produce non-zero STD values. 
 
Despite the 2.5 ms Gaussian side band (as seen in fig. 2.10) at an offset of 1.4 ppm 
delivering over 85% of the maximum excitation intensity, the equivalent point in in 
the negative control experiment in fig. 2.11 provided only a modest STD 
amplification factor of less than 10. Conversely the sideband at a 0.6 ppm offset is 
responsible for a significantly greater STD amplification factor. In combination these 
data suggest that although Gaussian pulse trains generate significant side bands, their 
effect on saturation and ability to provide accidental excitation in STD could be 
limited. The excitation sideband at 2 ppm in fig. 2.10 provides no control 
amplification in fig. 2.11 and suggests the small side band does not cause significant 
excitation of the ligand. The 1.8 ppm and 2 ppm offsets in fig. 2.10 correlate to 1.5% 
and 6.4% of the maximum excitation for a Gaussian pulse train respectively. Since 
both of these offsets provide zero STD amplification factor in the control experiment, 
they must be below the lower excitation limit where false positive data could occur in 
a 256 scan STD NMR experiment. 
 
2.4.4  The trade-off between bullishness and discretion 
Typically selective saturation is positioned to be applied around 0 ppm in order to 
excite protons of upshifted methyl groups within the protein. It is not unreasonable to 
suggest that efficiency of protein excitation has a direct influence protein saturation 
and hence STD signal of ligand. Optimal positioning of shaped excitation pulses with 
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respect to protein methyl protons clearly boosts efficiency.  This is something that 
should be striven for by anyone conducting an STD experiment, and is shown clearly 
in fig. 2.8 as the shaped pulse offset position is reduced, with respect to the nearest 
ligand resonance. This will be different for different ligands, but ligand methyl groups 
are typically most upshifted and hence usually the benchmark against which STD 
experiments should be optimised. In the unlikely case of a mixture of ligands with 
solely aromatic protons, much less caution can be exercised and significant gains are 
to be had by applying the offset position at a value above zero.   
 
The particular protein target used in STD experiments has an effect on optimisation of 
a shaped pulse, and larger proteins possessing greater numbers of upshifted methyl 
protons are amenable to shaped pulses with far larger offsets, by virtue of dipolar line 
broadening extending the protein excitation envelope. 
 
As a result of these factors, fig. 2.8 should be considered as data specific to the 
WGA/GlcNAc system, and STD optimisation should be tailored for each new 
protein-ligand system, something which is especially important when moving towards 
more quantitative STD NMR experiments(Angulo and Nieto, 2011, Kemper et al., 
2010a).  








2.4.5  Conclusions 
This chapter provides compelling evidence that Gaussian shaped excitation pulses can 
comfortably be shorter than 50 ms in length, and rationally placed in order to 
minimise direct excitation of the ligand. The approach illustrated here at 14.1 T with 
µRQ¶VFDQVDQGµRII¶VFDQVVKRZVKRZDPV*DXVVLDQSXOVHFDQEHSODFHG
as close as -1.8 ppm upfield from the nearest ligand resonance to provide the 
maximum saturation of the protein and deliver optimal STD amplification factors: up 
to nineteen times greater amplification factors than that obtained with a 10 ms pulse 
train. In light of the control experiments and if one wishes to exercise severe caution, 
it is suggested that the optimal signal is obtained with a 2.5 ms Gaussian pulse placed 
at 2.5 ppm away from the nearest ligand resonance. 
 
 
Broadly speaking, 1H STD NMR can be optimised by using shorter-length Gaussian 
shaped pulses that are rationally placed at relatively short offset distances from the 
closest ligand resonance. Our examples have measured STD amplification factor 
values over a range of offset positions in the presence and absence of protein to 
identify the optimum offset position for each pulse length. 
 
The increased efficiency in saturating the protein with shorter length pulses is due to 
exciting a larger population of upshifted methyl groups in the protein. Our work in 
this chapter certainly suggests that the widespread use of 20 ms and 50 ms Gaussian 
pulses in STD NMR in current practice is disadvantageous, and that the application of 
shorter-length pulses should certainly be considered, given appropriate checks on 




This approach described in this chapter could equally be applied to E-burp or other 
pulse schemes. Optimisation of any STD shaped pulse can dramatically improve the 

















Chapter 3  
 
Initial investigations into 
quantitative STD NMR 
spectroscopy with Heat 
Shock Protein 90 and 

















3.1 Introduction  
This chapter explores the concept of quantitative STD NMR (qSTD) and assesses its 
accuracy and application with respect to two fragment ligands of the therapeutic 
target Hsp90. The ability to infer information pertaining to a ligand binding mode 
simply from a series of 1D NMR experiments is an exciting prospect. Here it is 
shown that correlations are observed between experimental STD intensities and 
intermolecular proton-proton contacts between the ligand and protein. Hsp90 and its 
fragment ligands are an ideal model system to use for the investigations in this 
chapter as Hsp90 is an extremely well characterised protein, structures in both free 
DQG ERXQG IRUP DUH UHDGLO\ DYDLODEOH DQG LW¶V D VHWXS WKDW KDV SUHYLRXVO\ EHHQ
extensively explored by NMR.  
 
3.1.1 STD NMR as a screening tool  
 
The uses of STD NMR in a screening context are varied. To this day, basic STD 
experiments are used to evaluate the quality and suitability NMR fragment screening 
libraries(Doak et al., 2013),W¶VDOVRXVHGIRULGHQWLI\LQJFRPSRXQGVELQGLQJWRYLUXV
particles(Benie et al., 2003), and also for screening mixtures to characterise peptides 
binding to membrane proteins(Meinecke and Meyer, 2001). In these scenarios STD 
NMR is typically used in conjunction with a series of complementary techniques ± 
such as affinity chromatography, isothermal titration calorimetry (ITC), Surface 
Plasmon resonance (SPR) and x-ray crystallography.  
 
 






3.1.2 STD NMR for Group Epitope Mapping (GEM)  
 
The STD NMR experiment is a powerful experiment despite its principal 
functionality as a screening tool in industrial and academic research, it is often 
employed to infer the binding mode through a process called ³*URXS (SLWRSH
0DSSLQJ´(Mayer and Meyer, 2001, Mayer and James, 2004). Group epitope mapping 
enables the qualitative identification of parts of a ligand that are in closer contact with 
a protein receptor than other parts of the ligand. Historically, this has been utilised to 
investigate binding epitopes of carbohydrate ligands to receptors. 
  
All this has been made possible since the iQFHSWLRQRI WKH µEXLOG-up FXUYH¶ and the 
µDmplification factor¶(Mayer and Meyer, 2001, Mayer and James, 2004). As shown in 
fig. 3.1, a build up curve is achieved by plotting amplification factor against the total 
saturation time of the experiment. An amplification factor is a reflection on the size of 
an STD signal relative to that same signal in a reference spectrum (calculations shown 
in methods section). This is calculated for each individual proton of a ligand at a 
range of saturation times. The rate of the build up of this curve - gradient or initial 
rate - gives a distinct value that may be compared against those for other neighboring 













Careful analysis of the H3 proton in fig. 3.1 suggests a faster buildup than the OMe 
protons. This appears to be true across all concentrations, with the magnitude of 
signal reaching a maximum with the highest ligand ratio (100:1). This leads to the 
conclusion that the H3 proton is in receipt of greater saturation transfer from the 
Figure 3.1: STD amplification factor as a function of STD saturation time (s), 
LOOXVWUDWHGIRUSURWRQVRIȕ-GalOMe binding to Ricinus communis agglutinin I. Three 
different ligand concentrations (A) 0.5 mM, (B) 1 mM and (C) 4 mM were examined in 
the presence of 40 ȝ0SURWHLQ)LJXUHWDNHQIURP0D\HU	0H\HU(Mayer and Meyer, 
2001)) 
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protein, and is most likely orientated closer to the binding site than the OMe group in 
the ligand.  
 
 
3.1.3 Quantitative STD NMR of Hsp90   
Despite the increasing use of quantitative STD methods to solve pressing biological 
problems - such as elucidating the protein-peptide interactions of integrin 
ĮYȕ(Wagstaff et al., 2010), or analysing a complex between Ferredoxin-NADP+ 
reductase with its coenzyme(Antonini et al., 2014) - Heat Shock Protein 90 (Hsp90) 
remains an under-explored, fertile field to be ploughed with these tools. Given the 
advance of Hsp90 inhibitor lead compounds to late-stage clinical trials(Woodhead et 
al., 2010) there is now wider access to this well-characterised protein, along with 
access to more industrial data and information(Murray et al., 2010). As a result it feels 
both appropriate and timely to probe this protein further.  
 
Figure 3.2: Domain structure and cellular roles of Hsp90. Proteins highlighted in red 
indicate those that are known to be stabilized by Hsp90 (Ali et al., 2006, Moser et al., 2009) 
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Hsp90 is relatively large for a globular protein. ,W¶VIRXQGLQ bacteria and all branches 
of eukarya, but it is absent in archaea. Cytoplasmic Hsp90 is essential for viability 
under all conditions in eukaryotes (Chen et al., 2006, Prodromou et al., 1997). 
 
7KHRYHUDOOVWUXFWXUHRI+VSFRQWDLQVDPL[WXUHRIĮ-KHOLFHVȕ-sheets, and random 
coils. Such is its nature as a cytoplasmic protein, the protein is globular, largely non-
polar on the inside and polar on the exterior. Hsp90 contains nine helices and eight 
anti-parallel beta sheets, which join together to form numerous Įȕ
sandwiches. 310 helices comprise almost 11% of the protein's constitution, much 
higher than the average of 4% found in other proteins (Goetz et al., 2003).  
 
Hsp90 is a molecular chaperone that assists in the stabilization, folding, transport and 
maintenance of other proteins in the cell (Bukau et al., 2006). It possesses an N-
terminal ATP-binding domain (25 kDa), a middle domain (12 kDa), and a c-terminal 
domain (40 kDa).  
 
The region of the protein near the N-terminus has a high-affinity ATP-binding site. 
ATP binds to a large cleft in the side of protein, which is 15 Å deep (see figure 3.3). 
This cleft has a high affinity for ATP, and in the presence of a suitable protein 
substrate, Hsp90 cleaves the ATP into ADP and Pi.   
 
Several of the proteins stabilized by Hsp90 are implicated in cancer progression, such 
as RAF and MEK (Workman et al., 2007), and are known to drive aberrant cell 
division and cell survival. Its multi-functional role as the fulcrum of various 
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intracellular signalling pathways therefore makes it an attractive target for direct 
inhibition. 
 
Ordinary Hsp90 function depends on the conversion of ATP to ADP via the N-
terminal ATPase domain(Pearl and Prodromou, 2006). This nucleotide-binding site 
has been fully characterised crystallographically(Prodromou et al., 1997) and 
inhibition of this site has been shown to cause the down-regulation of the proteins that 
bind to Hsp90(Vilenchik et al., 2004). This was subsequently explored and elaborated 
upon by the Astex FBDD platform, and ultimately led to the development of 
AT13387 and late stage clinical trials. 
 
Figure 3.3: The crystal structure of the ATP binding site of Hsp90. ATP is shown as a 
ball and stick model, and negatively charged regions of the are shown in red (positive 
regions shown in blue). Figure taken from (Ali et al., 2006) 
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The N-terminal domain of the protein possesses a mass of 24.5 kDa. STD NMR 
spectroscopy is generally suited to scenarios wherein the protein receptor in question 
has a large mass. A large molecular weight ensures efficient spin diffusion, by virtue 
RI WKH ODUJH URWDWLRQDO FRUUHODWLRQ WLPH Ĳc), ensuring optimal saturation transfer 
between the protein and ligand.  
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3.2 Materials and Methods 
 
3.2.1 Protein Production and purification 
 
Hsp90 (N-terminal domain) protein was provided by Astex Pharmaceuticals after 
having been expressed and purified, as set out in the accompanying paper(Murray et 
al., 2010) +VSĮ ZDV FORQHG LQWR D S(7 YHFWRU DQG WKHQ H[SUHVVHG LQ %/
(DE3). The protein was purified using a Ni2+ affinity column, thrombin tag-cleaved, 
and then purified by gel filtration. 
 
The amino acid sequence for the Human Hsp90 protein (post thrombin cleavage) was 








3.2.2 Identification of the protein by Mass Spectrometry 
In order to confirm the identity of the N-terminal domain Hsp90 construct, the protein 
underwent electrospray time-of-flight (ESI-TOF) mass spectrometry at Astex 
Pharmaceuticals using an Agilent 1200 LC and Bruker MicroTOF mass spectrometer, 
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3.2.3 Fragment Ligands 
 
Astex Pharmaceuticals provided a range of fragment ligands. The focus of analysis 




Figure 3.4: Fragment ligands were provided as freeze-dried compounds 
that were subsequently diluted into 100 mM DMSO stocks. Numbers 
denote protons or proton groups. Fragments A and B are available as PDB 
structures at rscb.org 




3.2.4 NMR Experimental Setup 
 




ligand (DMSO final 2%) in 20 mM Tris, 100 mM NaCl, 1 mM DTT, and 15% D2O at 
pH 7.2. The ratio of ligand to protein for all NMR experiments was 100:1, unless 
otherwise specified. All experiments were carried out at 5 °C in order to optimise the 
efficiency of binding and achieve improved signal-to-noise. 
 
Samples for inversion recovery were prepared in exactly the same way for each 
individual ligand in the absence of protein. 
 
3.2.4.2 STD NMR 
 
STD NMR experiments were performed at 500 MHz using a Bruker DRX500 
spectrometer equipped with a TXI cryoprobe, using a standard Bruker STD sequence. 
67'105GDWDVHWVZHUHREWDLQHGRYHUVFDQVVFDQVµRQ¶DQGVFDQVµRII¶
saturation) with a 40 ms Gaussian shaped pulse (positioned at -3 ppm) and an 
extended relaxation delay of 7 seconds. Water suppression was achieved using a 
standard Bruker 3-9-19 WATERGATE sequence. Spectra were acquired with 16384 
data points and a spectral width of 12 ppm.  
 
Datasets were processed and analysed using Bruker Topspin 3.2 and absolute 
intensities quantified using MestReNova (Mnova). Intensities were used to calculate 
STD amplification factors (STDAF) from the STD difference spectra ሾܫௌ்஽ ൌ ሺܫ െ ܫ଴ሻሿ 
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and the control spectra ሺܫ଴ሻ  as has been previously described using the 
equation(Meyer and Peters, 2003):  
 ܵܶܦ஺ி ൌ ቀூೄ೅ವூబ ቁ ൈ ܮ݅݃ܽ݊݀ܧݔܿ݁ݏݏ     (Equation 6) 
 
Repeating the same STD experiment for a range of saturation times - between 0.5 and 
5 seconds ± enables the calculation of initial rates as laid out previously(Begley et al., 
2010). Buildup curves for all individual protons were fit to equation 7 by plotting 
STDAF against saturation time (t) using KaleidaGraph software: 
 ܵܶܦ஺ி ൌ ܵܶܦ஺ிெ௔௫ሺ ? െ ݁ି ௞ೄ೅ವ௧ሻ    (Equation 7) 
 
The initial rate (STDFit) is then determined by multiplying together the two 
KaleidaGraph output values for kSTD and STDAFMax, as this product is the first 
derivative of equation 7:  ܵܶܦி௜௧ ൌ ݇ௌ்஽ሺܵܣܨ஺ிெ௔௫ሻ   (Equation 8) 
 
The rate can also be determined by manually inputting a given pair of [x, y] co-
ordinates and a measured value for STDAFMax into equation 7 in order to solve for kSTD. 
The initial rate (STDFIT) is again then calculated by multiplying with kSTD. In addition 
WKHUHZDVDQµHUURU¶DVVRFLDWHGZLWKHDFKRIWKHVHYDOXHVLQ.DOHLGD*UDSKZKLFKZHUH
multiplied and used to calculate % error for each rate. These were used to determine 
the upper and lower bounds of the estimate for rate. 
 
3.2.4.3 Inversion Recovery for Longitudinal Relaxation Time constant (T1) 
 





Inversion recovery experiments were performed at 500 MHz using a Bruker DRX500 
spectrometer equipped with a TXI cryoprobe. Spectra were acquired with 8 scans, 
32768 data points, and a spectral width of 20 ppm. Datasets were processed and 
analysed with Bruker Topspin 3.2. For each individual sample a series of 15 
consecutive expHULPHQWVZHUHVHWXSZLWKGHOD\WLPHVĲHDFKRI
1.2, 1.4, 1.6, 1.8, 2, 2.2, 2.4, 2.6, 2.8 and 3 seconds. Each delay time results in a 
differing integral value (a broad range from negative to positive), which when plotted 
against delay time allows the data to be fit to equation 9 using KaleidaGraph: ܯ௧ ൌ ܯ଴ሺ ? െ  ?݁ି ಜ೅భ)    (Equation 9) 
 
 
The equation is then solved for T1, or given by KaleidaGraph. This T1 value extracted 
for each proton is unique, and is a reflection of the type of chemical environment a 
proton experiences.  
 
Calculating the T1 values allows for the second prong of this analysis, analyzing STD 
group epitope mapping considering relaxation of the ligand (GEM-CRL)(Kemper et 
al., 2010b, Kemper et al., 2010a). This depends upon acquiring a single set of STD 
values at a fixed saturation time, and then dividing each value by the T1 for each 
proton. This normalises the data and corrects for differences in longitudinal 
relaxation. In theory this information should be as useful as an initial rate. As part of 
this analysis all comparisons and association between experimental data and the 
binding site structure will include both initial rates and T1-adjusted data.  
 











3.2.5 Correlation of Experimental STD NMR data with Hsp90 structural data 
 
 
Building on from calculated STD initial rates (STDFIT), it is suggested in the same 
study thDW³1RUPDOLVHGSTDFIT values were taken as measures of distance-dependent 
saturation transfer efficiency and used to estimate relative distance between protein 
[Sic@DQGDOOUHVROYDEOHSURWRQVRQDJLYHQOLJDQGZKHQERXQG´(Begley et al., 2010). 
This gives an expectation that initial rates of STD buildup could be used in a fully 
quantitative way.  
 
However, in practice almost all studies normalise initial rates to the maximum STDFit, 
and express others as a percentage of this.   
Figure 3.5: An AutoDock conformation of a ligand bound to protein. Relative 
STDFit values for protons of the ligand (normalised to 100) are colour coded. Figure 
adapted from(Begley et al., 2010) 




Initial rates are usually utilized as a qualitative tool, an augmentation for other 
information, as exemplified by recent studies(Tanoli et al., 2013). In this particular 
instance in fig. 3.5 STDFit is used to corroborate an AutoDock pose in order to assess 
its general suitability(Begley et al., 2010). However, the approach herein is followed 
to gain more precise information. To begin with we take distance information from 
two publicly available PDB structures: 2XDK and 2XDL (Fragments  A and B) 
and probe deeper. All subsequent structural data comes from in-house Astex PDB 
files that are unpublished. All inter-proton distances discussed and explored in this 
thesis are listed in appendix B. 
 
The restraint measurements taken for comparison were the inter-proton distances 
between each individual proton of the ligand and all protons of side chains in the 
binding site, within 6Å. Each individual distance (r) was then processed as ଵ௥ల as NOE 
transfer is dependent to the reciprocal of the 6th power of distance. This lends greater 
weight to the saturation transfer pathways that are in close proximity(Neuhaus and 
Williamson, 1989). These were summated for each individual ligand proton to give an 
overall value for the sum of distances that might contribute saturation transfer. 
 
'RQRUPHWK\OJURXSVZHUHWUHDWHGE\µVXPDYHUDJLQJ¶IRUH[DPSOHLIWKHLQGLYLGXDO
distances between the three protons of a methyl group and a ligand proton were 6 Å, 5 
Å and 4 Å respectively, then this would be averaged to 5 Å and therefore treated as ଵሺହሻల.  
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In the case of methyl, methylene, or symmetrical recipient protons of the ligand, all 
saturation transfer signal is driven through multiple equivalent protons that appear at 
one frequency, yet there are multiple intermolecular proton-proton distances to deal 
with as given by the crystal structure. In this instance, any initial rate or T1-adjusted 
STD value is processed as usual, and the final value is then divided according to the 
proportions. For example, if one proton of a CH2 group possesses twice as many 
intermolecular pathways (as the sum of all 1/Å6) than the other, the experimental STD 
value (or rate) is divided in a ratio of 2:1 between them for the purposes of 
correlation. 
 
More accurately this can be expressed as: ሺܵܶܦ ൈ ݂ሻ where STD is an initial rate or 
T1-adjusted STD value, and f represents the fraction of the total cumulative distances 
that a particular proton provides (as the sum of 1/Å6), from all protons in the group. f 
is a different fractional value for each proton, but all add up to 1. The merits of this 
approach shall be discussed later.  
  




3.3.1 Identification of the protein by Mass Spectrometry 
 
The UV chromatogram output from the LC-MS yielded a single peak containing a 
single protein species with an elution time of 20.5 minutes.  
&
Figure 3.6: Hsp90 LC-MS and accompanying spectrum for Hsp90 
UV and Total Ion Chromatogram (TIC) 
Raw Mass Spectrum 





The distribution of multiply charged species in fig. 3.6 is consistent with the singly 
charged species (shown in fig. 3.7). However the final mass is 147 Da short of the 
expected mass (24508.7 Da). Given the protein sequence this is likely due to N-
&
Figure 3.7: Deconvoluted mass spectrum showing the singly-charged species 
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terminal cleavage of the GS dipeptide (mass 144 Da, a legacy of thrombin cleavage. 
Protein sequence begins at the first D residue). An alternative and less likely 
explanation is that is could be the result of a missing C-terminal glutamic acid 
residue. 
 
Neither of these modifications is likely to alter protein folding and neither of these 
residues is considered to play a role in the binding site.  
 
3.3.2 Initial Rate of STD buildup as shown for Fragment A 
Consecutive STD experiments (as in fig. 3.8) with different saturation periods (0 ± 5 
seconds) were applied to Fragment A.  
Figure 3.8: An example of an STD reference and difference spectrum for fragment 
A bound to Hsp90, in this instance acquired at a saturation time of 5 seconds. The 
absolute intensities of each peak are measured and applied to the STD 
amplification factor formula 
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The data were fit to give values for initial rates (fig. 3.9A) 
 
B 
Figure 3.9: Data acquired for each proton were processed as amplification factors 
(A) and fit to the curves to give the initial rates in (B). Protons 5 and 2 clearly have 
the steepest initial rates, whilst proton 6 clearly receives the least. Rates and errors 
as calculated by Kaleidagraph. 
A 






The STD values are typically normalised as a percentage of the maximum value. For 















More interesting is to quantify all the individual interactions. As is clearly observable, 







Figure 3.10: Initial STD rates normalised in percentage terms. 
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A positive correlation may be observed between the sum of the intermolecular proton-
proton distances and the initial rate of STD build up. This is an interesting result, and 
appears to be the first time anyone has ever tried correlating the two variables to this 
degree of accuracy. 
Given a reasonably high-resolution crystal structure, we are thus able to show that 
experimental STD NMR data has a direct relationship with the structure of the 
binding site. 
Figure 3.11: The initial rate of STD build up for the 6 individual protons of 
Fragment A plotted against the sum of the intermolecular proton-proton distances, 
as derived from the crystal structure (methodology explained in section 3.2.5, three 
dimensional structure in fig. 3.32).  
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3.3.4 Inversion Recovery for Longitudinal Relaxation Time constant (T1) and its 
application in the GEM-CRL method 
The inversion recovery experiment was performed for Fragment A with the data 



















After obtaining the experimentally determined T1 values, it is now possible to assess 
STD data without having to consider the rate of build up over a series of saturation 
times. The T1 values are fairly similar, but they are subtly different enough to cause 
distortions in the STD signal recorded at a given saturation time. A proton with a 
Figure 3.12: 1H Inversion recovery data for Fragment A. All T1
 
values are 
similar, as is to be expected for all aromatic protons. The small 
differences in T1
 
can be observed in the rate of the curves 
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shorter T1 decays faster during the sequence and inadvertently reduces the STD 
intensity. This manifests itself most clearly at longer saturation times.   
 
Figure 3.13 shows the effect of modulating STD amplification factors for protons 
according to their respective T1 values, by dividing STD amplification factor by the 















Within each proton grouping, STD buildup is observed as the saturation time 
increases, and for each saturation time, the patterns across the amplification factors 
remain consistent.   
Now it is prudent to analyse this T1-adjusted data in the same way as we did for the 
STD initial rates previously, in the context of the structural data. 
Figure 3.13: 1H T1
 
-adjusted STD amplification factors for each proton of 
the ligand, across all saturation times 




Figure 3.14: (A) STD amplification factor ± adjusted for T1 ± plotted against the sum of the 
intermolecular proton-proton distances for each individual proton (as derived from PDB 
2XDK), at each of the ten saturation times. The same positive correlation between the two 
variables may be observed, and this is maintained across all of the saturation periods, as 
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Fig. 3.14A shows the correlation between the sum of the intermolecular proton-proton 
distances for a given proton, and the T1-adjusted STD.  
 
To support these findings, the same analysis was carried out for five further fragments 
(B ± F) known to bind to Hsp90. From this, it was suspected that similar trends might 
be observed. First though, I will walk through the case of fragment B, in order to 
explain how we dealt with ligands that possess methyl and methylene groups 
 
3.3.5 Fragment B 
STD spectra were acquired for the usual set of saturation times (0.5 s ± 5 s). Fig 
3.15A and 3.14B are example spectra acquired with five seconds saturation.  
B 
A 
Figure 3.15: STD difference (A) and reference (B) spectra for fragment B binding to Hsp90 
chemical shift / ppm 
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As with fragment A the STD build up curve is constructed by plotting the 




















Quantitative STD with a fragment such as fragment B necessitates some additional 
treatment. For the correlation of the intermolecular structure as in fig 3.16 it was 
essential to split the initial rate for proton groups 7 and 5. These protons belong to 
Figure 3.16: STD buildup curves for fragment B in the presence of Hsp90 (A), and (B) 
correlation of STD initial rates with the sum of the intermolecular proton-proton contacts 
A 
B 
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methyl groups and as such comprise three protons. This is reflected in the 
significantly steeper initial rates for these groups. In order to deal with cases such as 
these, the initial rate was divided into three values, in proportion with the 
intermolecular distance values for each individual proton as derived from the crystal 
structure. In this particular example it is worth noting that the similarity of the initial 
rates for proton groups 5 and 7 could be due to amide bond rotamer exchange, which 
may be distorting the rate values.  
The same division treatment applies to T1-adjusted STD values. The T1 for the whole 
group is used to divide the STD for the whole group, the final values which is then 
divided in the appropriate proportions. This is explained in the methods section.  
 
It may also come to your attention that two proton groups, the methylene proton 
groups of the ethylamide, do not feature in the analysis. The reason for this is because 
the STD signal for these groups is not sufficiently strong to measure, and also 
happens to fall in a chemical shift range that is obscured by biological buffers. 
 
In terms of the T1-adjusted STD method the same principles as fragment A may be 








Figure 3.17: Inversion recovery curves for fragment B 
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As with before, the T1 values derived from inversion recovery experiments can be 
used as a factor to divide STD amplification factor values at all saturation times. 























Figure 3.18:  (A) T1-adjusted STD amplification factors for all protons of 
fragment B. (B) these values plotted against intermolecular structure to 
provide a similar correlation as initial rate  
A 
B 
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Figure 3.19: Example STD difference (A) and reference (B) spectra for fragment C binding 




Figure 3.20: STD build up curves for fragment C binding to Hsp90 
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Fig 3.21A shows how there is a strong positive correlation between the initial rates of 
STD build up and the sum of the intermolecular proton-proton contacts. Inversion 
recovery data enabled calculation of accurate T1 values that were then used to 
modulate STD values at each fixed saturation time. As fig 3.21D shows, these T1-
adjusted STD values also correlate very well with intermolecular structure, at all 








Figure 3.21: (A) Correlation of STD initial rates for fragment C with Hsp90 structure. 
(B) Inversion recovery curves for fragment C and associated T1 values. (C) T1-adjusted 
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Figure 3.22: Example STD difference (A) and reference (B) spectra for 
fragment D binding to Hsp90 
A 
B 
Figure 3.23: STD build up curves for fragment D binding to Hsp90 
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STD build up curves for fragment D in the presence of Hsp90 are reasonable, with a 
fairly large degree of error caused by the points at 2 and 4.5 seconds (visible in fig. 
3.23). Nonetheless, a reliable positive correlation is still observed with structure in fig 
3.24A. Again, accurate inversion recovery experiments yielded reliable T1 results, 







Figure 3.24: (A) Correlation of STD initial rates for fragment D with Hsp90 structure. (B) 
Inversion recovery curves for fragment D and associated T1 values. (C) T1-adjusted STD 
values at each fixed saturation time, and (D) these values correlated against intermolecular 
structure 
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Figure 3.25: Example STD difference (A) and reference (B) spectra for 
fragment E binding to Hsp90 
A 
B 
Figure 3.26: STD build up curves for fragment E binding to Hsp90 
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STD build up curves for fragment E are reasonable (see fig. 3.26), as are the initial 
rates derived herein. Again a good correlation is made between these rates and 
intermolecular structure (fig 3.27A). A similar trend may be observed with T1-





Figure 3.27: (A) Correlation of STD initial rates for fragment E with Hsp90 structure. 
(B) Inversion recovery curves for fragment E and associated T1 values. (C) T1-
adjusted STD values at each fixed saturation time, and (D) these values correlated 
against intermolecular structure 
A B 
C D 
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Figure 3.29: STD build up curves for fragment F binding to Hsp90 
chemical shift / ppm 
A 
B 
STD Difference spectrum 
STD Reference spectrum 
Figure 3.28: Example STD difference (A) and reference (B) spectra for fragment F 
binding to Hsp90 
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STD build up curves in fig. 3.29 show a set of very smooth fits and this is reflected in 
the initial rates with very small associated error. Correlation between initial rates and 
structure is broadly positive, bar one data point of proton group 2. Inversion recovery 
curves in fig 3.30B are good and give a varied range of T1 values. Correlation of T1-
adjusted STD values with intermolecular structure is similar if not slightly weaker 
than that caused by initial rates (fig 3.30D). 
 
 
Figure 3.30: (A) Correlation of STD initial rates for fragment F with Hsp90 structure. (B) 
Inversion recovery curves for fragment F and associated T1 values. (C) T1-adjusted STD 









3.4.1 Initial observations based on fragment A 
 
3.4.1.1 Initial rate of STD buildup  
 
The curiosity piqued by the ease with which STD NMR data for Fragment A could be 
quantified - and used to produce six unique initial rate values for six unique protons - 
led to pursuing if there were any correlations with the crystal structure. 
 
The buildups and initial rates in fig. 3.9A and 3.9B allow for a unique comparison 
with the crystal structure in fig 3.11. Plotting initial STD rates against the sum of 
intermolecular proton-proton contacts, using restraints measured from the crystal 
structure. This plot suggests there is a definite correlation between the rate of 
saturation transfer and the position of protons in the ligand, relative to amino acid side 
chains that comprise that binding site. The correlation is made on the basis of 6 
protons, but it is clear and unambiguous. 
 
Alternatively, it is possible to simply compare against the single shortest 
intermolecular proton-proton distance. In this instance, as shown by fig. 3.31, the 
correlation is very similar, and emphasizes the importance and distance dependence 








The graph in fig. 3.31 provides a simple correlation without scouring restraints from 
the crystal structure. As expected, it is a mirror image of fig 3.11, and illustrates the 
significance of the single closest magnetisation transfer pathway. 
 
 
The STD values are typically normalised as a percentage of the maximum value. For 





Figure 3.31: Correlating initial rate data with the single-shortest intermolecular proton-
proton contact. The nearest amino acid residue is highlighted for each proton  




Presenting the information in this manner is not very informative regarding fragment 
orientation, due to the relatively small number of unique protons. However, the data 
does suggest the side of the fragment containing proton 6 is not the primary contact 
side. However, even suggesting this is not particularly insightful, because the Hsp90 
ADP binding site is a 15 Å deep pocket(Prodromou et al., 1997, Schulte et al., 1998), 
allowing for many different orientations of a small fragment.  
 
Quantifying all the individual interactions, as our analysis has focused on, is much 
more informative for small fragments binding to a protein such as Hsp90.  
 
3.4.1.2 1H T1-adjusted STD data 
 
Similar conclusions exist for the T1-adjusted STD data as apply to initial rate data. 
This can be evidenced by the correlations with intermolecular structure in figs. 3.14A, 
3.18B, 3.21D, 3.24D, 3.27D and 3.30D (for fragments A ± F respectively). The 
Figure 3.32: Initial STD rates normalised in 
percentage terms.  
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correlation between the T1-adjusted STD - at any given saturation time period ± and 
the distance restraints is consistently equally as good as that between the restraints 
and the initial rate.  
 
3.4.2 Observations across the 5 subsequent fragments 
 
Generally speaking, the same patterns for fragment A are observed across the full 
spectrum of fragments that were examined. This is what provides the most weight to 
any conclusions: the patterns are repeated in subsequent investigations with fragments 
B - F. 
 
Intense STD signals were observed from protons at the tip of the phenyl rings of 
fragments C, E and F (protons 4, 4 and 6 respectively). Conversely the single proton 
adjacent to the nitrogen atom in the pyrazole ring consistently received less saturation 
transfer (protons 1, 1 and 3 respectively). This cannot be circumstantial, but must 
relate to binding mode similarities and the precise shape of the binding site 
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3.4.3 Examining experimental STD data in the context of overall structure 
 
The novel aspect of this work is the comparison of experimental STD NMR data 
directly up against atomic-resolution structural data, and so it is appropriate to look at 




For fragments, the Hsp90 binding site is particularly large (15Å deep(Prodromou et 
al., 1997)DQGVRLWLVQRWSRVVLEOHWRVLPSO\VD\VRPHWKLQJVXFKDV³RQHKDOIRIWKH
ligand protrudes whilst the RWKHU LVEXULHG´$VVKRZQ LQ ILJ3, protons 2 and 5 
receive the largest saturation transfer, yet exist at opposing ends of the binding site; 
Figure 3.33: Fragment A bound in the Hsp90 crystal structure, with the relative degrees of 
saturation of individual protons on the right. Lines emanating from proton 5 represent inter-
proton distances between it and atoms of the protein within 6 A.  
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orientation would not be possible to deduce on this basis. Therefore, the experimental 
STD data is not capable of inferring ligand orientation on its own. 
 ,W¶V D VLPLODU VWRU\ ZLWK WKH S\UD]ROHV IUDJPHQWV & ( DQG ) WKDW ZHUH DQDO\VHG
Overlays of the ligands of the crystal structures are shown below. The protons within 
WKH UHG FLUFOHV DUH PRUH ³67' GRPLQDQW´ Ln terms of the saturation transfer they 
receive, as derived from the experimental STD data. 
 
Again, looking at the surface image (fig 3.33) it may seem counter-intuitive that two 
SURWRQVIURPRSSRVLWHHQGVRIWKHOLJDQGFDQEH³67'GRPLQDQW´&ORVHUDQDO\VLVRI
the amino acid side chains involved in these saturation transfer pathways makes it 
clearer. 
 
In the case of the proton at the tip of the phenyl ring (at the bottom in fig. 3.34A and 
3.34B), these have the shortest intermolecular pathways to L107 and F138 for 
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saturation transfer (highlighted in fig. 3.34A and 3.34B). Methionine 98 (not shown) 
provides the main STD pathway for the circled protons at the top of the molecule 
(methyl group).  
 
However, an observation of fragments C, E and F overlaid as in fig. 3.35 did open the 




3.4.4 Binding mode clustering 















Figure 3.35: Overlay of the crystal structures of bound pyrazole 
fragment ligands C, E and F to Hsp90  
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When fragments of a particular chemotype from a screening library are known to bind 
to a protein, there is a very high probability that they bind in a similar mode. In the 
screening library from which these fragments were selected there were multiple 
chemotypes including phenols (such as fragment B) and aminopyrimidines (such as 
fragment A).  The pyrazoles were interesting to analyse simply because there were so 
many of them that bound with a reasonable KD, and with good solubilities.  
 
As fig. 3.35 shows, all pyrazoles in this analysis bind with the same mode. Assuming 
the STD analysis thus far is correct, one would expect to see equivalent protons 
ZLWKLQWKHS\UD]ROHFKHPRW\SH³OLJKWXS´RUUHFHLYHFRPSDUDEOHVDWXUDWLRQWUDQVIHU
This is indeed the case with these fragments.    
 
This is a useful approach, particularly if specific screening hits cannot be validated by 
crystallography.  
 
With a set of initial rates from buildups, or T1-adjuted STD values, I am suggesting 
that you can say - with confidence - whether or not the binding mode of a particular 
fragment falls into line with binding mode of the others within the chemotype.   
  
&RQYHUVHO\WKLVDOVRPHDQVWKDWDQ\µURJXH¶ELQGLQJPRGHVKRXOGEHHDV\WRLGHQWLI\
from its own STD pattern. A case in point is the additional fragment G (yellow in fig. 
3.36) that binds in the same mode with respect to the pyrazole group, but the phenyl 
ring is clearly displaced relative to the other fragments. This should manifest itself as 
either a reduction or an increase in the STD to the tip of the ring, relative to the other 
fragments. This gives a powerful insight into binding mode from relatively primitive 
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data. In practice this particular fragment could not be tested due to not being soluble 














3.4.5 Caveats and situations in which the method may not be applicable 
 
3.4.5.1 Dealing with experimental data of methyl, methylene or symmetrical protons 
In assessing the reliability and validity of these results (particularly with respect to 
fragments B, D, E and F) it is of course prudent to ask questions about the treatment 
of the experimental data - whether that be initial rates or T1-adjusted STD values - for 
the protons of the methyl & methylene groups, as well as the protons that are 
symmetrical or equivalent in the spectrum.    
 
Figure 3.36: Additional fragment G overlaid with the other 
S\UD]ROHVµ(TXLYDOHQW¶SURWRQVDWWKHWLSRIWKHSKHQ\OULQJFLUFOHG
red) should have different STD properties 
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It is clear that the most reliable data shown thus far relate to Fragments A and D. This 
is simply because these data represent a straightforward case of one proton versus one 
distance measurement. The results of fragments A and D require no alternative 
treatment whereas fragment B, C, E and F do. Fragments B and F possess methyl 
JURXSV ZKHUHLQ WKH µLQIRUPDWLRQ¶ IRU WKUHH SURWons is driven through one chemical 
VKLIW$VH[SODLQHGHDUOLHUIRU WKHVHZHWDNHDµVXPDYHUDJLQJ¶DSSURDFKDQGGLYLGH
data to take into account multiple proton contributions. Fragments C, E and F possess 
symmetrical protons where the information for two protons is encoded in one 




adjusted STD data points in a correlation that have been created by division of an 
experimental value, as with methyl or symmetrical protons), the points made about 
binding mode clustering still hold.  
 
Finally, it is also worth mentioning that there is considerable doubt surrounding the 
validity of simply taking proton-proton measurements from a crystal structure. The 
crystal structures in question are all solved to a resolution of 2 Å or better. However 
this relates to the position of all non-hydrogen atoms fit to the electron density. The 
position of protons ± added internally by Astex ± is unlikely to be perfect despite the 
virtues of stereochemistry. This, allied with the knowledge that a crystal structure is a 
merely snapshot in time of a protein-ligand complex (and not to mention, represents 
the complex at an extremely cold temperature, hence no dynamics), suggests that all 
results should be treated with caution. 




However, it cannot be ignored that the power of these findings is that they are 
repeatable across a range of fragments, and indeed across multiple proteins, as we will 
see later on.    
 
3.4.6 INPHARMA 
The INPHARMA method is another ligand-observed NMR tool considered to be 
useful and informative regarding protein-ligand binding modes(Dias and Ciulli). 
INPHARMA can help determine the relative binding orientation of two ligands that 
compete to bind to the same binding pocket on a particular protein(Orts et al., 2009, 
Sanchez-Pedregal et al., 2005). If the orientation of one ligand is known, this infers 
upon the binding mode of the other competitive ligand by intermolecular NOE 
transfer to the other, mediated by the protein. Inter-ligand NOEs by INPHARMA 
depend upon running a NOESY experiment with a long mixing time. 
Figure 3.37: NOESY experiments are run with pairs of competitively binding ligands. 
INPHARMA inter-ligand NOEs are observed as small NOEs between competing ligands. 
This occurs between regions of ligands that bind in the same part of a protein pocket    
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The experimental rationale is illustrated in figure 3.37. We decided to test out the 
INPHARMA principle using two fragment ligands used to investigate binding to 
Hsp90, fragments A and B, and use it as a method against which we could directly 
compare STD NMR.  
 
After trialing a series of conditions only two sets of experimental conditions yielded a 
single INPHARMA NOE, and in both cases the same NOE. The samples were 
prepared as typical STD experiments (see earlier in this chapter) and NOESY 
experiments acquired with 16 scans (5 hours) and 2048 x 256 data points at 275K. In 
one case the sample was prepared in 90% H2O and 10% D2O, and the other prepared 
in 100% D2O. In both instances the NOESY experiment was run with a 1 second 
mixing time. 
 
A suspected INPHARMA NOE between fragments A and B is shown below in figure 
3.38. 
 

















Figure 3.38: NOESY experiment for Hsp90 in the presence of two competitive binding 
fragment ligands. Fragment ligands are shown (A) and INPHARMA NOE shown in (B) 









  Quantitative STD with Hsp90 
 
 120 
The majority of NOEs are clearly intra-molecular, but at ~(8.25, 1) ppm a small cross 
peak is observed. This is observed to be between protons 5 and 7, of fragments A and 
B respectively. No other intermolecular NOEs could be seen under any conditions. 
 
The plausibility of this INPHARMA NOE was assessed by overlay of the bound 












Figure 3.39: (A) fragments A (cyan) and B (yellow) overlaid according to the 
bound crystal structures with Hsp90. Fragments A (B) and B (C) bound to 
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The closest protein side chain to both of these protons is Methionine 98, so an 
INPHARMA NOE between these two protons is certainly plausible, as agreed by the 
overlays in fig. 3.39A. However, the relative binding modes would expect to produce 
many more intermolecular NOEs than just the one. 
 
After correspondence with members of the structural and computational group at 
EMBL (Heidelberg) they too suggest that more INPHARMA NOEs should be 
observable. However they state that their attempts with ligand binding to Hsp90 also 
proved fruitless, and attributed this to the fact that although their ligands bound with 
micromolar dissociation constants, the koff was too low in their case.  
 
I would suggest that this is a severe limitation of the method, and along with the 
knowledge that single NOESY INPHARMA experiments are routinely known to take 
24 hours, this surely reduces the efficiency of the method and reduces the extent to 
which one may apply the method to other protein-ligand problems. On this basis, 
quantitative STD appears in a relatively favourable light, in terms of how much 
information may be weaned from experiment and how efficient the methods are. 
 
Alternative methods exist to try and maximize the INPHARMA NOE signals. 
Recently hyperpolarization techniques have been developed to overcome the 
inherently low sensitivity of a two-step NOE transfer(Lee et al., 2012).  The 
³K\SHUSRODUL]HGELQGLQJSRFNHW12(´WHFKQLTXHLQYROYHVK\SHUSRODUL]LQJRQHOLJDQG
dissolving it in heated D2O and then immediately injecting it into a pre-prepared 
sample of protein and partner ligand. This could well be one option to attempt, but it 
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seems a rather large amount of effort to go to, especially in light of how easy it is to 












Quantifying data from 
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4.1 Introduction  
This chapter investigates the Water-Ligand Observed via Gradient SpectroscopY 
(WaterLOGSY) experiment and attempts to quantify LOGSY data using a similar process as 
was done for the quantitative STD experiments, based on initial rates of LOGSY signal build 
up.  LOGSY is predominantly used as a screening tool in FBDD, but this chapter illustrates 
attempts to obtain more useful information from the experiment, and interpret any 
subsequent findings.  
 
 
4.1.1 WaterLOGSY  
As described in the main introduction, WaterLOGSY(Dalvit et al., 2000) is another ligand-
observed NMR screening technique. In this experiment selective saturation is targeted at 
bulk water, and the water magnetisation is transferred to the ligand via the protein.  
 
In this chapter we deal with ligands that are all validated hits for Hsp90 and are certain that 
all bind to the target protein. As a result, we are less preoccupied with the binary question of 
whether or not something binds, but are more interested in other properties of these binding 
events, that will become evident.  
 
 
4.1.2 Current uses for the WaterLOGSY experiment 
LOGSY was used as the primary screening tool in the development of the Hsp90 inhibitor 
AT13387(Murray et al., 2010). Here, 1600 compounds from a fragment library were 
VFUHHQHG LQ FRFNWDLOV RI IRXU &RPSRXQGV ZHUH GHILQHG DV KDYLQJ D µPHGLXP¶ RU µVWURQJ¶
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LOGSY signal if the largest aromatic signal in a particular LOGSY difference spectrum 
(generated as explained below) was greater than > 10% (medium) or > 20% (strong) of the 
same signal in a 1D spectrum. Compounds passing either of these barriers then underwent 
LOGSY in competition mode wherein they were individually screened in the presence of 
ADP ± known to bind weakly to the ATP-ase domain of Hsp90 ± and displacement of the 
ADP LOGSY signal was monitored. Ultimately 1600 compounds were reduced to only 125, 
simply on the basis of the WaterLOGSY experiment. 
 
Another example of LOGSY as a screening tool is a study that took a library of 2000 
FRPSRXQGV WR VFUHHQ DJDLQVW WKH NH\ $O]KHLPHU¶V GLVHDVH WDUJHW ȕ-secretase (BACE-
1)(Geschwindner et al., 2007). Again LOGSY was used as the initial step to narrow the field 
down before compounds were characterised by BIAcore (SPR). A relatively low overall hit 
rate of 0.5% was reported for compounds that bound with modest affinities in the low 
millimolar range.  
 
There are several examples involving LOGSY in the scientific literature, but as yet the 
experiment has not been considered in any real quantitative terms. Armed with the Hsp90 
protein and a series of fragment ligands, we are in a position to speculatively explore the 
possibilities of quantifying data from LOGSY experiments, using the same exact samples 









At high concentrations of ligand the free ligand becomes dominant. This needs to be 
corrected by running an identical parallel experiment in the absence of protein. The 
maximum differences in signal are attained with high concentrations of ligand, but without 
the control sample this would not be obvious (see fig. 4.1).  This forms the basis of all 














Fig. 4.1 illustrates that differences in signal intensity between samples with and without 
protein provide the biggest and most equitable signal. If examined in isolation without 
considering any control spectrum, any single signal in a LOGSY spectrum could appear 
vanishingly small or even negative. This is why it is essential to run a ligand-only control in 
SDUDOOHODQGDQDO\VHWKHGLIIHUHQFHEHWZHHQWKLVDQGWKHµZLWKSURWHLQ¶VDPSOH 
Figure 4.1: LOGSY signal intensity for one proton - for a fixed 
protein concentration (10 ɊM) - as a function of ligand 
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4.1.4 Quantification of LOGSY NMR signal magnitude ±  
4.1.4.1.SALMON ± Solvent Accessibility, Ligand binding, and Mapping of ligand 
Orientation by NMR spectroscopy(Ludwig et al., 2008) 
Before our analysis that forms the basis of this chapter, researchers had previously set up an 



















 Figure 4.2: 1D spectrum (top) of ligand CB1954 and LOGSY spectra (bottom) 
of both free ligand (black) and bound ligand (grey). Arrows illustrate 
differences in signal intensity caused by the presence of the protein. Figure 
adapted from Ludwig et al(Ludwig et al., 2008) 
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Two spectra were acquired ± on both LOGSY sample and ligand-only reference sample ± at 
800 MHz with a NOESY mixing time of 1.2 s.  
 
Their publication suggests that the change in sign of the H3 and H6 signals is typical of 
binding, and they are intrigued by the fact that the signal of the aziridine group protons does 
not change sign. They attribute this fact to the aziridine group protruding from the protein 
and being more accessible to bulk water. However, I believe they are missing a key aspect of 
this data; indicated by the red arrow in fig. 4.2: whilst the H3 and H6 protons appear to 
qualitatively change sign, there is a difference in their signals that can actually be measured 
and fully quantified. On this basis, the same treatment can be applied to the aziridine signal, 
despite the fact that both signals are qualitatively negative. The aziridine signal does not 
change sign, but is clearly reduced, and this change can be measured. This one key 
difference between the approaches of the SALMON methodology and how we approach the 
matter; we aim to quantify signals absolutely and observe any possible trends.    
 
It is also worth noting that the authors concluded by suggesting that simple interpretation of 





Furthermore the analysis does not provide an explanation of how to deal with proton groups. 
For the purposes of the ligand CB1954, this does not matter ± since only the aziridine group 
possesses more than one proton ± EXW DV LQ WKH TXDQWLWDWLYH 67' FKDSWHU LW¶V D SUREDEOH
scenario and addressed in the methods.  
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4.1.4.2.Increasing the NOE mixing time of a LOGSY experiment 
 
Increasing the NOE mixing period of a LOGSY experiment is known to cause increases in 
signal magnitude. This idea is illustrated in fig. 4.3 for three protons of a ligand binding to 
protein.  
Immediately visible on the above example spectrum shows that two peaks LQ WKH µZLWK
SURWHLQ¶/2*6<VSHFWUXPDUHSRVLWLYHZKHUHDVWKHUHPDLQGHUDUHQHJDWLYH2IFRXUVH WKLV
GRHVQ¶W PDWWHU RQFH WKH UHIHUHQFH VSHFWUXP LV WDNHQ LQWR DFFRXQW EXW LV DQ LQWHUHVWLQJ
observation nonetheless. The second point is how adjusting the NOE mixing time alters the 
size of the subsequent signal. All signals become either more positive or less negative as the 
mixing time is increased. This phenomenon is well documented from the original ePHOGSY 
experiment(Dalvit et al., 2001) and suggests that this is a variable that we can examine as 
part of our analysis. 
Figure 4.3: An example of both a LOGSY and a control spectrum for a fragment ligand 
bound to Hsp90. Three proton resonances are shown. The difference between experiments 
allow a subtraction which then gives a resultant difference spectrum 
With Protein 
Without Protein 
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4.2 Methods 
4.2.1 Protein production and purification 
Human Hsp90 protein was provided as explained in chapter 3 section 3.2.1. 
4.2.2 Fragment ligands 
The identity of the fragment ligands used in this chapter is the same as in chapter 3.  
 
Figure 4.4: Fragment ligands were provided as freeze-dried compounds that were 
subsequently diluted into 100 mM DMSO stocks. Numbers denote protons or 
proton groups. Fragments A and B are available as PDB structures at rscb.org 
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4.2.3 NMR Experimental Setup 
 
4.2.3.1 Sample Preparation 
 
 
The samples examined by LOGSY NMR were the same as were used for quantitative STD 
DQDO\VLV7KHVHZHUHSUHSDUHGDVȝ0+VSSURWHLQDQGP0IUDJment ligand (DMSO 
final 2%) in 20 mM Tris, 100 mM NaCl, 1 mM DTT and 15% D2O at pH 7.2. The ratio of 
ligand to protein for all NMR experiments was always 100:1, unless otherwise specified. All 
experiments were carried out at 5 °C in order to optimise the efficiency of binding and 





LOGSY experiments were performed at 500 MHz using a Bruker DRX500 spectrometer 
equipped with a TXI cryoprobe. LOGSY experiments were carried out using the ePHOGSY 
sequence of Dalvit et al.(Dalvit et al., 2000) incorporating a CPMG period of 10 ms. 
Experiments were performed over 512 scans (plus 8 dummy scans) and spectra acquired 
with a TD of 16384 and a spectral width of 12 ppm. 
 
1H spectra were referenced to 3-(Trimethylsilyl) propanoic acid (TSP). Data was processed 
and analysed using Bruker Topspin 3.2. LOGSY difference spectra were generated by 
subtraction of LOGSY spectra from companion reference spectra, and signals were 
quantified by integration of each resolvable peak where no overlaps were present.  
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4.2.4 Varying the NOE mixing period and calculation of initial rates 
 
As explained previously, it has been observed that increasing signal is achieved by 
increasing the NOE mixing period, which can be attributed to the fact that WaterLOGSY 
experiments constructively use all magnetisation transfer processes to maximize 
magnetisation transfer to ligand. As a result it was decided to attempt to measure the 
integrals for all protons across a range of LOGSY experiments with increasing NOE mixing 
periods (0.3, 0.5, 0.8, 1.0 and 1.2 s). 
 
From this we expected to observe LOGSY build up, therefore data was processed in a similar 
manner to STD data. LOGSY differences as absolute integrals (as opposed to an STD 
amplification factor) were plotted against the NOE mixing time (as opposed to saturation 
time), and curves fit to the same equations as previously used to calculate the initial rate of 
STD build up (see section 3.2.4.2): ܮܱܩܵ ஽ܻ௜௙௙ ൌ ܮܱܩܵ ஽ܻ௜௙௙ெ௔௫ሺ ? െ ݁ି ௞ಽೀಸೄೊ௧ሻ  (equation 10) 
:KHUH µ/2*6< GLIIHUHQFH¶ VLJQDOV ZHUH VXEVWLWXWHG in place of STD amplification factor 
and NOE mixing time substituted for saturation time. 
 
It was decided to use integrals rather than intensity from peak height due to the line 
broadening that can be associated with a binding event, which would have led to 
inaccuracies in the subtraction event. With STD experiments peak heights are suitable to 
PHDVXUH VLQFH LW LV WKH VDPH SK\VLFDO VDPSOH WKDW LV XVHG WR JHQHUDWH ERWK µRQ¶ DQG µRII¶
resonance spectra. 
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4.2.5 Treatment of methyl, methylene and symmetrical protons of the ligand 
 
As we must again deal with cases wherein individual chemical shifts encode the data of more 
than one proton, concessions need to be made in our treatment of the data. Whereas 
assessing quantitative STD data against actual structural restraints in the previous chapter 
enabled us to split processed rate values in proportion with distances derived from the 
structure, here we have no such information to guide our analysis.  
 
As a result, here we have simply divided by the number of protons in the group. So a 
thHRUHWLFDO UDWH RI ³´ IRU D PHWK\O JURXS ZRXOG EH SURFHVVHG DV D UDWH RI ³´ IRU HDFK
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4.3 Results 
4.3.1 Quantitative LOGSY for fragment A 
Fragment A LOGSY spectra in fig. 4.5 shows positive LOGSY signals in the presence of 
Hsp90 (A) before subtraction for protons 5 and 3, but is negative for the remainder. The 
difference spectrum shows all protons positive with varying intensities. Acquisition of the 
above spectra at varying mixing times allows for production of buildup curves in fig. 4.6A. 
 
Figure 4.5: LOGSY (A), control (B) and LOGSY difference (C) spectra for 
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Protons 5 and 3 can be clearly seen to have both the largest LOGSY signals in the difference 




















Figure 4.6: (A) LOGSY buildup curves for protons of fragment A, 
and (B) initial rate values of LOGSY buildup derived from (A) 
A 
B 
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LOGSY spectra for fragment B in fig. 4.7 shows exclusively negative LOGSY signals in the 
presence of Hsp90 before subtraction. After subtraction of controls the difference spectrum 
shows all protons positive with varying intensities. Acquisition of the above spectra at 
varying mixing times allows for production of buildup curves in fig. 4.8 
 
chemical shift / ppm 
Figure 4.7: LOGSY (A), control (B) and LOGSY difference (C) spectra for 
Fragment B acquired with an NOE mixing period of 1 second 
LOGSY Spectrum 




LOGSY difference spectrum 
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Proton 1 can be clearly seen to have the shallowest rate of LOGSY buildup in fig. 4.8. In 
contrast protons 3 and 2 possess steep initial rates of LOGSY buildup. Methyl protons 5 and 
7 also possess steep initial rates of LOGSY buildup, but this takes into account multiple 
SURWRQVDVZHOODVDµZREEO\¶EXLOGXSFXUYH$JDLQLWLVZRUWKQRWLQJWKDWWKHVLPLODULW\LQ




















Figure 4.8: (A) LOGSY buildup curves for protons of fragment B, and 
(B) initial rate values of LOGSY buildup derived from (A) 
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Fragment C exhibits different LOGSY spectra to that of fragment B, with all signals 
appearing positive in (A) before the controls are taken into account. These signals are 
accentuated once the signals from control spectra are taken subtracted, with proton 1 
appearing noticeably stronger. LOGSY buildup curves are shown in fig. 4.10. 
 
LOGSY Spectrum 
LOGSY Control Spectrum 




chemical shift / ppm 
Figure 4.9: LOGSY, control and LOGSY difference spectra for Fragment C 
acquired with an NOE mixing period of 1 second 
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Initial rates derived from the LOGSY buildup curves in fig. 4.10A are illustrated in a bar 























Figure 4.10: (A) LOGSY buildup curves for protons of fragment C, and (B) 
initial rate values of LOGSY buildup derived from (A) 
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4.3.4 Quantitative LOGSY for fragment D 
 
As with fragment A, fragment D exhibits a mixture of signals in fig. 4.11. Signals for 
protons 5 and 6 appear positive before subtraction of controls, whereas all appear positive 
after subtraction. Initial rates of LOGSY buildup for all protons of the fragment by 
acquisition of multiple spectra at differing mixing times is shown in fig. 4.12.  
Figure 4.11: LOGSY (A), control (B) and LOGSY difference (C) spectra for 
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As expected, proton 5 and 6 shown much steeper initial rates of LOGSY buildup than 
























Figure 4.12: (A) LOGSY buildup curves for protons of fragment D, and (B) 
initial rate values of LOGSY buildup derived from (A) 
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4.3.5 Quantitative LOGSY for fragment E 
Similar to fragment B, all LOGSY signals appear negative in the LOGSY spectrum (fig. 
4.13A), whereas all appear positive after subtraction of controls. Again, the left-most signal 
at 7.8 ppm appears to be of the greatest intensity. LOGSY build up curves were constructed 
in fig. 4.14.  
Figure 4.13: LOGSY (A), control (B) and LOGSY difference (C) spectra for 




Quantitative LOGSY with Hsp90 
 143 
Build up curves for fragment E in the presence of Hsp90 shows that the proton at position 1 
has the steepest rate of LOGSY buildup. This is similar to fragment C in that the proton on 






















Figure 4.14: (A) LOGSY buildup curves for protons of fragment E, and 
(B) initial rate values of LOGSY buildup derived from (A) 
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LOGSY spectra for fragment F in the presence of Hsp90 is entirely positive, signals which 
are accentuated following subtraction of control spectra. Six protons are observable with that 
of proton 3 providing the largest signal. LOGSY build up curves produced by acquisition of 




Figure 4.15: LOGSY (A), control (B) and LOGSY difference (C) spectra for Fragment F 
acquired with an NOE mixing period of 1 second 
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LOGSY build up curves for fragment F in the presence of Hsp90 show proton 3 as the 
standout LOGSY dominant signal, as determined by initial rate. This is tempered by the fact 
that this signal is caused by three equivalent protons of the methyl group. This aside, proton 





















Figure 4.16: (A) LOGSY buildup curves for protons of fragment F, and 
(B) initial rate values of LOGSY buildup derived from (A) 
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4.4 Discussion 
4.4.1 Initial observations of quantifying data from LOGSY spectra  
 
The first point to observe from the creation of LOGSY difference spectra, created as a 
subtraction of the integrals from two different samples, one with both protein and ligand and 
the other just ligand, is that in each case a valid, positively phased spectrum is produced. It is 
also clear that these spectra are arrived at from variable component spectra. 
 
For example fragments C and F both produce completely positive LOGSY spectra simply 
IURPWKHµZLWKSURWHLQ¶VDPSOHZLWKRXWDFFRXQWLQJIRUWKHUHIHUHQFHVSHFWUD7KLVLVDXVHIXO
property for positive binding fragments, as they would be observed from a fragment screen 
without the need for a reference. However, this is not necessarily typical of fragment ligands 
examined here. Fragments B and E, whose LOGSY spectra exhibit only negative peaks, 
exemplify this, but they produce a characteristic difference spectrum once the reference has 
been taken into account. Fragments A and D, on the other hand, display a mixture of both 
positive and negative peaks. What this means is unclear at this point and shall be probed 
further in the discussion chapter.  
 
Increasing the NOE period for the LOGSY experiment has enabled the tentative plotting of 
buildup curves (see figs. 4.6A, 4.8A, 4.10A, 4.12A, 4.14A and 4.16A). Initial rates derived 
herein are the subject of focus for this chapter and will be treated as a value to determine 
ZKHWKHURUQRWDFHUWDLQSURWRQRUJURXSRISURWRQV LV µ/2*6<GRPLQDQW¶7KDW LV WR VD\
stand out clearly above values of other parts of the ligand. 
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4.4.2 Protons of greatest LOGSY enhancements  
Identification of individual protons that received the greatest LOGSY enhancement (as 
measured by crude initial rate) provided trends in the data. For each case, protons that were 
LOGSY-dominant were distinct from those that were determined to be µSTD-dominant¶.  
 
Apart from proton 5 of fragment A, a distinct and different set of protons WKDWDUHµ/2*6<-
GRPLQDQW¶ FRPSDUHG WR WKRVH WKDW DUH µ67'GRPLQDQW¶7KLV is the first clear sign that the 
quantitative STD and LOGSY experiments inform on different interaction processes 
regarding each individual protein-ligand complex. 
 
Figure 4.17: Fragments A, B and D. Most significant STD (circled red) and 
LOGSY (circled green) enhancements are shown, being defined as those 
protons that exhibit the steepest initial rate in STD and LOGSY experiments 
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4.4.3 Potential for binding mode clustering  
Chapter three mentioned the possibility of grouping similar fragments of the same 
chemotype, on the basis of similar STD buildup patterns. For fragments C, E and F this 
relied upon the relatively strong STD received by the proton at the tip of the phenyl ring.  
 
Supporting this concept of binding mode clustering is the LOGSY data of the remaining 
fragments as can be seen from the enhancements below.  
 
The single proton of the pyrazole ring (protons coloured red in each fragment in fig. 4.18) is 
in each instance the clearest signal with the greatest rate of LOGSY buildup. Not only are the 
LOGSY-dominant protons distinct from the STD dominant protons, the same pattern exists 
across fragments within a particular chemotype.  
 
Figure 4.18: Fragments C, E and F. Most significant STD (circled red) and 
LOGSY (circled green) enhancements are shown, being defined as those 
protons that exhibit the steepest initial rate in STD and LOGSY experiments 
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4.4.4 Conserved, bound water molecules 
The nucleotide binding site of Hsp90 is well characterised. The apo-structure of Hsp90 
contains a series of ordered water molecules inside the pocket, and on binding of ADP, 
hydrogen bonds are formed with three of the conserved waters(Prodromou et al., 1997). Two 
of these water molecules remain conserved in the crystal structures for every fragment under 
analysis in this chapter. These are shown below for fragments A and D.  
Figure 4.19: (A) Structure of fragment D bound to Hsp90 with two conserved water 
molecules buried at the bottom of the cleft visible behind. (B) The same as (A) but with 
the protein surface switched off, and the STD-dominant F138 switched on. (C) 
Another viewpoint of that shown in (B), and (D) the protein surface structure of 
bound fragment A. STD (red) and LOGSY (green) dominant protons are highlighted 
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Fig. 4.19 A shows the position of the two key conserved water molecules at the base of the 
binding cleft. Highlighted are both the LOGSY and the STD dominant protons. As figs. 4.19 
b and c also illustrate; not only are the LOGSY dominant protons distinct to the STD 
dominant ones, they are also positioned closest to the bound water molecules.  
 
It is exactly the same situation for all the other fragments, as is made clear in figure 4.21. 
This is perhaps least surprising for the three pyrazole fragments given that they all bind with 
the same mode, as can be seen below in fig. 4.20. 
 
It is clear that the proximity to the bound water is correlated with a larger LOGSY signal, at 
least in our experiments looking at these six fragments binding to Hsp90. In fig. 4.21 all 6 
fragments including the three pyrazoles are shown as their bound crystal forms in relation to 
the conserved water molecules. These viewpoints how that regions of greatest LOGSY 
enhancement are orientated closer towards the water molecules. 
Figure 4.20: Bound-ligand overlays for compounds C, E and F. The conserved water 
molecules at the bottom of the binding cleft are visible. In (A) the protein surface is 
switched on, whilst in (B) the surface has been switched off and the side chains of the two 
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It is suspected that measurement of the intermolecular proton-proton distances between 
water and ligand may provide a more quantitative assessment of our hypothesis. However in 
practice this is impossible, since hydrogen atoms cannot be accurately added to the oxygen 





Figure 4.21: Crystal structures of Fragments A ± F bound to Hsp90. In each case the model 
is shown with protein removed whilst two conserved water molecules remain present. In each 
figure the illustrative intermolecular distances (< 6 Å) between bound water and ligand 
protons are shown as white lines  
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4.4.5 Validity of quantifying LOGSY data 
Within this chapter, the method of quantification could be described as experimental.  Whilst 
there is no doubt that running consecutive LOGSY experiments for two samples that contain 
protein and no protein ± and then subsequently subtracting the integrals of one from the other 
± is valid, the subsequent quantification leaves room for doubt. Following this the integral of 
the difference signal was plotted against the NOE mixing time n order to generate a LOGSY 
buildup curves. All available data were simply fitted to the same equations that were used for 
analysing STD data. The resulting build up curves all have significant errors associated with 
them if using the method from chapter three. 
This is a reflection of the fact that LOGSY data is fitted to equations that are not optimal. 
Nonetheless, despite a significant error, the initial rates provide a qualitative observation. 
Unlike quantitative STD where errors were minimal, LOGSY analysis is not concerned with 
correlating experimental data and precise atomic-resolution data of crystal structure side 
Figure 4.22: Initial rate of LOGSY build up values for fragment A as per fig. 4.7b. Y axis 
truncated in order to include associated error bars in calculating each initial rate 
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chains. Rather, LOGSY quantification allows a qualitative selection of protons that are 
LOGSY dominant. 
 
Another point to observe is that running a single experiment for a fixed NOE period is all 
that is required. Unlike the STD analysis where build up curves routinely crossed each other, 
necessitating the acquisition of a rate or a T1-adjusted STD value, the ranking order of 
protons (in terms of LOGSY difference signal) is the same when taken at any single fixed 
NOE mixing period. With the exception of fragment E, those protons identified as having the 
greatest LOGSY enhancements at the NOE mixing period of 0.3 s are also the same as those 
ranked in first place at 1.2 s. Perhaps this renders the calculation of a full rate unnecessary, 
which could in fact be beneficial in terms of throughput and efficiency. If the required 
information can be extracted from one experiment rather than five, it makes sense to only run 
one experiment. 
 
Another point to make is that we have, as with the quantitative STD chapter, taken the liberty 
to split the experimental values in proportion with the protons of the group, where more than 
one proton is represented by one chemical shift. It is questionable as to whether dividing a 
rate by 3 for a methyl group or 2 for a methylene/symmetrical group is the best way to treat 
the data, but on reflection, it is the most equitable treatment.  
 
For fragments A, B, C, D and F the majority of protons experience a reduced LOGSY 
intensity in experiments where the NOE mixing period has been increased from 1.0 to 1.2 
seconds. This tallies with previous observations in which it was observed that increasing the 
NOE mixing period increased LOGSY signal up to a point, after which it became 
reduced(Dalvit et al., 2001), as shown in fig. 4.23. 















Referring to fig. 4.23, perhaps it is not optimal to look at build up over a range of mixing 
times up to 1.2 seconds, as the long, slow decay of LOGSY signal has already begun by this 
point. This is no doubt a factor in why fitting the quantitative LOGSY data to STD build up 
curves is associated with such a large error. If indeed one mixing period is sufficient to rank 
protons in order of LOGSY enhancements, experience in this thesis suggests that a mixing 
period of 1 second is optimal. 
 
4.4.6 Conclusions and the differences between this analysis and SALMON 
 
In this chapter we have determined that the LOGSY experiment may tentatively be used to 
produce LOGSY build up curves that give a series of initial rate values, much like their STD 
equivalents. We also determined that these initial rates are associated with a large degree of 
Figure 4.23: NOE-ePHOGSY spectra for HSA with increasing 
mixing time. The entire spectrum is displayed for each time. Figure 
taken from Dalvit et al.(Dalvit et al., 2001) 
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error, and that for the purposes of our analysis acquiring data over one mixing period (1 s) is 
probably sufficient. 
 
7KH VLJQLILFDQW ILQGLQJ LV WKDW QRW RQO\ DUH WKH SURWRQV GHHPHG WR EH µ/2*6< GRPLQDQW¶
IRXQG WR EH FRQVLVWHQWO\ GLIIHUHQW WR WKRVH WKDW DUH µ67'-GRPLQDQW¶ EXW ZH KDYH DOVR
determined that they are always positioned closest to conserved, bound water molecules in 
the Hsp90 binding site. On this basis, it is proposed that this provides a rationale for a 
simple, easy quantitative LOGSY experiment that can help inform on ligand binding mode 
orientation, so long as water-mediated interactions in the site of importance can be 
confirmed. 
 
The SALMON methodology(Ludwig et al., 2008) that arrived with similar conclusions to 
this analysis relied on simply testing one NOE mixing period, whereas we have at least 
probed a range of mixing periods. A more crucial weakness than this however is that 
SALMON is simply interested in the sign of the LOGSY signal, and does not bother to 
quantify any of the effects. It even completely disregards those signals that do not change 
sign between LOGSY and control samples, emphasizing the need to produce a difference 
spectrum. Our analysis proposes that all protons of the ligand provide vital information that 
can assist in orientating the ligand towards the bound water.  
 
)XUWKHUPRUHLWLVVXJJHVWHGWKDWWKHERXQGIDFHDQGWKHµGHSWKLQWKHFOHIW¶DUHPRUH
significant than the particular position of bound water. Our results suggest that the LOGSY 
dominant signals are strictly orientated toward the conserved water, but at the same time do 
not necessarily contradict the conclusions of SALMON, that this is due to these parts of the 
ligand being less solvent-exposed.
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5.1 Introduction 
This chapter takes the principles of the previous two chapters and applies them to a 
different protein, that of the oncogenic protein Ras. In applying the insights derived 
from Hsp90 to Ras, it should be possible to verify our approaches by examining 
whether the evidence either corroborates or contradicts. Ras is sufficiently different to 
Hsp90 so as to provide another compelling test case.  
 
5.1.1 Ras 
Ras is a well-known GTP-binding protein that acts as a nucleotide-dependent switch 
for a number of principal growth signalling pathways in the cell(Schubbert et al., 
2007, Vetter and Wittinghofer, 2001). Ras responds to extracellular signals and is 
converted from a GDP-bound form to a GTP-bound form, aided by guanine 
nucleotide exchange factors (GEFs), in particular SOS1. RasGTP is the active form 
involved in direct interactions with downstream effector molecules such as PI3K and 
Raf (figure 5.1). 
Figure 5.1: The Ras signalling pathway highlighted with proteins affected by mutations in cancer. Growth 
factor binding to extracellular cell receptors causes activation of receptor complexes, which include 
adaptors such as SHC, GRB2 and Gab. These proteins recruit SHP2 and SOS1, increasing Ras±GTP levels 
by catalysing nucleotide exchange on Ras. The GAP NF1 binds to Ras±GTP and accelerates the conversion 
of Ras±GTP to Ras±GDP, thus terminating signalling. Figure taken from (Schubbert et al., 2007) 
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Germline mutations affecting components of the Ras±Raf±MEK±ERK pathway are 
known to underpin developmental disorders, such as Noonan syndrome and Costello 
syndrome. Studies suggest that strength and duration of signalling through the Ras±
Raf±MEK±ERK pathway regulates various developmental processes. Further 
structural, biochemical and functional analyses of these mutant proteins will extend 
our understanding of Ras signalling in development and cancer, hence the interest in 
Ras as a therapeutic target. (Schubbert et al., 2007) 
The gene for Ras is frequently mutated, and is implicated in over 20% of human 
cancers(Schubbert et al., 2007). Mutated Ras exists in a prolonged GTP-bound state, 
which enables enhanced Ras-dependent signalling and consequently cancer cell 
survival and growth(Schubbert et al., 2007, Vetter and Wittinghofer, 2001). 
Mutations in Ras are generally associated with poor outcomes and prognoses, and as 
such Ras has long been considered a critical oncogenic target for drug discovery. This 
chapter applies the concepts explored in this thesis thus far and tests them out on this 
most pivotal of cellular oncoproteins.  
 
5.1.2 A realm of untapped potential 
Despite its critical importance, Ras remains an impregnable protein for small-
molecule inhibitors, even 30 years since its discovery. Ras binds to guanine 
nucleotides with a picomolar affinity ± nucleotides that are also present at high 
concentrations in the cell ± making the design of conventional competitive inhibitors 
to the nucleotide binding site very tough. Some small molecules have been reported in 
the past as having activity against Ras, but these are largely with unknown 
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mechanisms of action and are also in the absence of key structural 
information(Taveras et al., 1997).  
 
In a more recent development, a covalent inhibitor to KRas (another GTPase member 
of the Ras superfamily) has been developed(Ostrem et al., 2013), targeting a novel 
binding pocket in the G12C mutant via a disulphide bond. Crystal structures of the 
compound ± replete with covalent warhead ± binding to KRas identified the novel 
pocket. Furthermore, the compound selectively altered the affinity of Ras for GTP, 
not GDP. Such selectivity is essential in ensuring non-mutated protein is left 
unscathed.  
 
Covalent inhibitors to KRasG12C are one thing, but a site more amenable to a starting 
point for FBDD is clearly far more relevant for this quantitative STD and LOGSY 




5.1.3 A Ras Binding Site for FBDD  
Despite the difficulty presented by the Ras family of proteins to traditional methods of 
drug discovery, a small-molecule binding pocket has recently been identified(Maurer 
et al., 2012). The group from Genentech carried out a fragment screen with a 3,300 
compound library using STD NMR and HSQC fingerprinting, and found 25 
compounds that produced the same chemical shift perturbations (CSPs) that 
consistently mapped onto a site on KRas. These were V8, L56, D57, T74 and G75.    




Fig. 5.2 highlights the small-PROHFXOHELQGLQJVLWHLVEHWZHHQWKHĮKHOL[DQGWKHȕ-
VKHHWȕ- ȕ2WKHUUHVLGXHVVXUURXQGLQJWKHSRFNHW WKDWDOVRGLVSOD\&63LQ+64&
fingerprints include K5, L6, V7, S39, D54, I55, L56 and T74. From this point 
IRUZDUGVWKLVELQGLQJVLWHVKDOOEHUHIHUUHGWRDVWKHµILUVWVLWH¶RI5DV 
 
The site itself was shown to measure 7 x 7 Å at the opening and have a depth of 5 
Å(Maurer et al., 2012). This is large enough to accommodate a ligand benzyl (in 
addition to a chloryl) group, and as such makes it an amenable system for the 
fragment ligands under observation in this chapter. It is also noteworthy how much 
shallower this is than the nucleotide binding site of Hsp90 - 15 Å ± that underwent 
analysis in the previous chapters.  The Ras binding site is significantly less cavernous 
DQGPRUHµJURRYH-OLNH¶FRPSDUHGWRDSURWHLQVXFKDV+VSEXW67'DQG/2*6<
Figure 5.2: (A) Structure of KRas bound to GTP. Large spheres display amino acids 
that displayed consistent CSPs in the NMR screen. (B) Ligand DCAI bound to KRas. 
Amino acid residues of Ras that directly interact with DCAI are shown. Spheres 
indicate atoms that are within 4 Å. Figure adapted from (Maurer et al., 2012) 
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are still expected to function perfectly well. Any differences in the implications of 
quantifying ligand-observed NMR data between the two proteins will serve as an 
interesting comparison for a later discussion. 
 
5.1.4 Previous STD and LOGSY on Ras  
STD NMR has been tentatively used to identify an epitope of a sugar-derived 
inhibitor to Ras(Peri et al., 2006). Here a single spectrum was used to determine that 
benzyl and phenylhydroxylamine moieties constituted a major interaction surface 












Aside from the fact that this is a single spectrum acquired at a single, fixed saturation 
time ± thus ignoring the effect of longitudinal relaxation ± the insight gleaned from 
this sort of analysis is limited. To say that two large functional groups at either end of 
Figure 5.3: (A) 1H NMR spectrum of compound 5 and Ras-GDP and 
(B) the equivalent STD spectrum. Spectrum acquired with a 
saturation time of two seconds, on a sample with a ligand ratio of 
20:1. Figure adapted from Peri F, at al(Peri et al., 2006)   
A 
B 
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a compound are involved in major interactions with a long groove-like binding site is 
not sufficient.  
 
Another more recent piece of work(Duppe et al., 2014) looked at the GTP-binding 
protein Rheb ± a member of the Ras superfamily ± focusing on targeting (or 
µPDVNLQJ¶ the c-terminal CAAX-box. This is involved in membrane insertion and is 
critical for the normal functioning and subsequent downstream processes of Rheb. 
The group targeted the CAAX-ER[ZLWKDSHSWLGRPLPHWLF µUHFHSWRU¶ DQGXVHG67'
NMR once again as a confiUPDWLRQ WKDW WKHLU µUHFHSWRU¶ ERXQG WR 5KHE $JDLQ D
VLQJOH67'VSHFWUXPZDVGHHPHGVXIILFLHQW WRDVVHUW³WKH OLSRSKLOLF&+JURXSVRI
Pro, Lys, and AC5C show strong STD signals, indicating large nonpolar association 
DUHDV´$JDLQDIDLUO\YDJXHDQGQRWso insightful statement. 
 
There is little reported in the literature of quantitative STD against the Ras target, and 
certainly nothing quantitative with fragments ligands. This chapter takes a fully 
quantitative approach using a set of fragment ligands to Ras, in conjunction with a full 
VHW RI SURSULHWDU\ VWUXFWXUHV ,Q DGGLWLRQ D µVHFRQG¶ ELQGLQJ VLWH LV SUREHG LQ WKH
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5.2 Materials and Methods  
 
5.2.1 Protein production and purification 
Purified HRasG12V was provided by Astex Pharmaceuticals, after having been 
expressed and purified. HRasG12V was cloned into the pET28 vector and was 
subsequently expressed in BL21 (DE3). The protein was purified using a Ni2+ affinity 
column, thrombin tag-cleaved, and then purified by gel filtration. 
 










5.2.2 Identification of the protein by Mass Spectrometry 
 
In order to confirm the identity of the HRasG12V construct the protein was tested by 
electrospray time-of-flight (ESI-TOF) mass spectrometry at Astex Pharmaceuticals 
using an Agilent 1200 LC and a Bruker MicroTOF mass spectrometer internally 
calibrated using Agilent low concentration Tunemix. 
 
 




5.2.3 Fragment ligands to Ras 
 
5.2.3.1 Single fragments binding to the first Ras binding site 
Astex Pharmaceuticals provided a range of known fragment ligand hits for the first 
Ras binding site. Under investigation in this chapter is an initial set of fragment 
ligands H ± L to investigate binding to Ras individually 
Figure 5.4: Fragment ligands H ± L. Fragments were provided as freeze-dried 
compounds subsequently diluted into DMSO stocks of 100 mM. Coloured 
numbers denote protons or proton groups 
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5.2.3.2 Fragments binding to the second site in Ras, after saturation of the first site 
In addition to the 5 ligands under investigation binding to the first binding site in Ras, 
it was subsequently decided to investigate two ligands that bound to the second site.  
 
In order to facilitate investigations into the second site, fragments M and N are 
relatively tight-binding fragments used to saturate the first site, and then either of the 
weak binding fragments are then added in excess. It is the signals of the weak-binding 
fragment in the second site that we measure. 
 
Figure 5.5: Binding sites on the Ras protein. Different viewpoints and surfaces are 
VKRZQ7KHµILUVWVLWH¶LVKLJKOLJKWHGLQEOXH± as introduced earlier on - whereas the 
VXVSHFWHGµVHFRQGVLWH¶LVKLJKOLJKWHGLQUHGFRPSULVing amino acid residues Y64, 
Q99 and I100 




5.2.4 NMR experimental setup 
5.2.4.1 Sample preparation 
6DPSOHV IRU 67' DQG /2*6< ZHUH SUHSDUHG DV  ȝ0 5DV SURWHLQ DQG  P0
fragment ligand (final DMSO concentration of 2%) in 20 mM Tris, 100 mM NaCl 1 
mM DTT and 15% D2O at pH 7.2. For all experiments the ratio of ligand to protein 
was 100:1, unless specified otherwise. All experiments were carried out at 5 °C. In 
addition, for LOGSY experiments an extra, identical sample for each fragment was 
made up but without the protein.  
 
An exception to this sample setup is made for the two-site binding experiments. In 
this instance fragment O or P is present as usual at a 100 times excess to the protein (5 
P0WRȝ0LQWKLVFDVHEXWLQDGGLWLRQLIVDWXUDWLQJZLWKIUDJPHQW0LQ the first 
VLWHWKLVZDVSUHVHQWDWȝ0DQGLIVDWXUDWLQJZLWKIUDJPHQW1WKLVZDVSUHVHQWDW
200 ȝ0 7KH UHODWLYHO\ WLJKW ILUVW-site binders are present at roughly 20 times the 
Figure 5.6: Four further fragments. Fragment M or N is used to saturate the first 
site, and fragment O or P is present in excess as a weak-binding fragment to the 
second site.  This provides four combinations: M+O, M+P, N+O and N+P. 
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value of their KD (25 ȝ0 DQG  ȝ0 IRU 0 DQG 1 UHVSHFWLYHO\ WR HQVXUH URXJKly 
90% occupancy of the first site. STD and LOGSY NMR spectra for 2-site binding 
experiments are listed in appendix C. 
 
5.2.4.2 STD NMR 
As in chapter 3, STD NMR experiments were performed at 500 MHz using a Bruker 
DRX500 spectrometer equipped with a TXI cryoprobe using a standard Bruker STD 
sequence 67' 105 GDWDVHWV ZHUH REWDLQHG RYHU  VFDQV  VFDQV µRQ¶ DQG 
VFDQVµRIIVDWXUDWLRQZLWKDPV*DXVVLDQVKDSHGSXOVH (positioned at -3 ppm) and 
a delay of 7 seconds. Water suppression was achieved using a standard Bruker 3-9-19 
WATERGATE sequence. Datasets were processed and analysed using Bruker 
Topspin 3.2 and the absolute intensities (peak heights) were quantified using 
MestReNova (Mnova). Intensities were used to calculate STD amplification (STDAF) 
from STD difference spectra ሾܫௌ்஽ ൌ ሺܫ െ ܫ଴ሻሿ  and the control spectra ሺܫ଴ሻ  as has 
been previously described using the equation(Meyer and Peters, 2003):  
 ܵܶܦ஺ி ൌ ቀூೄ೅ವூబ ቁ ൈ ܮ݅݃ܽ݊݀ܧݔܿ݁ݏݏ     (Equation 6) 
 
Repeating the same STD experiment for a range of saturation times - between 0.5 and 
5 seconds ± enables the calculation of initial rates as laid out previously(Begley et al., 
2010). Buildup curves for all individual protons were fit to equation 7 by plotting 
STDAF against saturation time (t) using KaleidaGraph software: 
 ܵܶܦ஺ி ൌ ܵܶܦ஺ிெ௔௫ሺ ? െ ݁ି ௞ೄ೅ವ௧ሻ    (Equation 7) 
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The initial rate (STDFit) is then determined by multiplying together the two 
KaleidaGraph output values for kSTD and STDAFMax, as this product is the first 
derivative of equation 7:  ܵܶܦி௜௧ ൌ ݇ௌ்஽ሺܵܶܦ஺ிெ௔௫ሻ   (Equation 8) 
 
The initial rate (STDFIT) is again then calculated by multiplying with kSTD.  
 




Inversion recovery experiments were performed using a Bruker AV3 600 MHz NMR 
spectrometer equipped with a QCI-F cryoprobe. Datasets were processed and 
analysed with Bruker Topspin 3.2. For each individual sample a series of 15 
FRQVHFXWLYHH[SHULPHQWVZHUHVHWXSZLWKGHOD\WLPHVĲHDFKRI
1.2, 1.4, 1.6, 1.8, 2, 2.2, 2.4, 2.6, 2.8 and 3 seconds. Each delay time results in a 
differing integral value (a broad range from negative to positive), which when plotted 
against delay time allows the data to be fit to equation 9 using KaleidaGraph: ܯ௧ ൌ ܯ଴ሺ ? െ  ?݁ି ಜ೅భ)    (Equation 9) 
 
The equation is then solved for T1, or given by KaleidaGraph.  
 
As before calculating the T1 values allows for the second prong of this analysis, 
analyzing STD considering relaxation of the ligand (GEM-CRL)(Kemper et al., 
2010). This depends upon acquiring a single set of STD values at a fixed saturation 
time, and then dividing each value by the T1 for each proton. This normalises the data 
and corrects for differences in longitudinal relaxation. As part of this analysis all 
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comparisons and association between experimental data and the binding site structure 
will include both initial rates and T1-adjusted data.  
 
5.2.4.4 LOGSY NMR 
 
As in chapter 4, LOGSY experiments were performed at 500 MHz using a Bruker 
DRX500 spectrometer equipped with a TXI cryoprobe. LOGSY experiments were 
carried out using the ePHOGSY sequence of Dalvit et al(Dalvit et al., 2000), 
incorporating a CPMG period of 10 ms. Experiments were performed over 512 scans 
and spectra acquired with 16384 points and a spectral width of 12 ppm. 1H spectra 
were referenced to 3-(Trimethylsilyl) propanoic acid (TSP). Data was processed and 
analysed using Bruker Topspin 3.2. LOGSY difference spectra were generated by 
subtraction of LOGSY spectra from companion reference spectra, and signals were 
quantified by integration of each resolvable peak. 
 
LOGSY experiments were repeated for a range of NOE mixing periods (0.3, 0.5, 0.8, 
1.0 and 1.2.s). The integral for each peak observed in a LOGSY difference spectrum 
was recorded at each mixing time and used to construct a LOGSY buildup curve. 





5.2.5 Correlation of Experimental STD NMR data with Ras structural data 
 
 
As in previous chapters, experimentally determined initial rates were correlated 
against distance restraints taken from the appropriate bound crystal structure PDB 
files (not in public domain). Every inter-proton distance (r) between each ligand 
Quantitative STD and LOGSY with Ras 
 171 
proton and HYHU\SURWHLQVLGHFKDLQRIWKHFU\VWDOVWUXFWXUHSURYLGLQJLW¶VZLWKLQc
was then processed as ଵ௥ల. This lends greater weight to the saturation transfer pathways 
that are in close proximity. These were summated for each individual ligand proton to 
give an overall value for the sum of distances that might contribute saturation transfer. 
 
5.2.6 Computational docking of fragments into Ras  
Fragment ligands were computationally docked into the Ras protein with GOLD 
(Verdonk et al., 2003), and ranked using the Goldscore scoring function(Verdonk et 
al., 2003). GOLD and Goldscore docks and then ranks various protein-ligand binding 
poses according to fitness. Goldscore is optimised for ligand binding position and 
takes into account hydrogen bonding energy, van der Waals energy, and ligand 
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5.3 Results  
5.3.1 Identification of the HRas G12V protein by Mass Spectrometry 
The UV chromatogram output from the LC-MS yielded a single significant peak 
containing a single protein species with an elution time of 18 minutes. The 
distribution of charged species in the spectrum is consistent with the singly charged 
species (as shown in figs. 5.7 and 5.8). The final mass of 19176 Da is the correct mass 
that would be expected for the HRasG12V construct.  
Figure 5.7: LC-MS and accompanying spectra for HRas 
Raw Mass Spectrum 
UV and Total Ion Chromatogram 










Figure 5.8: Deconvoluted mass spectrum of HRasG12V, with the sequence data 
below 
Deconvoluted Mass Spectrum 
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5.3.2 Quantitative STD 














Fragment H STD spectra in fig. 5.9 show positive STD signals in the presence of Ras 
for all protons of the ligand except for the signal at ~8.9 ppm. The associated build up 
curves for this data is shown in fig. 5.10A, with the subsequent positive correlation 
with intermolecular structure in 5.10B. Protons 4 and 5 dominate the STD signal 
whereas proton 1 has the weakest STD build up, and this is reflected in the structure 
correlation. Isopropyl protons were not considered for analysis due to the 
impossibility of interpreting 6 protons through one chemical shift.  
Figure 5.9: STD (A) and STD reference spectra (B) for fragment H, acquired at a 
saturation time of 5 seconds in this example 
A 
B 

























Figure 5.10: (A) STD build up curves for fragment H with associated initial 
rates and errors, and (B) these initial rates plotted against the sum of the 




Quantitative STD and LOGSY with Ras 
 176 
Inversion recovery data for fragment H in fig. 5.11A allows us to modulate single-
point STD values and correlate these values with structural restraints. An equally 
good, if not better correlation with intermolecular proton-proton distances is 
observed.  
Figure 5.11: (A) Inversion recovery curves for fragment H with associated T1 values, 
and (B) STD amplification factors modulated by T1 plotted against the sum of 
structural restraints, for each saturation time. 
B 
A 
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5.3.2.2 Fragment I 
Fragment I STD spectra in fig. 5.12 shows positive STD signals in the presence of 
Ras for all protons of the ligand. The associated build up curves for this data is shown 
in fig. 5.13A, with the subsequent positive correlation with intermolecular structure in 
5.13B. Protons 2 and 3 show the strongest STD signal, and this is reflected in the 
structure correlation where this half of the sulfone clearly receives a greater number 
of intermolecular pathway contributions for STD transfer. 
Figure 5.12: STD (A) and STD reference spectra (B) for fragment I, acquired at a 
saturation time of 5 seconds in this example 
A 
B 



























Figure 5.13: (A) STD build up curves for fragment I with associated initial 
rates and errors, and (B) these initial rates plotted against the sum of the 
intermolecular proton-proton distances derived from the crystal structure 
A 
B 
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There are good correlations between T1-adjusted STD values and intermolecular 
proton-proton contacts that can be observed, as shown in fig. 5.14B. 
Figure 5.14: (A) Inversion recovery curves for fragment I with associated T1 
values, and (B) STD amplification factors modulated by T1 plotted against the 
sum of structural restraints, for each saturation time. 
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Fragment J STD spectra in fig. 5.15 shows positive STD signals in the presence of 
Ras for all protons of the ligand. Protons 10 and 11 show the greatest STD signal in 
fig. 5.15, and this is shown in the structure correlation where this half of the sulfone is 
clearly in receipt of a greater number of possible intermolecular pathway 
contributions for STD transfer. The 4 protons of the phenylamine group are clearly in 
receipt of less STD signal, and this is reflected by the structure. 
Figure 5.15: STD (A) and STD reference spectra (B) for fragment J, acquired at 
a saturation time of 5 seconds in this example 
A 
B 
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Figure 5.16: (A) STD build up curves for fragment J with associated initial 
rates and errors, and (B) these initial rates plotted against the sum of the 
intermolecular proton-proton distances derived from the crystal structure 
A 
B 
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Inversion recovery data for fragment J in fig. 5.17A allows us to modulate single-
point STD values and correlate these values with structural restraints. An equally 
good correlation with intermolecular proton-proton distances is observed. 
Figure 5.17: (A) Inversion recovery curves for fragment J with associated 
T1 values, and (B) STD amplification factors modulated by T1 plotted 
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Fragment K STD spectra in fig. 5.18 shows positive STD signals in the presence of 
Ras for all protons of the ligand. The associated build up curves for this data is shown 
in fig. 5.19A, with the subsequent positive correlation with intermolecular structure in 
fig 5.19B. Protons 2 and 3 dominate the STD signal, and this is reflected in the 
structure correlation where this half of the sulfone clearly receives a greater number 
of intermolecular pathway contributions for STD transfer. 
Figure 5.18: STD (A) and STD reference spectra (B) for fragment K, 
acquired at a saturation time of 5 seconds in this example 
A 
B 



























Figure 5.19: (A) STD build up curves for fragment K with associated initial 
rates and errors, and (B) these initial rates plotted against the sum of the 
intermolecular proton-proton distances derived from the crystal structure 
A 
B 
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Fragment L STD spectra in fig. 5.20 show positive STD signals in the presence of Ras 
for all protons of the ligand. Proton 3 dominates the STD signal according to build 
ups in fig. 5.21, whilst the remainder of the phenolic ring is fairly STD dominant, and 
this is reflected in the structure correlation where this half of the fragment clearly 
receives a greater number of intermolecular pathway contributions for STD transfer. 
Figure 5.20: STD (A) and STD reference spectra (B) for fragment L, acquired 
at a saturation time of 5 seconds in this example 
A 
B 
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The 3 protons of the phenylamine group are clearly less STD dominant, and this is 
reflected by the structure 
Figure 5.21: (A) STD build up curves for fragment L with associated initial 
rates and errors, and (B) these initial rates plotted against the sum of the 
intermolecular proton-proton distances derived from the crystal structure 
A 
B 

























Inversion recovery of fragment L in fig. 5.22A allows us to modulate single-point 
STD values and correlate these values with structural restraints.  
Figure 5.22: (A) Inversion recovery curves for fragment L with associated 
T1 values, and (B) STD amplification factors modulated by T1 plotted 
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5.3.3 Quantitative LOGSY 


















Negative LOGSY signals for all protons of fragment H become positive once the 
reference is taken into account in fig. 5.23c. Fig. 5.24 shows how proton 6 is the 
VLJQDO ZLWK WKH JUHDWHVW µ/2*6< HQKDQFHPHQW¶ LQ WHUPV RI VLJQDO LQWHJUDO LQ WKH







Figure 5.23: LOGSY (A), control (B) and difference (C) spectra for fragment H binding to Ras 

























Figure 5.24: (A) Fragment H displayed with the highlighted region of 
LOGSY dominance, and (B) the LOGSY build up curves for 
quantitative LOGSY data of this fragment in the presence of Ras 
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Small negative LOGSY signals for all protons of fragment I become positive once the 
reference is taken into account in fig. 5.25. Fig. 5.26 shows how the signal for protons 




Figure 5.25: LOGSY (A), control (B), and difference (C) spectra for 
fragment I binding to Ras 
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conclude too much from this as 3 overlapping protons appearing at the same 























Figure 5.26: (A) Fragment I displayed with the highlighted regions of LOGSY 
dominance, and (B) the LOGSY build up curves for quantitative LOGSY data 
in the presence of Ras 
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Again, negative LOGSY signals produce a completely positive LOGSY difference 




Figure 5.27: LOGSY (A), control (B), and difference (C) spectra for 
fragment J binding to Ras 
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Figure 5.28: (A) Fragment J displayed with the highlighted region 
of LOGSY dominance, and (B) the LOGSY build up curves for 
quantitative LOGSY data of this fragment in the presence of Ras 
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5.3.3.4 Fragment K 
Negative LOGSY signals in (A) again produce a positive LOGSY difference 





Figure 5.29: LOGSY (A), control (B), and difference (C) spectra for fragment K binding to Ras 
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Figure 5.30: (A) Fragment K displayed with the highlighted region 
of LOGSY dominance, and (B) the LOGSY build up curves for 
quantitative LOGSY data of this fragment in the presence of Ras 
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5.3.3.5 Fragment L 
Following the trends for all of the other sulfone fragments, a positive LOGSY 





Figure 5.31: LOGSY (A), control (B), and difference (C) spectra for 
fragment L binding to Ras 
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In this instance a full LOGSY build up curve was not possible, but taking the LOGSY 
difference value based on a single NOE mixing period offers up proton 1 as the 

























Figure 5.32: (A) Fragment L displayed with the highlighted region 
of LOGSY dominance, and (B) the LOGSY difference integrals 
(at 1s NOE mixing period) of this fragment in the presence of Ras 
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5.3.4 Two-site binding 
5.3.4.1 )UDJPHQW0ȝ02P0 
 
Figure 5.33: NMR data for fragment O bound to the Ras 2nd site, after saturation of the first site 
with fragment M. (A) STD build up curves and (B) LOGSY build up curves highlight protons 2 










Figure 5.34: NMR data for fragment P bound to the Ras 2nd site, after saturation of the 
first site with fragment M. (A) STD build up curves and (B) LOGSY build up curves 
highlight protons 1 and 3 as STD dominant, with proton 3 also in receipt of the greatest 
degree of LOGSY enhancement (C) 






Figure 5.35: NMR data for fragment O bound to the Ras 2nd site, after 
saturation of the first site with fragment N. (A) STD build up curves and (B) 
LOGSY build up curves highlight protons 2 and 4 as STD dominant, with no 
proton in receipt of any significant LOGSY enhancement (C) 






Figure 5.36: NMR data for fragment P bound to the Ras 2nd site, after 
saturation of the first site with fragment N. (A) STD build up curves and (B) 
LOGSY build up curves highlight protons 1 and 3 as STD dominant, with 
proton 3 also in receipt of the greatest degree of LOGSY enhancement (C) 
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5.3.5 Computational docking of fragment ligands into Ras ± Top 9 ranked poses 
As mentioned previously, each fragment ligand was individually docked into Hsp90 
using GOLD. For this analysis the top 9 ranked poses were taken and shown below. 
This was done in order to compare with the binding modes present in the crystal 
structure, and consequently to examine how useful employing quantitative STD and 
LOGSY alongside computational techniques could prove to be. 
5.3.5.1 Fragment H 
 
 Rank 1 2 3 4 5 6 7 8 9 
H Fitness 40.29 39.75 39.29 38.26 37.34 36.62 36.07 35.74 34.59 





Figure 5.37: Top 9 ranked poses for fragment H binding to Ras. Correct binding 
mode from crystal structure (magenta) is overlaid with the numbered docking pose 
(green). Fitness of all ranked poses is as shown in the table  
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Poses 1 ± 3 show solutions in which the phenol group is correctly orientated, but with 
the aminopyrimidine and isopropyl groups facing the opposite direction. Poses ranked 
5, 6, 7 and 8 orientate the fragment with the phenol group out of the pocket, which 
goes against the crystal structure as well as the other poses. Pose 4 appears to be most 
correct. 
 
5.3.5.2 Fragment I 
 
 Rank 1 2 3 4 5 6 7 8 9 
I Fitness 41.54 41.35 40.12 39.82 39.67 39.56 38.24 38.17 38.13 





Figure 5.38: Top 9 ranked poses for fragment I binding to Ras. Correct binding mode 
from crystal structure (magenta) is overlaid with the numbered docking pose (green).  
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All poses bar number 7 show solutions in which the correct phenol group is orientated 
most deeply in the binding cleft (ortho), and with the other phenol group facing 
outwards (para). Poses ranked 1, 2, 4, 8 and 9, whilst orientated correctly, point the 
para phenol group 180° in the wrong direction, compared to the crystal structure. 
Poses 3, 5 and 6 appear to be closest to the correct solution. 
 
5.3.5.3 Fragment J 
 Rank 1 2 3 4 5 6 7 8 9 
J Fitness 41.63 41.43 39.65 39.25 39.22 39.07 38.9 38.83 38.8 
 





Figure 5.39: Top 9 ranked poses for fragment J binding to Ras. Correct binding mode 
from crystal structure (magenta) is overlaid with the numbered docking pose (green). 
Quantitative STD and LOGSY with Ras 
 205 
All poses correctly position the phenol group in the binding site with the 
aminobenzene portion of the fragment pointing outwards. In this instance all poses are 
fairly similar to that found in the crystal structure. 
 
5.3.5.4 Fragment K 
 
 Rank 1 2 3 4 5 6 7 8 9 
K Fitness 43.56 41.39 41.09 40.61 40.32 39.48 39.06 39.05 39.01 
 
Once again the phenol group is orientated correctly in the binding site in all poses. 
There is little variation in binding mode between all nine poses. 





Figure 5.40: Top 9 ranked poses for fragment K binding to Ras. Correct binding 
mode from crystal structure (magenta) is overlaid with the numbered docking pose 
(green). 
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5.3.5.5 Fragment L 
 
 
 Rank 1 2 3 4 5 6 7 8 9 
L Fitness 42.35 41.66 40.64 40.29 40.27 39.76 39.57 39.47 37.28 
 
Once more, the phenol group is correctly positioned in the binding site, however in 
poses 3, 5 and 6 the group is orientated incorrectly by 180°, despite the para proton of 
the group still being in the correct position in all poses. Poses 1, 2 and 4 are close 
approximations of the bound mode represented in the crystal structure, although the 
aminopyridine group still does not perfectly overlay in any model. 
 





Figure 5.41: Top 9 ranked poses for fragment L binding to Ras. Correct binding 
mode from crystal structure (magenta) is overlaid with the numbered docking pose 
(green). 
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5.4 Discussion  
5.4.1 Initial comments on the experimental setup 
Generally speaking, the experimental setup investigated in this chapter is at least 
equally reliable, if not more reliable than the setup for Hsp90. Although there is a 
small difference in molecular weight in favour of Hsp90, the fragment ligands here 
present a more convincing case. In this chapter fragments H ± L are all largely 
aromatic, with separate, well-defined chemical shifts for each proton environment, 
due to the presence of heteroatoms acting as symmetry breakers. Furthermore, with 
no CH3 or CH2 groups to consider, no leap of faith regarding multiple protons through 
a single chemical shift is required to interpolate experimental data to fit structural 
data. In addition, there are more protons to consider for each fragment, lending 
validity to any correlations. More, reliable data points to consider in our correlations 
should lend significant weight to any findings herein. 
 
5.4.2 Initial observations of quantitative STD in the presence of Ras 
In general, all fragment ligands provide a series of smooth, well-fitting STD build up 
curves. Resulting initial rates derived from these build ups are accompanied with 
minimal error. 
 
Fragment H is identified as being µ67'-GRPLQDQW¶DWSURWRQDQG of the phenolic 
ring. A reasonable correlation with the sum of the intermolecular proton-proton 
distances is observed, with proton 1 clearly in receipt of the least STD. The fragment I 
STD pattern shows a very good correlation with the structure. That said, it is also the 
case that in fragment I one chemical shift frequency provides the data for three 
protons: 1, 7 and 6. In this instance the data has been split according to the rules of 
Quantitative STD and LOGSY with Ras 
 208 
interpolation laid out in previous chapters, however it is worth noting that the STD 
intensities for protons 2 and 3 are so much stronger than the others in terms of STD 
intensity; this should have little bearing on any conclusions. The quantitative STD 
data for fragment J is unanimous in defining the whole of the phenolic ring ± protons 
9 ± 12 - as STD dominant, in comparison to the phenylamine group which is firmly 
declared as being STD inferior. A very smooth correlation between the structure and 
experimental data is observed here.  
 
Fragment K once again provides a series of strong STD build up curves, with the 
phenolic ring of protons 1 ± 4 dominating the STD signal. The STD data and structure 
are again well correlated. And finally, fragment L produced a series of decent build 
up curves, although the final 2 points of the data for each curve do show a slight 
decline. Once again, protons 1 ± 4 of the phenolic ring are STD dominant, whilst the 
remainder of the compound is inferior in terms of STD signal. 
 
It is evident that the correlation between initial rate and the sum of the intermolecular 
proton-proton contacts is very good. This is clear across all five of the fragments 
under investigation in this chapter, binding to Ras. This implies that our STD analyses 
are valid across different protein targets, and as such the findings and subsequent 
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5.4.3 Potential for binding mode clustering 
Whilst fragments I to L are all of the same chemotype, fragment H has many 
similarities to this group despite not possessing a sulfonyl group. All fragments 
contain a phenolic ring on one portion of the molecule. Protons that were determined 
to be in greatest receipt of saturation transfer difference signal are highlighted red. 
 
 
In all instances it is the phenolic group that is STD dominant. For fragments H and I 
WKLVLVQ¶WWKHFDVHIRUWKHZKROHRIWKHULQJZKHUHDVLWLVWKHFDVHIRUIUDJPHQWV-± L. 
In this sense it seems safe to suggest that binding mode clustering taking into account 
quantitative STD data is equally as valid when applied to Ras as it is for Hsp90. 
 
 
Figure 5.42: Examining the 5 fragment ligands together. STD-dominant regions for 
each fragment in the presence of Ras are circled red 
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5.4.4 The intriguing case of fragment H  
Fragment H has interesting STD properties that lead very neatly into a discussion on 
the Ras binding site. Aside from the usual good correlation between initial rate of 
STD build up, there is also the presence of an extra peak at ~8.9 ppm. The peak at this 


















Figure 5.43: STD spectra for Fragment H. The peak at ~8.9 ppm represents the 
proton at position 2. 
2 
4 6 
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What can be clearly observed is how this peak appears negative in the processed STD 
difference spectrum. This is a phenomenon I never observed before. Typically, even if 
DOLJDQGGRHVQ¶WELQGWRDSURWHLQDQHJDWLYHUHVXOWsimply appears amongst the noise 
with zero intensity. Consequently, the negative build up curve that was produced by 
this data was excluded from the analysis in fig. 5.10. This result could be caused by a 
positive NOE between the isopropyl protons and the proton at position 2, causing 
inversion of the STD signal. Furthermore, fragment H binds with an extraordinarily 
weak KD of 13 mM, which really is testing the upper limit of STD applicability. 
 
Closer inspection of the binding site provides a potential explanation for this puzzling 
result. Only two protons of the protein are within 6 Å of proton 2. Of those, one is the 
gamma proton of Serine 39 - which apart from being distant would be excluded from 
analysis being an exchangeable ± and the other is the beta proton of serine 39, which 
UHVLGHV  c DZD\ ,W¶V IDLU WR VD\ WKDW WKLV SDUWLFXODU SURWRQ RI WKH OLJDQG LV
unusually distant from the binding site, especially for a small fragment. Closer 
examination of the binding site reveals a little more. 
 
5.4.5 Closer examination of the binding site 
As was alluded in the introduction(Maurer 
et al., 2012), the Ras binding site is a 
GLIIHUHQW W\SH RI µEHDVW¶ DOWRJHWKHU WR WKDW
of Hsp90. With a depth of 5 Å, the binding 
site does not allow much room for 
rotation. It is sufficiently large to 
accommodate a benzyl and a chloryl 
Figure 5.44: Crystal structure for fragment J 
bound to Ras. The phenolic group in greatest 
receipt of STD is clearly buried deepest. 
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group(Maurer et al., 2012), and so it is fair to assume that the phenol group present in 
all fragments examined here is accommodated. As such, with such limited chemical 
space to sample, figuring out a potential binding mode becomes much more trivial.  
 
For all fragments examined here with a phenol group, this is easy. As fragment J 
shows in fig. 5.44, the phenolic moiety is the half of the fragment that is buried in the 
cleft. This information can be easily determined from the quantitative STD data on its 
own, in a qualitative sense, and this notion is bolstered when considering the identical 
binding mode of all other fragment ligands under consideration in this chapter, as 
shown by the overlays in fig. 5.45.  
Although there are several fewer intermolecular proton-proton distances to measure in 
the periphery for the halves of the fragments that are not part of the phenolic group, 
there are still enough to aid with distinguishing the binding mode more precisely than 
Figure 5.45: Overlays of the bound structures for fragments H ± L. A 
common, conserved binding mode can be observed 
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this binary choice.  The quantitative STD method clearly works on Ras, and good 
correlations are observed between experimental STD and the sum of the structural 
restraints, however this protein-ligand setup seems to be answering a slightly different 
question to that of the Hsp90 case. 
 
5.4.6 Initial observations of quantitative LOGSY of 5 fragment ligands in the 
presence of Ras 
Quantitative LOGSY is ± at least on first glance ± significantly harder to interpret. 
Generally speaking the data looks reasonable. A series of buildup curves can be 
generated from good quality LOGSY spectra, although it is worth noting that in all 
instances the component LOGSY spectrum (with protein) possesses exclusively 
negative signals before subtraction, rather than inversion of the signal that would 
indicate a significant LOGSY transfer. 
 
Data for fragment H suggests that proton 6 of the phenol group has the greatest 
LOGSY buildup. Fragment I is tougher to assess due to a splitting of a gradient 
representing 3 protons. However, whichever way you look at it, protons 1, 6 and 7 are 
LOGSY dominant, and these are opposing ends of the fragment. Protons 1, 3 and 12 
are LOGSY dominant in fragment J, whereas proton 1 in both fragments K and L is in 
receipt of the greatest LOGSY NOE transfer. Patterns are not instantly clear. Protons 
that we define as LOGSY dominant come from multiple parts of a fragment, and 
differ wildly between fragments of a chemotype.  
 
It is worth mentioning at this point that in all Astex repository crystal structures with 
any fragment, on no occasion were conserved water molecules observed in the 
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binding pocket. This is perhaps to be expected given that the binding site is so small. 
In terms of the hypothesis I put forward in the previous chapter, this protein would 
clearly be unsuitable for testing such a claim. However, all is not lost. 
 
Fragments K highlights the proton next to the hydroxyl group as being LOGSY 
dominant. Further to this, the protons highlighted by fragment J and I all exclusively 
reside next to hydroxyl or amine groups.  
 
In the absence of conserved, bound water molecules in the binding site, there appears 
to be a relationship between the proximity of a proton in a ligand to an exchangeable 
group that determines the magnitude of a signal. This has been observed in other 
screening projects for protons adjacent to exchangeable groups by the Astex screening 
team. 
 
5.4.7 How insightful is STD and LOGSY in conjunction with docking poses? 
Docking poses were generated by GOLD in section 5.3.5 and ranked according to the 
Goldscore function. Clear limitations exist for docking programs such as GOLD, for 
instance it is known that using ensembles of protein structures increases 
performance(Korb et al., 2012), as does acquisition of more than ten poses. In 
addition other scoring functions such as ChemPLP, ASP and Chemscore may be 
employed. These all place greater emphasis on a different combination of factors 
LQFOXGLQJ K\GURJHQ ERQGLQJ 9DQ GHU :DDOV DQG UHSXOVLYH WHUPV ǻ* K\GURSKRELF
contact areas, and databases of known structures. 
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The poses generated in this analysis are certainly varied in nature. In most cases the 
general binding mode is roughly approximated by GOLD, however in certain 
instances it get it completely wrong. For example poses 5 ± 8 for fragment H are 
severely wrong to the extent that our STD analysis could very quickly and easily 
eliminate these from consideration.  
 
Other more subtle discrepancies between crystal structure and binding mode pose, 
such as an aminopyridine ring being shifted 4 Å as for fragment L, are less likely to 
be flagged up by our quantitative analysis as clearly being incorrect, and so may well 
be beyond our remit. This analysis does however suggest a definite role for 
quantitative STD analysis as part of assessment with a computational approach. This 
is likely to be of much more use, and have wider applicability for situations wherein a 




very much speculative. Whereas for the first site it was possible to refer back to 
myriad crystal structures, here we are working blind. Nonetheless there are some 
interesting observations. 
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The rationale here was to saturate the first site with one of two known fragment hits ± 
fragments M and N, shown in fig. 5.46 ± at a concentration sufficiently greater than 
their dissociation constants, and then to saturate the second binding site with one of 
two proposed fragment hits to the second site, at a significantly higher concentration 
than the first site binder. This gave 4 different combinations to analyse: M+O, M+P, 




Before proceeding to discuss this any further, what is clear is that it does not matter 
ZKHWKHULWLVIUDJPHQW0RUIUDJPHQW1WKDW¶VXVHGIRUVDWXUDWLQJWKHILUVWELQGLQJVLWH
Figure 5.46: A) and B) show two views of fragment M bound to Ras whereas C) 
and D) show two viewpoints of fragment N in the same orientations 
D C 
BA 
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All STD and LOGSY data acquired is very similar for either fragment irrespective of 
which compound was used for the initial saturation. This is clear from the results but 
DOVR FOHDU IURP WKH ERXQG FU\VWDO VWUXFWXUHV RI IUDJPHQWV 0 DQG 1 LQ WKH µILUVW¶
binding site. 
 
In terms of the experimental results, fragment O possesses four protons and from this 
two protons ± 2 and 4 ± are deemed STD dominant. In terms of the LOGSY buildup 
curves, no single rate of any proton stands out. Both of these observations hold 
whether fragment M or N is used to saturate the first site.  
 
Fragment P is smaller with only three protons to test. Proton 3 is deemed to be in 
receipt of slightly greater STD than the other two protons. In terms of LOGSY, in this 
instance there is more of a hierarchy; proton 3 is dominant, followed by proton 1 and 
then proton 2. Again, the data proves that the fragment used to saturate the first site is 
irrelevant. 
 
The data itself is robust with smooth, clear, buildup curves made possible from the 
data. The data for fragment O suggests that two protons from one end are STD 
dominant, and Fragment P suggests one proton is STD dominant. Without protons to 
sample from two different ends of a fragment ± as with fragments H to L - there is no 
clear trend, or enough data points to suggest a binding mode from STD data alone. 
LOGSY data for both fragments is once again unclear, at least on first glance. 
However, the fact that there is no LOGSY dominance exhibited in fragment O, but 
there is in fragment P, is instructive; there are no exchangeable protons present in the 
fragment O, but there are in fragment P. In the absence of exchangeable protons in 
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fragment O there is no LOGSY dominance, whereas fragment P displays a pattern of 
LOGSY dominance for its three protons in line ZLWKHDFKSURWRQ¶VUHODWLYHSUR[LPLW\
to the hydroxyl group. 
 
On this evidence, second site binding corroborates our assertions made on the basis of 
the first site Ras-fragment binding, and this does provide a genuine opportunity to 
perhaps speculate as to the nature of the second site. Given the effect of proximity to 
exchangeable protons, with this ligand-observed NMR data we can safely assert that 
the second binding site possesses no bound water much like the first site. Furthermore 
in the absence of structural data for the second site, quantitative STD - in combination 
with binding mode poses from a docking algorithm ± may be the most fruitful avenue 
to pursue.   
 
 
Generally speaking, we have seen compelling evidence to suggest that quantitative 
STD and LOGSY are both techniques that may be applied to Ras and a series of 
fragment ligands. STD data corroborates all the principles observed with Hsp90, 
whereas LOGSY suggests that in the absence of bound, conserved water molecules in 






































This chapter brings together the findings from the constituent chapters of this thesis, 
summarizes them, and places them into context. Over the course of this thesis we have 
determined that ligand-observed NMR methodologies are useful, powerful, convenient, and 
most importantly, full of potential. A number of fundamental biological questions, many of 
which will arise in the decades to come, will surely benefit from the rational implementation 
of the techniques and methods explored in this thesis. 
 
6.1 Quantitative STD 
 
On balance - based on what we have discovered with Hsp90 and Ras ± both initial STD 
rates, as well as T1-adjusted STD data can be said to give fairly positive correlations with 
distance restraints derived from crystal structures of the fragments bound to their proteins. 
This has been demonstrated for eleven fragment ligands in total, against two different 
proteins.  
 
In theory, an initial rate based on 10 experimental points, fit to a strict equation, should 
provide a reliable value for a gradient. However based on our data, simply taking an STD 
amplification factor value and dividing through by an experimentally determined T1 is 
equally as good in the majority of cases. This extends the applicability of quantitative STD 
as total experimental time is dramatically reduced if a rate need not be worked out. One STD 
experiment run for 20 minutes, along with a set of inversion recovery experiments (10 
minutes maximum) could provide the same fundamental information as a rate based on 3h 20 




We have shown that precise three-dimensional protein structures of bound ligands may be 
well correlated with STD NMR data derived from simple 1D NMR experiments, to a degree 





In this thesis quantitative LOGSY has proven itself to be a remarkable tool, to an extent 
completely unexpected. Investigations with Hsp90 showed that there was a direct correlation 
between the magnitude of a LOGSY signal and the proximity of that particular proton to 
bound water in the binding site. This promises to be an extremely useful NMR-based tool for 
investigating interactions between ligands and proteins where conserved, bound water is 
implicated.  
 
Investigations with Ras showed that in the absence of bound water in the binding site, 
quantitative LOGSY could no longer inform upon binding orientation. Where no bound 
water is present, the proximity of a proton to an exchangeable group tends to dominate. 
 
Although we were able to fit LOGSY difference data (based on the integral difference 
between two samples) to the same equations as were used to construct STD build up curves, 
in order to generate initial rates, they did not fit these equations perfectly and the subsequent 
fits were associated with very large errors. Furthermore, the lack of crossover of LOGSY 
build up curves (in contrast to STD build up curves) implies that differences in longitudinal 
relaxation appear to have little influence on the data. As a result it appears that once again, 
LOGSY data acquired from a single point encodes at least as much information as an 
experimentally derived rate. This has major benefits in terms of streamlining and extends 
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how broadly the method may be implemented: only two LOGSY experiments are required 
(with protein and without) run with 512 scans (2 x 22 minutes). 
 
The absence of a sign change without taking into account a control spectrum (as is the case 
for all fragment ligands to Ras) would, according to the principles of the SALMON (Ludwig 
et al., 2008) methodology, imply a complete lack of binding between all of our ligands and 
Ras, something which is patently untrue as evidenced by positive STD data and the fact that 
WKHVHDUHDOOYDOLGDWHGµKLWV¶IRU5DV7KLVJRHVWRXQGHUOLQHWKHLPSRUWDQFHRIPHDVuring the 




6.3 A comparison of proteins 
STD and LOGSY analyses in this thesis focused on fragments binding to two proteins: 
Hsp90 and Ras. Whilst we have been able to show that quantitative STD is suited to studying 
fragments binding to both proteins, some differences in the results obtained with both 
proteins did make themselves apparent. 
 
Differences in the nature of the binding sites ± deep, cavernous Hsp90 versus the small and 
VKDOORZµJURRYH-OLNH¶5DV± meant that STD informed upon different pieces of information. 
The quantitative approach undoubtedly works in terms of the correlations we were able to 
achieve with both proteins, but in qualitative terms STD on Ras can easily tell us which half 
of the fragment is orientated to point away from the binding site. However in a nucleotide-
binding site such as found in Hsp90 it is unlikely for a small fragment to noticeably protrude 
from the site as it would for Ras. In a case such as this the precise relationship between the 
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sum of the side chain contributions is likely to be more important, and so a full analysis as 
we have shown is invaluable.  
 
Both proteins prove that both techniques are clearly applicable to different types of proteins, 
but it is clear that quantitative LOGSY is likely to be far more useful for informing upon 
water-mediated interactions in a binding site. 
 
6.4 In combination with docking simulations 
 
One of the most promising ways in which we thought quantitative STD may be useful is in 
conjunction with suggested binding modes created with docking software. This was 
attempted in chapter 5 with the fragment ligands to Ras. Broadly speaking the mixture of 
binding poses generated by GOLD, in relation to the actual binding mode, were not 










An example is illustrated by binding modes 5 and 6 binding to Ras in figure 6.1. In both 
instances the binding mode is clearly incorrect; the phenol group is not directly in the 
5 6 
Figure 6.1: Binding poses ranked 5 and 6 (green) for fragment H binding to 
Ras. In both of these poses the fragment is orientated upside down to that in 
the crystal structure (magenta) 
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binding pocket, and protrudes from the top. In the absence of a crystal structure, our STD 
analyses would instantly be able to state that these modes would be unlikely (since the 
protons suggested by these poses at the base of the pocket receive minimal STD signal), and 
as a result they can be dismissed. 
 
As the myriad docking poses generated by GOLD for all five fragments to Ras shows, 
quantitative STD should come in handy for dismissing a wide variety of poses. In the 




















6.5 In a perfect world 
In this thesis an ongoing theme has been a discussion of the advantages and limitations of 
certain fragments that make up this study. Just as an aside, it would be interesting to try and 
describe what a perfect fragment amenable to quantitative STD and LOGSY might look like. 
'UDZLQJ XSRQ VRPH RI WKH LQVSLUDWLRQV DFTXLUHG GXULQJ WKLV LQYHVWLJDWLRQ ,¶YH LQYHQWHG D
FRPSRXQGWKDWVKDOOEHFDOOHGµIUDJPHQW=¶7KHSUHGLFWHG1H 1D spectrum for this fragment 
is shown in figure 6.2.  
Figure 6.2: Predicted 1H NMR spectra for fragment Z. (A) whole spectrum and (B) 
region between 7.4 ± 8.8 ppm expanded. All 11 protons appear at distinct chemical 





Fragment Z would be ideal for a number of reasons. Firstly, it is comprised exclusively of a 
large number of aromatic protons. This has the advantages of ensuring all chemical shifts are 
well away from any solvent peaks or those of biological buffer components such as DTT, 
7ULV RU ȕ-mercaptoethanol, meaning that no ligand information is lost. Significantly, these 
protons are also far from the position of application of the selective pulse, therefore fear of 
accidental excitation is even further alleviated, as explored in chapter 2.  The other advantage 
of aromatic protons is that they are single protons. Processing data as one chemical shift per 
proton avoids the need to split any data according to multiple protons of a group i.e. methyl 
protons. A large number of protons ensures that any trends modelled with data is based on 
substantial evidence. 
 
Fragment Z also possesses no symmetry, unlike several of the compounds in this 
investigation. The absence of symmetry is ensured by insertion of heteroatoms at key 
positions in the aromatic rings. Furthermore, there is no chance that the fragment might 
adopt different conformations which would remove a lot of valuable information i.e. 
chair/boat conformations that have axial and equatorial protons in both conformations. 
 
Other ideal additional properties of a perfect fragment would include: no tautomerism, a 
dissociation constant of between 10 Pm and 1 mM and good solubility in aqueous buffer. Of 
course, it is highly unlikely that fragments in an industrial fragment library will adhere to all 
of these conditions, but the more of them that a fragment satisfies, the more use quantitative 






6.6 Future experiments and the future of FBDD 
 
In future it may be interesting to conduct LOGSY experiments with varying ratios of 
H2O/D2O (as well as different co-solvents such as methanol) and move gradually from a 
solution of pure water towards a sample of pure D2O. It may be expected that an incremental 
reduction in the proportion of water molecules might cause an overall reduction in LOGSY 
signal, but it would be interesting to see whether the LOGSY signal to particular protons fell 
steadily, or whether there would be a discrete fall as bound water in the binding site was 
replaced. 
 
Another interesting experiment would be to carry out quantitative STD and LOGSY with 
IUDJPHQWVRQSHUGHXWHUDWHGSURWHLQ:RXOGDUHGXFWLRQLQWKHµSURWRQ-VLQN¶SURYLGHLQFUHDVHG
precision in quantitative STD and LOGSY? Large scale implementation of fragment 
screening processes with perdeuterated protein is unlikely and implausible, but on a one-off 
basis this would answer an interesting question. Perdeuteration rarely produces proteins with 
100% deuteration at every single proton position; so different deuteration levels might offer 
different saturation transfer pathways, which could enhance quantitative STD (and therefore 
minimise unwanted spin diffusion).   
 
To take this project forward in a very direct sense, the methods refined in this thesis could be 
applied to a range of further proteins and ligands of different shapes and sizes. I expect this 
would corroborate the findings established thus far, but it would provide further justification 
and reassurance of the methods. 
 
Based on observations in this thesis, I have reason to believe that quantitative ligand-
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observed NMR could easily form a significant part of early stage FBDD methodology. 
Despite the increasing popularity of SPR as an initial screen, and despite the ease and high-
throughput nature of crystallisation trials for validating hits, there is scope for ligand-
observed NMR to remain as both the principal screening tool and a tool for validating hits by 
quantification. 
 
It is clear from this thesis that the quantitative ligand-observed NMR techniques are likely to 
prove most useful in the absence of a crystal structure for a bound ligand. Despite advances 
in x-ray crystallography, it is still often the case that some proteins do not take particularly 
well to the crystallisation process. From the point of view of a pharmaceutical company 
interested in a new mutant of an interesting protein target, this can be infuriating, and in 
many cases this causes the termination of a screening programme entirely, irrespective of 
how theoretically solid and exciting pursuing such a target may be. This thesis suggests that 
this kind of thinking may be short-sighted, and provides justification for an alternative 
approach.  
 
In combination with docking poses of ligands bound to the target protein using software such 
as GOLD (which will take the apo- crystal structure of the protein, the ligand, and possibly 
some NOE restraints directly), methods refined in this thesis show that it is plausible to gain 
a handle on protein-ligand binding mode via an alternative route. Some computational 
docking programmes already automatically directly incorporate 2D HSQC NMR data in 
order to aid the narrowing down of binding mode solutions (in the form of chemical shift 
perturbations), so perhaps if one was minded to do so, quantitative STD NMR intensities 




No doubt most pharmaceutical and biotechnology companies are likely to stay fixed in their 
ways, and unwilling to proceed in the absence of tKH µJROG VWDQGDUG¶ RI WKH ERXQG-ligand 
crystal structure. But others may take an alternative view, and decide that a risk is worth 
taking. 
 
For just a small amount of extra effort, STD and LOGSY experiments could be run on hits, 
as single compounds, to assess if there are patterns of STD or LOGSY build up that are 
consistent with the binding mode of a particular chemotype (categorisation). This could help 
both as a function to narrow down the field of hits to put forward for x-ray screening, and aid 
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This appendix is an attachment of the publication, published in January 2014, 
which forms the basis of chapter two. 
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This table shows the proton numbers referred to in this thesis and their equivalent proton 
numbers in this appendix. In the following tables the identity of the recipient ligand proton is 
shown, along with the amino acid donor side chain, the distance (in Å), and in green, the 
distance written as (1/ Å6). The sum of all values in green is written at the bottom of each table ǲǳ. 
Data for exchangeable donor protons is not included, and donor methyl groups are ǲǳǤ  
 
Fragment 
           
               Hsp90 A 5 4 3 2 1 6 
       
  
16 17 18 19 20 21 
       
               
 
B 2 3 1 4 4 6 6 5 5 5 7 7 7 
  
27 28 33 20 21 22 23 17 18 19 24 25 26 
               
 
C 7 7 7 1 2 3 4 5 6 
    
  
13 14 15 17 18 19 20 21 22 
    
               
 
D 4 3 2 1 6 5 
       
  
13 14 15 16 17 18 
       
               
 
E 1 6 5 4 3 2 
       
  
16 17 18 19 20 21 
       
               
 
F 3 2 2 1 1 1 4 5 6 7 8 
  
  
20 19 18 17 16 15 21 22 23 24 25 
  
               Ras H 1 3 4 5 6 
        
  
25 26 27 28 29 
        
               
 
I 7 8 5 6 4 3 2 1 
     
  
19 20 21 22 23 24 25 26 
     
               
 
J 3 4 6 1 9 10 11 12 
     
  
20 21 22 23 24 25 26 27 
     
               
 
K 6 5 7 4 3 2 1 
      
  
27 28 29 32 33 34 35 
      
               
 
L 7 6 5 1 2 3 4 
      
  
21 22 23 24 25 26 27 
      
               
  
Proton numbers in the main 
thesis 
        
  
Proton numbers in this appendix 
         











































meth XXX 1 X H16 ILE 96 A HG22 3.4 3.79 0.000647331 0.00033564 
 




















meth XXX 1 X H16 MET 98 A HE2 4 4.88 0.000244141 7.43467E-05 
 













































meth XXX 1 X H16 MET 98 A HE3 5.12 
 
5.55112E-05 
































































     
SUM 0.008866004 0.007588978 
 























meth XXX 1 X H17 MET 98 A HE2 3.48 4.23 0.000563021 0.000174565 
exch 
 


























exch meth XXX 1 X H17 LYS 58 A HZ2 4.66 5.3 9.76528E-05 4.51175E-05 
 













































meth XXX 1 X H17 ILE 96 A HG23 5.26 5.42 4.72156E-05 3.94461E-05 
 


























































     
SUM 0.004925158 0.004244614 
 
















meth XXX 1 X H18 MET 98 A HE1 3.27 3.82 0.000817925 0.000323515 
 
meth XXX 1 X H18 LEU 107 A HD21 3.34 4.27 0.000720313 0.000164981 
exch 
 















meth XXX 1 X H18 LEU 107 A HD11 3.97 4.89 0.000255421 7.34385E-05 
 
meth XXX 1 X H18 THR 184 A HG21 4.19 5.00 0.000184806 6.42566E-05 
  

























meth XXX 1 X H18 VAL 150 A HG11 4.51 5.23 0.000118834 4.88641E-05 
 










meth XXX 1 X H18 VAL 186 A HG21 4.74 4.96 8.81718E-05 6.71599E-05 
 













































































































     
SUM 0.004987604 0.002189446 
 




















meth XXX 1 X H19 LEU 107 A HD21 1.96 2.61 0.017638578 0.003163421 
 









































meth XXX 1 X H19 LEU 107 A HD11 4.07 4.73 0.000220006 8.96747E-05 
exch 
 






























































































     
SUM 0.029142617 0.009863555 
 





































meth XXX 1 X H20 LEU 107 A HD23 3.43 4.06 0.000614095 0.00022438 
  









































































































































































































































     
SUM 0.000755883 0.000686536 
 
































exch meth XXX 1 X H17 LYS 58 A HZ2 2.99 3.53 0.0013995 0.000513916 
  






































meth XXX 1 X H17 ILE 96 A HG21 4.92 4.98 7.05033E-05 6.55577E-05 
 






















































     
SUM 0.002464506 0.002332227 
 
















































meth XXX 1 X H18 MET 98 A HE1 4.49 4.73 0.000122046 8.92962E-05 
 










XXX 1 X H18 MET 98 A HB3 4.61 
 
0.000104182 








































meth XXX 1 X H18 ILE 96 A HG23 5.35 5.62 4.26459E-05 3.17382E-05 










meth XXX 1 X H18 ILE 96 A HG22 5.68 
 
2.9779E-05 




















meth XXX 1 X H18 










     
SUM 0.011337412 0.011043231 
 













































meth XXX 1 X H19 ILE 96 A HG23 4.21 4.59 0.0001796 0.000106936 















XXX 1 X H19 ASP 102 A HB2 4.55 
 
0.000112702 



































meth XXX 1 X H19 MET 98 A HE2 5.32 
 
4.41093E-05 






















































     
SUM 0.010803373 0.010489316 
 




















meth XXX 1 X H20 ILE 96 A HG22 2.86 3.02 0.001827275 0.00131813 
 










XXX 1 X H20 LYS 58 A HD2 3.22 
 
0.000897149 















XXX 1 X H20 ALA 55 A HB1 3.73 
 
0.000371319 




















XXX 1 X H20 GLY 97 A H 4.59 
 
0.000106936 






























































































     
SUM 0.008078249 0.005239016 
 
















meth XXX 1 X H21 ILE 96 A HG23 2.98 3.39 0.001427915 0.000654999 
 









































meth XXX 1 X H21 MET 98 A HE2 4.41 5.08 0.000135947 5.81859E-05 
  






















































































































     
SUM 0.010975239 0.008975433 
 







































































XXX 1 X H22 ASN 51 A HD22 4.98 
 
6.55577E-05 










































































     
SUM 0.003422235 0.003283118 
 

















































XXX 1 X H23 MET 98 A HG3 4.8 
 
8.17622E-05 
 exch meth XXX 1 X H23 LYS 58 A HZ1 5.01 
 
6.32373E-05 

























































































     
SUM 0.001262815 0.001079229 
 





























XXX 1 X H24 LYS 58 A HD2 3.26 
 
0.000833095 





XXX 1 X H24 LYS 58 A HE3 3.5 
 
0.000543991 













































meth XXX 1 X H24 
ILE 96 A 
HG22 4.84 5.12 7.77907E-05 5.57285E-05 
  





meth XXX 1 X H24 


























meth XXX 1 X H24 

























     
SUM 0.003458404 0.003336978 
 





















































meth XXX 1 X H25 ILE 96 A HG22 3.69 4.25 0.000396134 0.000170495 
  


























































































































     
SUM 0.022175587 0.021711187 
 













































XXX 1 X H26 ALA 55 A HA 3.65 
 
0.000422905 



































XXX 1 X H26 ALA 55 A HB1 4.68 
 
9.51754E-05 





XXX 1 X H26 ASP 54 A HA 4.87 
 
7.49594E-05 












































     
SUM 0.008450598 0.008412854 
 






















































meth XXX 1 X H27 THR 184 A HG21 3.69 4.36 0.000396134 0.000145573 
  











































































































































     
SUM 0.010227643 0.009626546 
 
















































meth XXX 1 X H28 THR 184 A HG21 3.92 4.4 0.000275603 0.000129941 
 










meth XXX 1 X H28 VAL 186 A HG23 4.26 4.6 0.000167318 0.000104636 
 









































































































































     
SUM 0.006838668 0.005955062 
 






















meth XXX 1 X H33 MET 98 A HE1 2.59 3.4 0.003312847 0.000647331 
 











































































































































     
SUM 0.006156731 0.002172891 
 





















XXX 1 X H13 MET 98 A HG3 3.26 0.000833095 
  
 
XXX 1 X H13 MET 98 A HG2 3.32 0.000746744 
  methyl XXX 1 X H13 MET 98 A HE2 3.34 0.000720313 4.11 0.000207467 
methyl XXX 1 X H13 ALA 55 A HB2 4.03 0.000233437 4.81 8.07476E-05 
exch XXX 1 X H13 THR 184 A HG1 4.25 0.000169694 
  methyl XXX 1 X H13 MET 98 A HE1 4.32 0.00015385 
  methyl XXX 1 X H13 MET 98 A HE3 4.67 9.64048E-05 
  
 
XXX 1 X H13 ASN 51 A HB3 4.77 8.48965E-05 
  methyl XXX 1 X H13 ALA 55 A HB1 4.97 6.63532E-05 
  methyl XXX 1 X H13 THR 184 A HG21 5.06 5.95795E-05 
  methyl XXX 1 X H13 ILE 96 A HG23 5.13 5.48651E-05 5.296666667 4.52881E-05 
exch XXX 1 X H13 ASN 106 A HD22 5.15 5.3599E-05 
  methyl XXX 1 X H13 ILE 96 A HG22 5.2 5.05801E-05 
  methyl XXX 1 X H13 ALA 55 A HB3 5.43 3.90123E-05 
  
 
XXX 1 X H13 MET 98 A HB2 5.46 3.77437E-05 
  
 
XXX 1 X H13 MET 98 A HB3 5.49 3.6523E-05 
  methyl XXX 1 X H13 ILE 96 A HG21 5.56 3.38494E-05 
  
 
XXX 1 X H13 GLY 97 A H 5.58 3.3128E-05 
  methyl XXX 1 X H13 LEU 107 A HD21 5.6 3.24244E-05 
  
 
XXX 1 X H13 ALA 55 A HA 5.62 3.17382E-05 
  
 
XXX 1 X H13 MET 98 A HA 5.63 3.14014E-05 
  
 
XXX 1 X H13 GLY 97 A HA2 5.65 3.07404E-05 
  
 
XXX 1 X H13 ASP 102 A HB3 5.7 2.91575E-05 
  
 
XXX 1 X H13 THR 184 A HB 5.72 2.85512E-05 
  
 
XXX 1 X H13 ASN 106 A HB2 5.72 2.85512E-05 
  
 
XXX 1 X H13 ASN 106 A HB3 5.88 2.41956E-05 
  exch XXX 1 X H13 THR 152 A HG1 5.9 2.37076E-05 
  
 
XXX 1 X H13 LYS 58 A HD2 5.97 2.20879E-05 
  
 
XXX 1 X H13 ALA 55 A H 5.98 2.18672E-05 
  


























XXX 1 X H14 MET 98 A HG3 2.23 0.008131503 
  
 
XXX 1 X H14 MET 98 A HG2 2.81 0.002031244 
  exch XXX 1 X H14 THR 184 A HG1 3.05 0.001242227 
  methyl XXX 1 X H14 MET 98 A HE2 3.11 0.001105192 3.96 0.000259316 
methyl XXX 1 X H14 ALA 55 A HB2 3.68 0.000402636 4.203333333 0.000181316 
methyl XXX 1 X H14 ILE 96 A HG23 3.83 0.000316816 4.203333333 0.000181316 
 
XXX 1 X H14 GLY 97 A HA2 3.9 0.000284192 
  
 
XXX 1 X H14 GLY 97 A H 3.9 0.000284192 
  methyl XXX 1 X H14 ALA 55 A HB1 4.06 0.000223277 
  methyl XXX 1 X H14 ILE 96 A HG22 4.11 0.000207467 
  methyl XXX 1 X H14 MET 98 A HE3 4.26 0.000167318 
  
 
XXX 1 X H14 MET 98 A HA 4.51 0.000118834 
  methyl XXX 1 X H14 MET 98 A HE1 4.51 0.000118834 
  exch XXX 1 X H14 THR 152 A HG1 4.54 0.0001142 
  
 
XXX 1 X H14 MET 98 A HB2 4.61 0.000104182 
  
 
XXX 1 X H14 MET 98 A H 4.63 0.000101511 
  methyl XXX 1 X H14 THR 184 A HG21 4.65 9.89196E-05 
  methyl XXX 1 X H14 ILE 96 A HG21 4.67 9.64048E-05 
  
 
XXX 1 X H14 THR 184 A HB 4.83 7.87621E-05 
  methyl XXX 1 X H14 ALA 55 A HB3 4.87 7.49594E-05 
  
 
XXX 1 X H14 MET 98 A HB3 4.9 7.22476E-05 
  
 
XXX 1 X H14 GLY 97 A HA3 5.11 5.61661E-05 
  
 
XXX 1 X H14 ALA 55 A HA 5.25 4.77578E-05 
  
 
XXX 1 X H14 ILE 96 A H 5.47 3.73316E-05 
  methyl XXX 1 X H14 THR 184 A HG23 5.52 3.53481E-05 
  
 
XXX 1 X H14 ASP 102 A HB3 5.62 3.17382E-05 
  
 
XXX 1 X H14 LYS 58 A HD2 5.86 2.46953E-05 
  
 
XXX 1 X H14 ASN 51 A HB3 5.91 2.34679E-05 
  exch XXX 1 X H14 ASN 106 A HD22 5.94 2.27657E-05 
  
 
XXX 1 X H14 THR 152 A HB 5.94 2.27657E-05 
  


























methyl XXX 1 X H15 ALA 55 A HB2 2.45 0.004623847 3.243333333 0.000859113 
 
methyl XXX 1 X H15 ALA 55 A HB1 3.33 0.000733389 
  
 
methyl XXX 1 X H15 ILE 96 A HG22 3.58 0.000475009 3.86 0.000302326 
  
XXX 1 X H15 ALA 55 A HA 3.87 0.000297669 
  
 
methyl XXX 1 X H15 ILE 96 A HG23 3.88 0.000293096 
  
  
XXX 1 X H15 MET 98 A HG3 3.93 0.000271422 
  
 
methyl XXX 1 X H15 ALA 55 A HB3 3.95 0.00026328 
  
  
XXX 1 X H15 MET 98 A HG2 4.07 0.000220006 
  
 
methyl XXX 1 X H15 ILE 96 A HG21 4.12 0.000204464 
  
 
exch XXX 1 X H15 THR 184 A HG1 4.37 0.000143586 
  
  
XXX 1 X H15 GLY 97 A H 4.47 0.000125359 
  
  
XXX 1 X H15 LYS 58 A HD2 4.53 0.000115721 
  
 
methyl XXX 1 X H15 MET 98 A HE2 4.54 0.0001142 5.406666667 4.00334E-05 
  
XXX 1 X H15 ALA 55 A H 4.57 0.000109775 
  exch methyl XXX 1 X H15 LYS 58 A HZ3 4.99 6.47734E-05 
  
  
XXX 1 X H15 ASN 51 A HB3 5 0.000064 
  
  
XXX 1 X H15 ILE 96 A H 5.12 5.55112E-05 
  
  
XXX 1 X H15 GLY 97 A HA2 5.19 5.11677E-05 
  
  
XXX 1 X H15 LYS 58 A HE2 5.36 4.21707E-05 
  
  
XXX 1 X H15 ASP 54 A HB2 5.52 3.53481E-05 
  
  
XXX 1 X H15 SER 52 A HA 5.58 3.3128E-05 
  
  
XXX 1 X H15 THR 184 A HB 5.62 3.17382E-05 
  
 
methyl XXX 1 X H15 THR 184 A HG21 5.71 2.88525E-05 
  
  
XXX 1 X H15 LYS 58 A HD3 5.73 2.82535E-05 
  
 
methyl XXX 1 X H15 MET 98 A HE1 5.81 2.59982E-05 
  
  
XXX 1 X H15 ASP 54 A HB3 5.82 2.57313E-05 
  
  
XXX 1 X H15 MET 98 A HA 5.83 2.54676E-05 
  
  
XXX 1 X H15 ILE 96 A HB 5.87 2.4444E-05 
  
 
methyl XXX 1 X H15 MET 98 A HE3 5.87 2.4444E-05 
  
  
XXX 1 X H15 GLY 95 A HA3 5.87 2.4444E-05 
  
  
XXX 1 X H15 ASN 51 A HA 5.91 2.34679E-05 
  
  
XXX 1 X H15 LYS 58 A HB2 5.96 2.23112E-05 
  





















XXX 1 X H17 ASN 51 A HB3 3.26 0.000833095 
  
methyl XXX 1 X H17 THR 184 A HG21 3.33 0.000733389 4.02 0.000236943 
 
XXX 1 X H17 ASN 51 A HB2 3.42 0.000624947 
  
methyl XXX 1 X H17 VAL 186 A HG21 3.51 0.000534758 3.783333333 0.000340998 
methyl XXX 1 X H17 VAL 186 A HG23 3.59 0.000467125 
  
exch XXX 1 X H17 SER 52 A HG 3.6 0.000459394 
  
 
XXX 1 X H17 THR 184 A HB 3.76 0.000353894 
  
methyl XXX 1 X H17 THR 184 A HG22 3.89 0.000288604 
  
 
XXX 1 X H17 SER 52 A HA 3.99 0.000247835 
  
 
XXX 1 X H17 SER 52 A H 4.19 0.000184806 
  
methyl XXX 1 X H17 VAL 186 A HG22 4.25 0.000169694 
  
exch XXX 1 X H17 ASN 51 A HD22 4.47 0.000125359 
  
exch XXX 1 X H17 THR 184 A HG1 4.53 0.000115721 
  
methyl XXX 1 X H17 MET 98 A HE2 4.8 8.17622E-05 
  
methyl XXX 1 X H17 THR 184 A HG23 4.84 7.77907E-05 
  
 
XXX 1 X H17 LEU 48 A HA 5.04 6.10122E-05 
  
 
XXX 1 X H17 LEU 48 A HB3 5.25 4.77578E-05 
  
methyl XXX 1 X H17 LEU 48 A HD22 5.27 4.66806E-05 
  
methyl XXX 1 X H17 ALA 55 A HB2 5.27 4.66806E-05 
  
 
XXX 1 X H17 ASN 51 A HA 5.37 4.17018E-05 
  
 
XXX 1 X H17 VAL 186 A HB 5.37 4.17018E-05 
  
 
XXX 1 X H17 SER 52 A HB3 5.45 3.81611E-05 
  
methyl XXX 1 X H17 MET 98 A HE1 5.47 3.73316E-05 
  
methyl XXX 1 X H17 ALA 55 A HB3 5.47 3.73316E-05 
  
 
XXX 1 X H17 SER 52 A HB2 5.5 3.61263E-05 
  
methyl XXX 1 X H17 VAL 150 A HG13 5.51 3.57347E-05 
  
 
XXX 1 X H17 ASN 51 A H 5.56 3.38494E-05 
  
 
XXX 1 X H17 PHE 138 A HD1 5.64 3.10689E-05 
  
methyl XXX 1 X H17 ILE 91 A HG22 5.66 3.0416E-05 
  
methyl XXX 1 X H17 LEU 48 A HD23 5.74 2.79595E-05 
  
methyl XXX 1 X H17 VAL 150 A HG11 5.81 2.59982E-05 
  
exch XXX 1 X H17 ASN 51 A HD21 5.81 2.59982E-05 
  
methyl XXX 1 X H17 ILE 91 A HG21 5.82 2.57313E-05 
  
 
XXX 1 X H17 VAL 186 A H 5.87 2.4444E-05 
  
 
XXX 1 X H17 ASP 93 A HB3 5.89 2.39501E-05 
  
methyl XXX 1 X H17 VAL 186 A HG11 5.9 2.37076E-05 
  
 
XXX 1 X H17 ILE 91 A HB 5.94 2.27657E-05 
  






















XXX 1 X H18 ASN 51 A HB3 2.69 0.002639285 
  
  
XXX 1 X H18 ASN 51 A HA 4.1 0.000210522 
  
  
XXX 1 X H18 ASN 51 A HB2 4.18 0.000187475 
  
 
exch XXX 1 X H18 ASN 51 A HD22 4.39 0.000139705 
  
 
exch XXX 1 X H18 ASN 51 A HD21 4.65 9.89196E-05 
  
 
methyl XXX 1 X H18 ALA 55 A HB2 4.69 9.39643E-05 
  
 
methyl XXX 1 X H18 MET 98 A HE2 5.03 6.17436E-05 
  
  
XXX 1 X H18 ASP 54 A HB2 5.13 5.48651E-05 
  
 
methyl XXX 1 X H18 LEU 107 A HD21 5.3 4.51175E-05 
  
 
methyl XXX 1 X H18 MET 98 A HE1 5.55 3.4217E-05 
  
  
XXX 1 X H18 PHE 138 A HB2 5.61 3.20791E-05 
  
  
XXX 1 X H18 ALA 55 A H 5.63 3.14014E-05 
  
  
XXX 1 X H18 MET 98 A HG3 5.8 2.62683E-05 
  
  
XXX 1 X H18 MET 98 A HG2 5.81 2.59982E-05 
  
  
XXX 1 X H18 ASP 54 A HB3 5.9 2.37076E-05 
  
  
XXX 1 X H18 ASN 51 A H 5.9 2.37076E-05 
  
 
methyl XXX 1 X H18 ALA 55 A HB3 5.94 2.27657E-05 
  exch methyl XXX 1 X H18 LYS 58 A HZ3 5.95 2.25371E-05 
  
  
XXX 1 X H18 SER 52 A HA 5.97 2.20879E-05 
  
  
XXX 1 X H18 SER 52 A H 5.98 2.18672E-05 
  
  
XXX 1 X H18 ASN 106 A HB3 5.99 2.16491E-05 
  





















exch XXX 1 X H19 ASN 51 A HD21 3.78 0.000342807 
  
  
XXX 1 X H19 PHE 138 A HB2 3.93 0.000271422 
  
 
methyl XXX 1 X H19 LEU 107 A HD21 4.08 0.00021679 4.566666667 0.000110256 
  
XXX 1 X H19 ASN 51 A HB3 4.12 0.000204464 
  
 
exch XXX 1 X H19 ASN 51 A HD22 4.17 0.000190188 
  
 
methyl XXX 1 X H19 LEU 107 A HD23 4.56 0.000111227 
  
  
XXX 1 X H19 ASN 106 A HB3 4.68 9.51754E-05 
  
  
XXX 1 X H19 PHE 138 A HB3 4.81 8.07476E-05 
  
 
methyl XXX 1 X H19 LEU 107 A HD22 5.06 5.95795E-05 
  
  
XXX 1 X H19 ASN 51 A HB2 5.17 5.23669E-05 
  
  
XXX 1 X H19 PHE 138 A H 5.26 4.72156E-05 
  
  
XXX 1 X H19 ASN 51 A HA 5.39 4.07819E-05 
  
  
XXX 1 X H19 ASN 106 A HB2 5.53 3.49663E-05 
  
  
XXX 1 X H19 PHE 138 A HD1 5.66 3.0416E-05 
  
  
XXX 1 X H19 PHE 138 A HA 5.88 2.41956E-05 
  




















  methyl XXX 1 X H20 LEU 107 A HD21 2.35 0.005937352 2.743333333 0.002346003 
 
XXX 1 X H20 PHE 138 A HB2 2.44 0.00473872 
  methyl XXX 1 X H20 LEU 107 A HD22 2.85 0.001866082 
  methyl XXX 1 X H20 LEU 107 A HD23 3.03 0.001292243 
  
 
XXX 1 X H20 PHE 138 A HB3 3.08 0.001171374 
  
 
XXX 1 X H20 PHE 138 A HD1 3.91 0.000279859 
  
 
XXX 1 X H20 PHE 138 A HD2 3.95 0.00026328 
  exch XXX 1 X H20 ASN 51 A HD21 4.1 0.000210522 
  exch XXX 1 X H20 ASN 51 A HD22 4.27 0.000164981 
  methyl XXX 1 X H20 LEU 107 A HD11 4.49 0.000122046 4.986666667 6.50336E-05 
 
XXX 1 X H20 PHE 138 A H 4.55 0.000112702 
  
 
XXX 1 X H20 LEU 107 A HA 4.6 0.000105549 
  
 
XXX 1 X H20 LEU 107 A HG 4.66 9.76528E-05 
  
 
XXX 1 X H20 PHE 138 A HA 4.68 9.51754E-05 
  methyl XXX 1 X H20 LEU 107 A HD13 4.74 8.81718E-05 
  
 
XXX 1 X H20 ASN 106 A HB3 5.12 5.55112E-05 
  
 
XXX 1 X H20 PHE 138 A HE1 5.24 4.83072E-05 
  
 
XXX 1 X H20 PHE 138 A HE2 5.29 4.56316E-05 
  
 
XXX 1 X H20 ASN 51 A HB3 5.37 4.17018E-05 
  methyl XXX 1 X H20 MET 98 A HE1 5.38 4.12388E-05 
  
 
XXX 1 X H20 LEU 107 A HB3 5.49 3.6523E-05 
  
 
XXX 1 X H20 ASN 106 A HB2 5.67 3.00955E-05 
  methyl XXX 1 X H20 LEU 107 A HD12 5.73 2.82535E-05 
  
 
XXX 1 X H20 TYR 139 A HE2 5.8 2.62683E-05 
  
 
XXX 1 X H20 PHE 138 A HZ 5.82 2.57313E-05 
  exch XXX 1 X H20 TYR 139 A HH 5.89 2.39501E-05 
  
 
XXX 1 X H20 ASN 51 A HB2 5.96 2.23112E-05 
  



















methyl XXX 1 X H21 LEU 107 A HD21 2.38 0.005502224 3.086666667 0.001156276 
methyl XXX 1 X H21 LEU 107 A HD11 2.86 0.001827275 3.526666667 0.000519773 
 
XXX 1 X H21 PHE 138 A HD1 2.98 0.001427915 
  
methyl XXX 1 X H21 LEU 107 A HD22 3.02 0.00131813 
  
 
XXX 1 X H21 PHE 138 A HE1 3.34 0.000720313 
  
methyl XXX 1 X H21 LEU 107 A HD13 3.38 0.000670656 
  
 
XXX 1 X H21 PHE 138 A HB2 3.54 0.000508137 
  
methyl XXX 1 X H21 VAL 150 A HG21 3.71 0.000383492 4.49 0.000122046 
methyl XXX 1 X H21 LEU 107 A HD23 3.86 0.000302326 
  
methyl XXX 1 X H21 MET 98 A HE1 3.92 0.000275603 4.743333333 8.78007E-05 
 
XXX 1 X H21 PHE 138 A HZ 4.21 0.0001796 
  
methyl XXX 1 X H21 VAL 150 A HG11 4.24 0.00017211 5.036666667 6.12549E-05 
 
XXX 1 X H21 LEU 107 A HG 4.25 0.000169694 
  
methyl XXX 1 X H21 LEU 107 A HD12 4.34 0.000149645 
  
 
XXX 1 X H21 PHE 138 A HB3 4.42 0.000134112 
  
 
XXX 1 X H21 PHE 138 A HD2 4.44 0.000130528 
  
methyl XXX 1 X H21 VAL 186 A HG22 4.59 0.000106936 4.97 6.63532E-05 
methyl XXX 1 X H21 VAL 150 A HG22 4.59 0.000106936 
  
exch XXX 1 X H21 ASN 51 A HD22 4.6 0.000105549 
  
methyl XXX 1 X H21 VAL 186 A HG21 4.69 9.39643E-05 
  
 
XXX 1 X H21 PHE 138 A HE2 4.7 9.27711E-05 
  
methyl XXX 1 X H21 MET 98 A HE2 4.83 7.87621E-05 
  
methyl XXX 1 X H21 VAL 150 A HG13 5.06 5.95795E-05 
  
 
XXX 1 X H21 PHE 138 A HA 5.12 5.55112E-05 
  
 
XXX 1 X H21 LEU 107 A HB3 5.12 5.55112E-05 
  
methyl XXX 1 X H21 VAL 150 A HG23 5.17 5.23669E-05 
  
exch XXX 1 X H21 ASN 51 A HD21 5.18 5.17632E-05 
  
methyl XXX 1 X H21 THR 184 A HG21 5.3 4.51175E-05 
  
methyl XXX 1 X H21 LEU 48 A HD22 5.38 4.12388E-05 5.66 3.0416E-05 
 
XXX 1 X H21 LEU 107 A HA 5.38 4.12388E-05 
  
methyl XXX 1 X H21 MET 98 A HE3 5.48 3.69247E-05 
  
 
XXX 1 X H21 ASN 51 A HB3 5.57 3.34864E-05 
  
methyl XXX 1 X H21 VAL 186 A HG13 5.62 3.17382E-05 
  
methyl XXX 1 X H21 VAL 186 A HG23 5.63 3.14014E-05 
  
 
XXX 1 X H21 VAL 150 A HB 5.64 3.10689E-05 
  
methyl XXX 1 X H21 LEU 48 A HD23 5.67 3.00955E-05 
  
methyl XXX 1 X H21 VAL 186 A HG11 5.68 2.9779E-05 
  
methyl XXX 1 X H21 VAL 150 A HG12 5.81 2.59982E-05 
  
 
XXX 1 X H21 LEU 107 A HB2 5.82 2.57313E-05 
  
methyl XXX 1 X H21 LEU 103 A HD23 5.84 2.52071E-05 
  
methyl XXX 1 X H21 LEU 48 A HD21 5.93 2.2997E-05 
  
 
XXX 1 X H21 ASN 51 A HB2 5.94 2.27657E-05 
  



















methyl XXX 1 X H22 THR 184 A HG21 2.93 0.001580499 3.71 0.000383492 
methyl XXX 1 X H22 MET 98 A HE1 3.08 0.001171374 3.533333333 0.000513916 
methyl XXX 1 X H22 MET 98 A HE2 3.23 0.000880613 
  
methyl XXX 1 X H22 VAL 186 A HG22 3.42 0.000624947 3.623333333 0.000441927 
methyl XXX 1 X H22 VAL 150 A HG11 3.46 0.000582832 4.01 0.00024051 
methyl XXX 1 X H22 VAL 186 A HG21 3.53 0.000516835 
  
methyl XXX 1 X H22 VAL 150 A HG13 3.82 0.000321825 
  
methyl XXX 1 X H22 LEU 107 A HD11 3.86 0.000302326 4.763333333 8.56119E-05 
methyl XXX 1 X H22 VAL 186 A HG23 3.92 0.000275603 
  
methyl XXX 1 X H22 THR 184 A HG22 4 0.000244141 
  
methyl XXX 1 X H22 LEU 107 A HD21 4.13 0.000201511 5.033333333 6.14987E-05 
methyl XXX 1 X H22 THR 184 A HG23 4.2 0.000182181 
  
methyl XXX 1 X H22 VAL 150 A HG21 4.2 0.000182181 4.786666667 8.31383E-05 
methyl XXX 1 X H22 MET 98 A HE3 4.29 0.000160419 
  
 
XXX 1 X H22 PHE 138 A HD1 4.36 0.000145573 
  
 
XXX 1 X H22 PHE 138 A HE1 4.5 0.000120427 
  
methyl XXX 1 X H22 VAL 150 A HG22 4.52 0.000117265 
  
 
XXX 1 X H22 ASN 51 A HB3 4.62 0.000102837 
  
exch XXX 1 X H22 THR 184 A HG1 4.63 0.000101511 
  
methyl XXX 1 X H22 VAL 150 A HG12 4.75 8.70639E-05 
  
exch XXX 1 X H22 ASN 51 A HD22 4.8 8.17622E-05 
  
 
XXX 1 X H22 THR 184 A HB 4.88 7.40425E-05 
  
methyl XXX 1 X H22 LEU 107 A HD13 5.04 6.10122E-05 
  
 
XXX 1 X H22 ASN 51 A HB2 5.1 5.68302E-05 
  
methyl XXX 1 X H22 LEU 107 A HD22 5.27 4.66806E-05 
  
 
XXX 1 X H22 PHE 138 A HB2 5.34 4.31273E-05 
  
methyl XXX 1 X H22 LEU 107 A HD12 5.39 4.07819E-05 
  
 
XXX 1 X H22 LEU 107 A HG 5.4 4.03309E-05 
  
methyl XXX 1 X H22 LEU 48 A HD22 5.45 3.81611E-05 
  
methyl XXX 1 X H22 VAL 186 A HG13 5.47 3.73316E-05 
  
methyl XXX 1 X H22 VAL 186 A HG11 5.5 3.61263E-05 
  
 
XXX 1 X H22 VAL 150 A HB 5.58 3.3128E-05 
  
 
XXX 1 X H22 MET 98 A HG3 5.59 3.2774E-05 
  
methyl XXX 1 X H22 VAL 150 A HG23 5.64 3.10689E-05 
  
methyl XXX 1 X H22 LEU 107 A HD23 5.7 2.91575E-05 
  
 
XXX 1 X H22 VAL 186 A HB 5.8 2.62683E-05 
  
 
XXX 1 X H22 VAL 186 A HA 5.83 2.54676E-05 
  
exch XXX 1 X H22 ASN 51 A HD21 5.85 2.49497E-05 
  
 
XXX 1 X H22 PHE 138 A HZ 5.93 2.2997E-05 
  
methyl XXX 1 X H22 LEU 103 A HD23 5.96 2.23112E-05 
  




















XXX 1 X H13 PHE 138 A HB2 2.37 0.005642998 
  
 
XXX 1 X H13 PHE 138 A HD1 2.78 0.002166363 
  
exch XXX 1 X H13 ASN 51 A HD22 2.78 0.002166363 
  
exch XXX 1 X H13 ASN 51 A HD21 3.41 0.000636024 
  
 
XXX 1 X H13 PHE 138 A HB3 3.69 0.000396134 
  
meth XXX 1 X H13 LEU 107 A HD22 3.72 0.000377348 4.46 0.000127055 
 
XXX 1 X H13 ASN 51 A HB3 3.74 0.000365402 
  
 
XXX 1 X H13 LEU 107 A HB3 3.84 0.000311898 
  
 
XXX 1 X H13 PHE 138 A HA 4.12 0.000204464 
  
 
XXX 1 X H13 LEU 107 A HB2 4.12 0.000204464 
  
meth XXX 1 X H13 LEU 107 A HD23 4.42 0.000134112 
  
 
XXX 1 X H13 ASN 51 A HB2 4.47 0.000125359 
  
 
XXX 1 X H13 PHE 138 A HE1 4.5 0.000120427 
  
meth XXX 1 X H13 MET 98 A HE1 4.67 9.64048E-05 
  
 
XXX 1 X H13 PHE 138 A H 4.7 9.27711E-05 
  
meth XXX 1 X H13 LEU 48 A HD23 4.72 9.04374E-05 4.983333333 6.52951E-05 
meth XXX 1 X H13 VAL 186 A HG21 4.78 8.38364E-05 5.273333333 4.65038E-05 
meth XXX 1 X H13 THR 109 A HG21 4.85 7.68333E-05 4.963333333 6.68897E-05 
meth XXX 1 X H13 THR 109 A HG23 4.86 7.58896E-05 
  
meth XXX 1 X H13 LEU 48 A HD22 4.87 7.49594E-05 
  
 
XXX 1 X H13 PHE 138 A HD2 4.93 6.96496E-05 
  
meth XXX 1 X H13 LEU 107 A HD13 5.14 5.42277E-05 
  
meth XXX 1 X H13 THR 109 A HG22 5.18 5.17632E-05 
  
meth XXX 1 X H13 LEU 107 A HD21 5.24 4.83072E-05 
  
meth XXX 1 X H13 VAL 186 A HG22 5.25 4.77578E-05 
  
meth XXX 1 X H13 LEU 48 A HD21 5.36 4.21707E-05 
  
meth XXX 1 X H13 THR 184 A HG21 5.41 3.98856E-05 
  
meth XXX 1 X H13 VAL 150 A HG21 5.57 3.34864E-05 
  
 
XXX 1 X H13 LEU 48 A HA 5.59 3.2774E-05 
  
meth XXX 1 X H13 VAL 150 A HG11 5.71 2.88525E-05 
  
meth XXX 1 X H13 VAL 186 A HG23 5.79 2.65417E-05 
  
 
XXX 1 X H13 PHE 138 A HZ 5.86 2.46953E-05 
  
 
XXX 1 X H13 ASN 51 A HA 5.9 2.37076E-05 
  
 
XXX 1 X H13 LEU 107 A HG 5.92 2.32311E-05 
  
meth XXX 1 X H13 MET 98 A HE3 5.96 2.23112E-05 
  
   
SUM 0.009989653 
   
















XXX 1 X H14 LEU 107 A HB3 2.72 0.002469372 
  
 
XXX 1 X H14 LEU 107 A HB2 3.44 0.000603461 
  
meth XXX 1 X H14 MET 98 A HE1 3.61 0.000451811 4.413333333 0.000135332 
meth XXX 1 X H14 THR 109 A HG23 3.91 0.000279859 4.33 0.00015173 
meth XXX 1 X H14 LEU 107 A HD22 4.21 0.0001796 4.646666667 9.93461E-05 
meth XXX 1 X H14 LEU 107 A HD23 4.23 0.000174565 
  
 
XXX 1 X H14 PHE 138 A HB2 4.38 0.00014163 
  
meth XXX 1 X H14 THR 109 A HG22 4.42 0.000134112 
  
 
XXX 1 X H14 ASN 51 A HB3 4.49 0.000122046 
  
 
XXX 1 X H14 LEU 107 A HA 4.51 0.000118834 
  
meth XXX 1 X H14 THR 109 A HG21 4.66 9.76528E-05 
  
 
XXX 1 X H14 GLY 108 A HA3 4.72 9.04374E-05 
  
exch XXX 1 X H14 ASN 51 A HD22 4.77 8.48965E-05 
  
meth XXX 1 X H14 MET 98 A HE2 4.79 8.27917E-05 
  
meth XXX 1 X H14 MET 98 A HE3 4.84 7.77907E-05 
  
 
XXX 1 X H14 MET 98 A HG3 4.85 7.68333E-05 
  
 
XXX 1 X H14 MET 98 A HG2 4.96 6.71599E-05 
  
 
XXX 1 X H14 PHE 138 A HD1 5.09 5.75034E-05 
  
meth XXX 1 X H14 THR 184 A HG21 5.2 5.05801E-05 
  
exch XXX 1 X H14 ASN 51 A HD21 5.22 4.94284E-05 
  
 
XXX 1 X H14 LEU 107 A HG 5.25 4.77578E-05 
  
 
XXX 1 X H14 PHE 138 A HB3 5.31 4.46101E-05 
  
meth XXX 1 X H14 LEU 107 A HD13 5.42 3.94461E-05 
  
meth XXX 1 X H14 LEU 107 A HD21 5.5 3.61263E-05 
  
 
XXX 1 X H14 GLY 108 A H 5.57 3.34864E-05 
  
 
XXX 1 X H14 THR 109 A H 5.61 3.20791E-05 
  
meth XXX 1 X H14 VAL 150 A HG11 5.63 3.14014E-05 
  
exch XXX 1 X H14 THR 184 A HG1 5.76 2.7382E-05 
  
 
XXX 1 X H14 ASN 51 A HB2 5.77 2.70985E-05 
  
   
SUM 0.004318717 
   
















XXX 1 X H15 MET 98 A HG3 2.79 0.00212019 
  
 
XXX 1 X H15 MET 98 A HG2 2.93 0.001580499 
  
meth XXX 1 X H15 MET 98 A HE1 3.5 0.000543991 3.956666667 0.000260629 
meth XXX 1 X H15 MET 98 A HE2 3.81 0.000326927 
  
 
XXX 1 X H15 GLY 108 A HA3 3.87 0.000297669 
  
 
XXX 1 X H15 LEU 107 A HB3 4.11 0.000207467 
  
exch XXX 1 X H15 THR 184 A HG1 4.49 0.000122046 
  
meth XXX 1 X H15 MET 98 A HE3 4.56 0.000111227 
  
meth XXX 1 X H15 ALA 55 A HB2 4.71 9.15956E-05 
  
 
XXX 1 X H15 LEU 107 A HA 4.84 7.77907E-05 
  
 
XXX 1 X H15 MET 98 A HB2 4.87 7.49594E-05 
  
meth XXX 1 X H15 LYS 58 A HZ2 4.94 6.88079E-05 5.533333333 3.48401E-05 
 
XXX 1 X H15 MET 98 A HB3 4.95 6.79781E-05 
  
meth XXX 1 X H15 THR 184 A HG21 5.07 5.88779E-05 
  
 
XXX 1 X H15 ASP 102 A HB3 5.17 5.23669E-05 
  
 
XXX 1 X H15 MET 98 A HA 5.19 5.11677E-05 
  
 
XXX 1 X H15 LEU 107 A HB2 5.2 5.05801E-05 
  
 
XXX 1 X H15 GLY 108 A HA2 5.37 4.17018E-05 
  
meth XXX 1 X H15 THR 109 A HG23 5.4 4.03309E-05 
  
 
XXX 1 X H15 GLY 108 A H 5.47 3.73316E-05 
  
 
XXX 1 X H15 ASN 51 A HB3 5.52 3.53481E-05 
  
meth XXX 1 X H15 LEU 107 A HD23 5.53 3.49663E-05 
  
meth XXX 1 X H15 ALA 55 A HB1 5.58 3.3128E-05 
  
meth XXX 1 X H15 ILE 96 A HG23 5.71 2.88525E-05 
  
meth XXX 1 X H15 THR 109 A HG22 5.78 2.68184E-05 
  
meth XXX 1 X H15 LYS 58 A HZ1 5.79 2.65417E-05 
  
 
XXX 1 X H15 GLY 97 A HA2 5.82 2.57313E-05 
  
exch XXX 1 X H15 THR 152 A HG1 5.85 2.49497E-05 
  
meth XXX 1 X H15 LYS 58 A HZ3 5.87 2.4444E-05 
  





   















XXX 1 X H16 MET 98 A HG3 2.4 0.005232781 
  
 
XXX 1 X H16 MET 98 A HG2 3.2 0.000931323 
  
meth XXX 1 X H16 ALA 55 A HB2 3.38 0.000670656 3.873333333 0.000296136 
exch XXX 1 X H16 THR 184 A HG1 3.48 0.000563021 
  
meth XXX 1 X H16 ILE 96 A HG23 3.52 0.000525707 3.916666667 0.000277013 
meth XXX 1 X H16 ALA 55 A HB1 3.64 0.000429924 
  
 
XXX 1 X H16 GLY 97 A H 3.71 0.000383492 
  
meth XXX 1 X H16 ILE 96 A HG22 3.76 0.000353894 
  
 
XXX 1 X H16 GLY 97 A HA2 3.85 0.000307069 
  
meth XXX 1 X H16 MET 98 A HE2 3.97 0.000255421 4.586666667 0.000107403 
 
XXX 1 X H16 MET 98 A HA 4.29 0.000160419 
  
meth XXX 1 X H16 MET 98 A HE1 4.45 0.000128777 
  
meth XXX 1 X H16 ILE 96 A HG21 4.47 0.000125359 
  
meth XXX 1 X H16 ALA 55 A HB3 4.6 0.000105549 
  
meth XXX 1 X H16 LYS 58 A HZ2 4.65 9.89196E-05 5.4 4.03309E-05 
 
XXX 1 X H16 MET 98 A HB2 4.7 9.27711E-05 
  
 
XXX 1 X H16 MET 98 A H 4.74 8.81718E-05 
  
 
XXX 1 X H16 ALA 55 A HA 4.76 8.59722E-05 
  
exch XXX 1 X H16 THR 152 A HG1 4.83 7.87621E-05 
  
 
XXX 1 X H16 GLY 97 A HA3 4.93 6.96496E-05 
  
meth XXX 1 X H16 THR 184 A HG21 5.09 5.75034E-05 
  
 
XXX 1 X H16 MET 98 A HB3 5.1 5.68302E-05 
  
 
XXX 1 X H16 ILE 96 A H 5.11 5.61661E-05 
  
 
XXX 1 X H16 THR 184 A HB 5.12 5.55112E-05 
  
 
XXX 1 X H16 LYS 58 A HD2 5.17 5.23669E-05 
  
meth XXX 1 X H16 MET 98 A HE3 5.34 4.31273E-05 
  
 
XXX 1 X H16 GLY 108 A HA3 5.47 3.73316E-05 
  
 
XXX 1 X H16 HIS 154 A HD2 5.54 3.45893E-05 
  
meth XXX 1 X H16 LYS 58 A HZ3 5.61 3.20791E-05 
  
 
XXX 1 X H16 ALA 55 A H 5.78 2.68184E-05 
  
 
XXX 1 X H16 GLY 95 A HA3 5.86 2.46953E-05 
  
 
XXX 1 X H16 ASP 102 A HB3 5.92 2.32311E-05 
  
 
XXX 1 X H16 ILE 96 A HB 5.94 2.27657E-05 
  
meth XXX 1 X H16 LYS 58 A HZ1 5.94 2.27657E-05 
  
   
SUM 0.008462837 
   















XXX 1 X H17 THR 184 A HB 2.52 0.003904782 
  
 
XXX 1 X H17 SER 52 A HA 3.06 0.001218068 
  
meth XXX 1 X H17 ALA 55 A HB3 3.22 0.000897149 3.43 0.000614095 
exch XXX 1 X H17 THR 184 A HG1 3.24 0.00086443 
  
meth XXX 1 X H17 THR 184 A HG21 3.31 0.000760382 3.966666667 0.000256712 
meth XXX 1 X H17 ALA 55 A HB2 3.32 0.000746744 
  
exch XXX 1 X H17 SER 52 A HG 3.48 0.000563021 
  
meth XXX 1 X H17 ALA 55 A HB1 3.75 0.000359594 
  
meth XXX 1 X H17 THR 184 A HG22 3.96 0.000259316 
  
 
XXX 1 X H17 ASN 51 A HB3 4.5 0.000120427 
  
meth XXX 1 X H17 THR 184 A HG23 4.63 0.000101511 
  
 
XXX 1 X H17 THR 184 A H 4.66 9.76528E-05 
  
 
XXX 1 X H17 SER 52 A H 4.83 7.87621E-05 
  
 
XXX 1 X H17 ASP 93 A HB3 4.85 7.68333E-05 
  
 
XXX 1 X H17 ALA 55 A H 4.85 7.68333E-05 
  
 
XXX 1 X H17 SER 52 A HB3 4.87 7.49594E-05 
  
 
XXX 1 X H17 GLY 95 A HA3 4.9 7.22476E-05 
  
meth XXX 1 X H17 MET 98 A HE1 4.95 6.79781E-05 
  
 
XXX 1 X H17 GLY 97 A H 4.99 6.47734E-05 
  
 
XXX 1 X H17 ASP 93 A HB2 5.15 5.3599E-05 
  
meth XXX 1 X H17 MET 98 A HE2 5.16 5.29788E-05 
  
 
XXX 1 X H17 GLY 95 A H 5.17 5.23669E-05 
  
 
XXX 1 X H17 GLY 97 A HA2 5.18 5.17632E-05 
  
meth XXX 1 X H17 VAL 186 A HG23 5.18 5.17632E-05 
  
 
XXX 1 X H17 ASN 51 A HB2 5.23 4.88641E-05 
  
 
XXX 1 X H17 THR 184 A HA 5.33 4.36151E-05 
  
 
XXX 1 X H17 ASP 93 A H 5.44 3.85839E-05 
  
 
XXX 1 X H17 SER 52 A HB2 5.48 3.69247E-05 
  
 
XXX 1 X H17 MET 98 A HG3 5.51 3.57347E-05 
  
exch XXX 1 X H17 THR 152 A HG1 5.55 3.4217E-05 
  
 
XXX 1 X H17 ALA 55 A HA 5.59 3.2774E-05 
  
 
XXX 1 X H17 GLY 183 A HA2 5.69 2.94664E-05 
  
meth XXX 1 X H17 VAL 186 A HG21 5.7 2.91575E-05 
  
 
XXX 1 X H17 LEU 56 A H 5.92 2.32311E-05 
  
 
XXX 1 X H17 ILE 96 A H 5.95 2.25371E-05 
  
meth XXX 1 X H17 ILE 96 A HG22 5.98 2.18672E-05 
  
   
SUM 0.007125605 
   

















XXX 1 X H18 ASN 51 A HB3 3.16 0.001004332 
  
exch XXX 1 X H18 SER 52 A HG 3.25 0.000848594 
  
 
XXX 1 X H18 ASN 51 A HB2 3.43 0.000614095 
  
meth XXX 1 X H18 THR 184 A HG21 3.46 0.000582832 4.083333333 0.00021573 
 
XXX 1 X H18 SER 52 A HA 3.62 0.000444374 
  
meth XXX 1 X H18 VAL 186 A HG21 3.62 0.000444374 3.913333333 0.000278432 
meth XXX 1 X H18 VAL 186 A HG23 3.67 0.000409264 
  
meth XXX 1 X H18 THR 184 A HG22 3.87 0.000297669 
  
 
XXX 1 X H18 THR 184 A HB 3.88 0.000293096 
  
 
XXX 1 X H18 SER 52 A H 3.88 0.000293096 
  
exch XXX 1 X H18 ASN 51 A HD22 4.28 0.000162681 
  
meth XXX 1 X H18 VAL 186 A HG22 4.45 0.000128777 
  
exch XXX 1 X H18 THR 184 A HG1 4.8 8.17622E-05 
  
meth XXX 1 X H18 LEU 48 A HD22 4.91 7.13692E-05 
  
meth XXX 1 X H18 THR 184 A HG23 4.92 7.05033E-05 
  
 
XXX 1 X H18 LEU 48 A HA 4.97 6.63532E-05 
  
meth XXX 1 X H18 MET 98 A HE1 5.04 6.10122E-05 
  
 
XXX 1 X H18 SER 52 A HB2 5.05 6.02909E-05 
  
 
XXX 1 X H18 SER 52 A HB3 5.09 5.75034E-05 
  
meth XXX 1 X H18 ALA 55 A HB2 5.13 5.48651E-05 
  
meth XXX 1 X H18 ALA 55 A HB3 5.17 5.23669E-05 
  
 
XXX 1 X H18 LEU 48 A HB3 5.19 5.11677E-05 
  
 
XXX 1 X H18 PHE 138 A HD1 5.27 4.66806E-05 
  
 
XXX 1 X H18 ILE 91 A HG22 5.27 4.66806E-05 
  
 
XXX 1 X H18 ASN 51 A HA 5.29 4.56316E-05 
  
 
XXX 1 X H18 VAL 186 A HB 5.36 4.21707E-05 
  
meth XXX 1 X H18 LEU 48 A HD23 5.44 3.85839E-05 
  
 
XXX 1 X H18 ILE 91 A HG21 5.45 3.81611E-05 
  
 
XXX 1 X H18 ASP 93 A HB3 5.54 3.45893E-05 
  
 
XXX 1 X H18 ASN 51 A H 5.58 3.3128E-05 
  
exch XXX 1 X H18 ASN 51 A HD21 5.69 2.94664E-05 
  
meth XXX 1 X H18 VAL 150 A HG13 5.82 2.57313E-05 
  
 
XXX 1 X H18 ILE 91 A HB 5.83 2.54676E-05 
  
 
XXX 1 X H18 VAL 186 A H 5.85 2.49497E-05 
  
meth XXX 1 X H18 MET 98 A HE2 5.91 2.34679E-05 
  
meth XXX 1 X H18 VAL 186 A HG11 5.99 2.16491E-05 
  
   
SUM 0.003715929 
   


















meth XXX 1 X H16 THR 184 A HG21 2.95 3.65 0.001517288 0.000422905 
  


















































































































































































































































meth XXX 1 X H17 LEU 107 A HD11 4.34 5.15 0.000149645 5.3599E-05 
  





meth XXX 1 X H17 MET 98 A HE2 4.56 5 0.000111227 0.000064 
 












































































































































meth XXX 1 X H18 LEU 107 A HD11 3.37 4.06 0.000682685 0.000223277 
exch 
 































meth XXX 1 X H18 LEU 107 A HD21 4.56 5.316666667 0.000111227 4.42755E-05 
 










































































































meth XXX 1 X H19 LEU 107 A HD21 2.95 3.65 0.001517288 0.000422905 
  





meth XXX 1 X H19 LEU 107 A HD11 3.25 3.95 0.000848594 0.00026328 
  















































meth XXX 1 X H19 VAL 150 A HG21 4.51 5.33 0.000118834 4.36151E-05 
 


























































































meth XXX 1 X H20 VAL 150 A HG21 2.58 3.283333333 0.003390641 0.000798197 
 
meth XXX 1 X H20 LEU 107 A HD21 2.64 3.453333333 0.002953768 0.000589616 
  










meth XXX 1 X H20 VAL 150 A HG11 3.15 3.856666667 0.001023615 0.000303898 
 










meth XXX 1 X H20 VAL 186 A HG22 3.72 4.183333333 0.000377348 0.00018658 
 















meth XXX 1 X H20 MET 98 A HE1 3.97 4.86 0.000255421 7.58896E-05 
 















meth XXX 1 X H20 LEU 107 A HD11 4.15 4.963333333 0.000195754 6.68897E-05 
  















meth XXX 1 X H20 VAL 186 A HG13 4.61 5.123333333 0.000104182 5.52948E-05 
 















meth XXX 1 X H20 LEU 48 A HD22 4.77 5.253333333 8.48965E-05 4.75763E-05 
 
meth XXX 1 X H20 THR 184 A HG21 4.79 5.31 8.27917E-05 4.46101E-05 
 














































































































































meth XXX 1 X H21 THR 184 A HG21 2.55 3.26 0.003637131 0.000833095 
 
meth XXX 1 X H21 VAL 186 A HG22 3.05 3.283333333 0.001242227 0.000798197 
 
meth XXX 1 X H21 VAL 150 A HG13 3.06 3.453333333 0.001218068 0.000589616 
 





meth XXX 1 X H21 MET 98 A HE1 3.13 3.716666667 0.001063491 0.000379383 
 

























meth XXX 1 X H21 VAL 150 A HG22 4.01 4.45 0.00024051 0.000128777 
 





meth XXX 1 X H21 LEU 107 A HD21 4.16 5.046666667 0.000192948 6.05302E-05 
 








































































































































































XXX 1 X H20 ASN 51 A HB3 3.01 
 
0.001344625 
  methyl XXX 1 X H20 THR 184 A HG21 3.23 3.86 0.000302326 0.000906979 0.000302326 
 
XXX 1 X H20 ASN 51 A HB2 3.48 
 
0.000563021 
  methyl XXX 1 X H20 THR 184 A HG22 3.66 
    methyl XXX 1 X H20 VAL 186 A HG21 3.71 3.896666667 0.000285654 0.000856962 0.000285654 
methyl XXX 1 X H20 VAL 186 A HG23 3.71 















XXX 1 X H20 SER 52 A H 4.17 
 
0.000190188 
  exch XXX 1 X H20 ASN 51 A HD22 4.27 
 
0.000164981 
  methyl XXX 1 X H20 VAL 186 A HG22 4.27 
 
0.000164981 
  exch XXX 1 X H20 THR 184 A HG1 4.68 
 
9.51754E-05 
  methyl XXX 1 X H20 THR 184 A HG23 4.69 
 
9.39643E-05 










XXX 1 X H20 LEU 48 A HB3 5.21 
 
5.00004E-05 





XXX 1 X H20 ASN 51 A HA 5.27 
 
4.66806E-05 
  methyl XXX 1 X H20 VAL 150 A HG13 5.33 
 
4.36151E-05 
  methyl XXX 1 X H20 ALA 55 A HB2 5.35 
 
4.26459E-05 




















XXX 1 X H20 VAL 186 A HB 5.59 
 
3.2774E-05 
  exch XXX 1 X H20 ASN 51 A HD21 5.59 
 
3.2774E-05 





XXX 1 X H20 SER 52 A HB2 5.61 
 
3.20791E-05 





XXX 1 X H20 VAL 186 A H 5.91 
 
2.34679E-05 
  methyl XXX 1 X H20 LEU 48 A HD23 5.91 
 
2.34679E-05 








   






















methyl XXX 1 X H19 ALA 55 A HB2 3.32 4.21 0.0001796 0.000538801 0.0001796 
 




methyl XXX 1 X H19 MET 98 A HE2 4.13 5.003333333 6.37446E-05 0.000191234 6.37446E-05 
 


















methyl XXX 1 X H19 ILE 96 A HG22 4.69 4.966666667 6.66208E-05 0.000199862 6.66208E-05 

















































methyl XXX 1 X H19 






















































   





















methyl XXX 1 X H18 MET 98 A HE2 2.45 3.303333333 0.000769636 0.002308909 0.000769636 
 

























methyl XXX 1 X H18 ALA 55 A HB2 4.52 5.26 4.72156E-05 0.000141647 4.72156E-05 
methyl XXX 1 X H18 LEU 107 A HD21 4.61 5.303333333 4.49476E-05 0.000134843 4.49476E-05 
 






























































































   





























methyl XXX 1 X H17 ILE 96 A HG23 3 3.46 0.000582832 0.001748496 0.000582832 























methyl XXX 1 X H17 ALA 55 A HB2 4.03 4.573333333 0.000109296 0.000327887 0.000109296 
methyl XXX 1 X H17 MET 98 A HE2 4.06 4.833333333 7.84367E-05 0.00023531 7.84367E-05 
















































































































   















  methyl XXX 1 X H16 ALA 55 A HB2 2.31 2.833333333 0.00193292 0.005798761 0.00193292 
methyl XXX 1 X H16 ALA 55 A HB1 2.58 
 
0.003390641 
  methyl XXX 1 X H16 ILE 96 A HG22 2.62 3.063333333 0.001210137 0.00363041 0.001210137 










XXX 1 X H16 ALA 55 A HA 3.48 
 
0.000563021 
  methyl XXX 1 X H16 ALA 55 A HB3 3.61 
 
0.000451811 










XXX 1 X H16 ILE 96 A H 3.97 
 
0.000255421 




















XXX 1 X H16 ALA 55 A H 4.65 
 
9.89196E-05 



































XXX 1 X H16 MET 98 A HA 5.37 
 
4.17018E-05 










XXX 1 X H16 MET 98 A H 5.58 
 
3.3128E-05 















XXX 1 X H16 ILE 96 A HA 5.63 
 
3.14014E-05 
  methyl XXX 1 X H16 LYS 58 A HZ3 5.65 
 
3.07404E-05 





























   







































methyl XXX 1 X H15 MET 98 A HE2 3.28 4.113333333 0.00020646 0.000619381 0.00020646 
 




methyl XXX 1 X H15 ILE 96 A HG23 3.67 4.14 0.000198609 0.000595826 0.000198609 
methyl XXX 1 X H15 ALA 55 A HB2 3.7 4.073333333 0.000218927 0.000656782 0.000218927 































methyl XXX 1 X H15 THR 184 A HG21 4.35 5.033333333 6.14987E-05 0.000184496 6.14987E-05 
 
























































































   
















  methyl XXX 1 X H21 THR 184 A HG21 2.88 3.58 0.000475009 0.001425027 0.000475009 
methyl XXX 1 X H21 MET 98 A HE1 3.37 3.773333333 0.000346457 0.00103937 0.000346457 
methyl XXX 1 X H21 VAL 150 A HG11 3.44 3.97 0.000255421 0.000766264 0.000255421 
methyl XXX 1 X H21 VAL 186 A HG22 3.44 3.66 0.000416019 0.001248058 0.000416019 
methyl XXX 1 X H21 MET 98 A HE2 3.49 
 
0.000553411 
  methyl XXX 1 X H21 VAL 186 A HG21 3.6 
 
0.000459394 
  methyl XXX 1 X H21 VAL 150 A HG13 3.75 
 
0.000359594 
  methyl XXX 1 X H21 THR 184 A HG22 3.76 
 
0.000353894 
  methyl XXX 1 X H21 LEU 107 A HD11 3.89 4.706666667 9.19855E-05 0.000275956 9.19855E-05 
methyl XXX 1 X H21 VAL 186 A HG23 3.94 
 
0.000267315 
  methyl XXX 1 X H21 THR 184 A HG23 4.1 
 
0.000210522 
  methyl XXX 1 X H21 LEU 107 A HD21 4.13 4.943333333 6.853E-05 0.00020559 6.853E-05 
methyl XXX 1 X H21 VAL 150 A HG21 4.14 4.713333333 9.12076E-05 0.000273623 9.12076E-05 
 





XXX 1 X H21 ASN 51 A HB3 4.37 
 
0.000143586 
  exch XXX 1 X H21 ASN 51 A HD22 4.43 
 
0.000132305 
  methyl XXX 1 X H21 VAL 150 A HG22 4.43 
 
0.000132305 





XXX 1 X H21 PHE 138 A HE1 4.53 
 
0.000115721 
  methyl XXX 1 X H21 VAL 150 A HG12 4.72 
 
9.04374E-05 
  exch XXX 1 X H21 THR 184 A HG1 4.74 
 
8.81718E-05 










XXX 1 X H21 ASN 51 A HB2 5.01 
 
6.32373E-05 





XXX 1 X H21 PHE 138 A HB2 5.21 
 
5.00004E-05 
  methyl XXX 1 X H21 LEU 48 A HD22 5.26 
 
4.72156E-05 
  methyl XXX 1 X H21 LEU 107 A HD12 5.41 
 
3.98856E-05 
  methyl XXX 1 X H21 VAL 186 A HG13 5.49 
 
3.6523E-05 
  exch XXX 1 X H21 ASN 51 A HD21 5.49 
 
3.6523E-05 





XXX 1 X H21 VAL 150 A HB 5.54 
 
3.45893E-05 






































   




















  methyl XXX 1 X H22 LEU 107 A HD11 2.7 3.18 0.000967024 0.002901072 0.000967024 





XXX 1 X H22 PHE 138 A HD1 2.93 
 
0.001580499 
  methyl XXX 1 X H22 LEU 107 A HD21 3.12 3.616666667 0.000446837 0.001340511 0.000446837 
 
XXX 1 X H22 PHE 138 A HE1 3.22 
 
0.000897149 
  methyl XXX 1 X H22 LEU 107 A HD22 3.27 
 
0.000817925 
  methyl XXX 1 X H22 VAL 150 A HG21 3.38 4.19 0.000184806 0.000554418 0.000184806 
 
XXX 1 X H22 PHE 138 A HB2 3.61 
 
0.000451811 
  methyl XXX 1 X H22 VAL 150 A HG11 3.93 4.733333333 8.89196E-05 0.000266759 8.89196E-05 
methyl XXX 1 X H22 MET 98 A HE1 3.98 4.77 8.48965E-05 0.000254689 8.48965E-05 





XXX 1 X H22 PHE 138 A HZ 4.16 
 
0.000192948 
  methyl XXX 1 X H22 VAL 150 A HG22 4.32 
 
0.00015385 
  exch XXX 1 X H22 ASN 51 A HD22 4.37 
 
0.000143586 
  methyl XXX 1 X H22 VAL 186 A HG22 4.4 4.81 8.07476E-05 0.000242243 8.07476E-05 










XXX 1 X H22 PHE 138 A HB3 4.5 
 
0.000120427 










XXX 1 X H22 PHE 138 A HE2 4.69 
 
9.39643E-05 
  methyl XXX 1 X H22 VAL 150 A HG13 4.76 
 
8.59722E-05 
  methyl XXX 1 X H22 MET 98 A HE2 4.85 
 
7.68333E-05 
  methyl XXX 1 X H22 VAL 150 A HG23 4.87 
 
7.49594E-05 





XXX 1 X H22 LEU 107 A HB3 5.04 
 
6.10122E-05 





XXX 1 X H22 PHE 138 A HA 5.13 
 
5.48651E-05 
  methyl XXX 1 X H22 LEU 48 A HD22 5.14 5.603333333 3.23088E-05 9.69265E-05 3.23088E-05 
 
XXX 1 X H22 VAL 150 A HB 5.3 
 
4.51175E-05 





XXX 1 X H22 LEU 107 A HA 5.46 
 
3.77437E-05 
  methyl XXX 1 X H22 VAL 186 A HG23 5.46 
 
3.77437E-05 
  methyl XXX 1 X H22 MET 98 A HE3 5.48 
 
3.69247E-05 





XXX 1 X H22 ASN 51 A HB3 5.53 
 
3.49663E-05 
  methyl XXX 1 X H22 VAL 186 A HG11 5.54 
 
3.45893E-05 
  methyl XXX 1 X H22 LEU 48 A HD23 5.76 
 
2.7382E-05 
  methyl XXX 1 X H22 VAL 148 A HG11 5.84 
 
2.52071E-05 





XXX 1 X H22 LEU 107 A HB2 5.89 
 
2.39501E-05 
  methyl XXX 1 X H22 LEU 48 A HD21 5.91 
 
2.34679E-05 














   






















methyl XXX 1 X H23 LEU 107 A HD22 2.25 2.93 0.001580499 0.004741498 0.001580499 
 

















methyl XXX 1 X H23 LEU 107 A HD13 3.69 4.263333333 0.000166535 0.000499604 0.000166535 
 




















































































































   































XXX 1 X H24 LEU 107 A HD22 3.75 3.98 0.000251595 0.000754784 0.000251595 





































































































   
























































methyl XXX 1 X H25 LEU 107 A HD21 4.77 5.23 4.88641E-05 0.000146592 4.88641E-05 























































   
































XXX 1 X 
H25 THR 74 A HG21 3.97 4.913333333 0.000255421 7.10792E-05 
exch 
XXX 1 X 
H25 THR 74 A HG1 4.07 
   
 
XXX 1 X 





XXX 1 X 





XXX 1 X 





XXX 1 X 





























exch XXX 1 X H26 THR 74 A HG1 2.33 
   
 














meth XXX 1 X H26 LEU 56 A HD22 3.87 4.676666667 0.000297669 9.55832E-05 
 



















meth XXX 1 X H26 THR 74 A HG21 4.65 5.16 9.89196E-05 5.29788E-05 
 




meth XXX 1 X H26 VAL 7 A HG22 4.81 5.326666667 8.07476E-05 4.37791E-05 
































































































meth XXX 1 X H27 VAL 7 A HG22 2.63 3.15 0.003021799 0.001023615 
 















XXX 1 X H27 GLY 75 A HA3 3.38 
 
0.000670656 
 meth XXX 1 X H27 VAL 7 A HG21 3.39 
 
0.000658873 















XXX 1 X H27 LYS 5 A HB3 3.73 
 
0.000371319 
 meth XXX 1 X H27 LEU 56 A HD22 3.76 4.306666667 0.000353894 0.00015673 
 





XXX 1 X H27 LEU 56 A HB3 3.9 
 
0.000284192 
 exch XXX 1 X H27 THR 74 A HG1 3.94 





XXX 1 X H27 LYS 5 A HG2 4.77 
 
8.48965E-05 




















XXX 1 X H27 TYR 71 A HD1 5.01 
 
6.32373E-05 










XXX 1 X H27 LYS 5 A HB2 5.16 
 
5.29788E-05 



































XXX 1 X H27 LEU 6 A H 5.51 
 
3.57347E-05 
















































 meth XXX 1 X H28 VAL 7 A HG22 2.76 3.446666667 0.002262276 0.000596492 
 










XXX 1 X H28 LEU 56 A HB3 3.03 
 
0.001292243 






























XXX 1 X H28 LYS 5 A HA 4.05 
 
0.000226605 
 meth XXX 1 X H28 VAL 7 A HG21 4.16 
 
0.000192948 
 meth XXX 1 X H28 LEU 56 A HD22 4.35 4.84 7.77907E-05 7.77907E-05 
 





XXX 1 X H28 LYS 5 A HG3 4.48 
 
0.000123689 




















XXX 1 X H28 VAL 7 A H 4.77 
 
8.48965E-05 
 meth XXX 1 X H28 VAL 7 A HG13 4.79 5.473333333 8.27917E-05 3.71953E-05 
 



































XXX 1 X H28 LEU 56 A HG 5.32 
 
4.41093E-05 















XXX 1 X H28 ILE 55 A H 5.59 
 
3.2774E-05 
 meth XXX 1 X H28 VAL 7 A HG11 5.64 
 
3.10689E-05 





XXX 1 X H28 SER 39 A HB2 5.68 
 
2.9779E-05 










XXX 1 X H28 LEU 6 A HB3 5.85 
 
2.49497E-05 
 exch XXX 1 X H28 THR 74 A HG1 5.9 
   meth XXX 1 X H28 LEU 56 A HD12 5.91 
 
2.34679E-05 





XXX 1 X H28 SER 39 A HB3 5.96 
 
2.23112E-05 












































































































XXX 1 X H29 TYR 40 A H 4.79 
 
8.27917E-05 
 meth XXX 1 X H29 LEU 56 A HD13 4.84 
 
7.77907E-05 
 meth XXX 1 X H29 LEU 56 A HD22 4.95 
 
6.79781E-05 










XXX 1 X H29 ASP 54 A HB2 5.07 
 
5.88779E-05 
 exch XXX 1 X H29 SER 39 A HG 5.25 
   
 
XXX 1 X H29 VAL 7 A HA 5.34 
 
4.31273E-05 










XXX 1 X H29 ILE 55 A HB 5.49 
 
3.6523E-05 
 meth XXX 1 X H29 LEU 56 A HD23 5.6 
 
3.24244E-05 





XXX 1 X H29 LEU 6 A HB2 5.62 
 
3.17382E-05 





XXX 1 X H29 LEU 56 A HG 5.73 
 
2.82535E-05 


















































meth XXX 1 X H19 LEU 56 A HD11 2.99 3.423333333 0.0013995 0.000621305 














meth XXX 1 X H19 LEU 56 A HD21 3.77 4.27 0.000348299 0.000164981 
 





















































































































meth XXX 1 X H20 LEU 56 A HD22 3 3.713333333 0.001371742 0.000381431 
 




meth XXX 1 X H20 LEU 56 A HD13 3.41 4.113333333 0.000636024 0.00020646 
 

















































meth XXX 1 X H20 THR 74 A HG21 5.14 5.283333333 5.42277E-05 4.59782E-05 































































































meth XXX 1 X H21 LEU 56 A HD13 4.04 4.9 0.000229992 7.22476E-05 
  



















































































































meth XXX 1 X H22 LEU 56 A HD13 3.78 4.34 0.000342807 0.000149645 
  






















































     
SUM 0.004333954 0.003908725 
 





















meth XXX 1 X H23 THR 74 A HG23 2.05 2.733333333 0.013473389 0.002397974 
  




















meth XXX 1 X H23 LEU 56 A HD22 3.31 4.093333333 0.000760382 0.000212587 
  




















meth XXX 1 X H23 VAL 7 A HG22 4.36 4.79 0.000145573 8.27917E-05 
  









































































































































meth XXX 1 X H24 VAL 7 A HG22 2.42 2.746666667 0.004978607 0.002328972 
 




















meth XXX 1 X H24 THR 74 A HG23 3.13 4.06 0.001063491 0.000223277 
  










meth XXX 1 X H24 LEU 56 A HD22 3.84 4.326666667 0.000311898 0.000152433 
  













































meth XXX 1 X H24 VAL 7 A HG13 4.62 5.063333333 0.000102837 5.93446E-05 
exch 
 

































































XXX 1 X H24 TYR 71 A HB2 5.56 
 
3.38494E-05 










































































meth XXX 1 X H25 VAL 7 A HG22 2.56 3.073333333 0.003552714 0.001186703 
  






































































































































































































































































































meth XXX 1 X H26 VAL 7 A HG22 4.53 5.203333333 0.000115721 5.0386E-05 
  




















































































































































exch XXX 1 X H20 SER 39 A HG 2.76 
   
 






















meth XXX 1 X H20 LEU 56 A HD12 4.68 
   
meth XXX 1 X H20 LEU 56 A HD11 4.86 
   
 


































exch XXX 1 X H21 SER 39 A HG 2.63 
   
 



























meth XXX 1 X H21 LEU 56 A HD12 5.28 
   
 




meth XXX 1 X H21 LEU 56 A HD22 5.46 
   
meth XXX 1 X H21 LEU 56 A HD11 5.49 
   
meth XXX 1 X H21 LYS 5 A HZ1 5.82 
   
 

































































meth XXX 1 X H22 LEU 56 A HD21 3.62 
   
 




meth XXX 1 X H22 LEU 56 A HD11 3.9 
   
 









meth XXX 1 X H22 LEU 56 A HD23 4.43 
   
 




exch XXX 1 X H22 TYR 71 A HH 4.74 
   
 




meth XXX 1 X H22 LEU 56 A HD12 4.81 
   
 



















exch XXX 1 X H22 THR 74 A HG1 5.83 
   





































































meth XXX 1 X H23 LEU 56 A HD11 2.95 3.416666667 
 
0.000628614 
meth XXX 1 X H23 LEU 56 A HD13 3.16 
   
 












exch XXX 1 X H23 TYR 71 A HH 3.86 
   
meth XXX 1 X H23 LEU 56 A HD22 3.9 
   
meth XXX 1 X H23 LEU 56 A HD12 4.14 
   
 
























meth XXX 1 X H23 LEU 56 A HD23 5.11 
   
 















































































exch XXX 1 X H24 THR 74 A HG1 3.8 
   
 









meth XXX 1 X H24 LEU 56 A HD23 4.31 
   
 

























meth XXX 1 X H24 LEU 56 A HD21 4.77 
   
 




meth XXX 1 X H24 LEU 56 A HD13 4.92 
   
 














meth XXX 1 X H24 VAL 7 A HG21 5.14 
   
 




meth XXX 1 X H24 THR 74 A HG22 5.17 
   
 




meth XXX 1 X H24 THR 74 A HG23 5.31 
   
 





























meth XXX 1 X H24 VAL 7 A HG23 5.73 
   
meth XXX 1 X H24 LEU 56 A HD11 5.98 
   













































































XXX 1 X H25 GLY 75 A HA3 3.02 
 
0.00131813 
 meth XXX 1 X H25 VAL 7 A HG21 3.07 
   
 
XXX 1 X H25 GLY 75 A H 3.08 
 
0.001171374 
 meth XXX 1 X H25 VAL 7 A HG23 3.44 
   
 





XXX 1 X H25 THR 74 A HB 3.79 
 
0.000337415 




XXX 1 X H25 TYR 71 A HB3 3.95 
 
0.00026328 
 meth XXX 1 X H25 LEU 56 A HD23 3.97 
   
 

























XXX 1 X H25 LYS 5 A HG3 4.44 
 
0.000130528 
 meth XXX 1 X H25 VAL 7 A HG13 4.62 5.096666667 
 
5.70535E-05 
meth XXX 1 X H25 VAL 7 A HG11 4.8 
   
 










XXX 1 X H25 GLU 76 A H 5.02 
 
6.24853E-05 
 meth XXX 1 X H25 LEU 56 A HD21 5.12 
   
 
XXX 1 X H25 VAL 7 A HB 5.18 
 
5.17632E-05 
 exch XXX 1 X H25 THR 74 A HG1 5.2 
   
 



































XXX 1 X H25 LYS 5 A HE3 5.55 
 
3.4217E-05 
 meth XXX 1 X H25 LEU 56 A HD13 5.59 
   
 




















XXX 1 X H25 LEU 56 A HG 5.8 
 
2.62683E-05 
 meth XXX 1 X H25 VAL 7 A HG12 5.87 
   
 





XXX 1 X H25 MET 72 A HG2 5.97 
 
2.20879E-05 
 meth XXX 1 X H25 THR 74 A HG21 5.97 
   
 








































































 meth XXX 1 X H26 VAL 7 A HG22 2.43 3.096666667 
 
0.001134053 
meth XXX 1 X H26 VAL 7 A HG23 3.12 
   
 



































XXX 1 X H26 LEU 6 A H 3.53 
 
0.000516835 
 meth XXX 1 X H26 VAL 7 A HG21 3.74 
   
 




















XXX 1 X H26 ILE 55 A HA 4.41 
 
0.000135947 









XXX 1 X H26 VAL 7 A H 4.69 
 
9.39643E-05 
 meth XXX 1 X H26 LEU 56 A HD23 4.7 


































XXX 1 X H26 THR 74 A HB 5.38 
 
4.12388E-05 
 meth XXX 1 X H26 VAL 7 A HG11 5.38 
   
 





XXX 1 X H26 LYS 5 A HE2 5.55 
 
3.4217E-05 
 meth XXX 1 X H26 LEU 56 A HD13 5.59 
   
 



































XXX 1 X H26 GLU 76 A HG3 5.86 
 
2.46953E-05 
 meth XXX 1 X H26 VAL 7 A HG12 5.89 
   meth XXX 1 X H26 LEU 56 A HD21 5.94 
   































































































XXX 1 X H27 LYS 5 A HB3 4.46 
 
0.000127055 









XXX 1 X H27 LYS 5 A HE2 4.92 
 
7.05033E-05 




XXX 1 X H27 LYS 5 A HD2 4.96 
 
6.71599E-05 
 meth XXX 1 X H27 LEU 56 A HD22 4.97 
   
 

























XXX 1 X H27 LYS 5 A HB2 5.28 
 
4.61526E-05 
 meth XXX 1 X H27 VAL 7 A HG23 5.37 
   exch XXX 1 X H27 SER 39 A HG 5.38 
   
 





XXX 1 X H27 TYR 40 A H 5.48 
 
3.69247E-05 
 meth XXX 1 X H27 LEU 56 A HD12 5.53 
   
 
XXX 1 X H27 LYS 5 A HD3 5.55 
 
3.4217E-05 
 meth XXX 1 X H27 LEU 56 A HD23 5.6 
   
 
XXX 1 X H27 LEU 6 A HA 5.67 
 
3.00955E-05 
 meth XXX 1 X H27 LYS 5 A HZ2 5.77 
   
 





XXX 1 X H27 ILE 55 A HB 5.96 
 
2.23112E-05 
 meth XXX 1 X H27 VAL 7 A HG21 5.97 
   meth XXX 1 X H27 LYS 5 A HZ1 5.97 
   
 




























































































meth XXX 1 X H27 LEU 56 A HD22 5.71 
 
2.88525E-05 





XXX 1 X H27 ARG 41 A HD2 5.93 
 
2.2997E-05 




























































































































































meth XXX 1 X H29 LEU 56 A HD23 3.12 3.886666667 0.001084108 0.000290092 
 
meth XXX 1 X H29 LEU 56 A HD12 3.35 4.1 0.000707508 0.000210522 
  











































































XXX 1 X H29 TYR 71 A H 5.64 
 
3.10689E-05 
























































meth XXX 1 X H32 THR 74 A HG21 3.23 3.646666667 0.000880613 0.00042523 
 








































meth XXX 1 X H32 VAL 7 A HG22 4.37 4.83 0.000143586 7.87621E-05 
exch 
 
XXX 1 X H32 THR 74 A HG1 4.4 
 
0.000137811 
 exch meth XXX 1 X H32 LYS 5 A HZ2 4.42 5.266666667 0.000134112 4.68581E-05 
 
















































































XXX 1 X H32 TYR 71 A HD2 5.6 
 
3.24244E-05 
 exch meth XXX 1 X H32 LYS 5 A HZ3 5.63 
 
3.14014E-05 











































 meth XXX 1 X H33 VAL 7 A HG22 2.3 2.713333333 0.006755119 0.002506 





XXX 1 X H33 GLY 75 A HA2 2.85 
 
0.001866082 










XXX 1 X H33 GLY 75 A HA3 3.05 
 
0.001242227 
 meth XXX 1 X H33 LEU 56 A HD12 3.63 4.136666667 0.000437079 0.000199571 
 















XXX 1 X H33 LEU 56 A HB2 3.79 
 
0.000337415 
 meth XXX 1 X H33 LEU 56 A HD13 3.81 
 
0.000326927 
 meth XXX 1 X H33 THR 74 A HG22 3.84 4.616666667 0.000311898 0.000103283 
 










XXX 1 X H33 MET 72 A HA 4.48 
 
0.000123689 
 meth XXX 1 X H33 VAL 7 A HG13 4.49 4.976666667 0.000122046 6.58216E-05 
 
XXX 1 X H33 TYR 71 A HA 4.54 
 
0.0001142 
 meth XXX 1 X H33 THR 74 A HG21 4.66 
 
9.76528E-05 

























XXX 1 X H33 THR 74 A H 4.96 
 
6.71599E-05 















XXX 1 X H33 LYS 5 A HD3 5.2 
 
5.05801E-05 

























XXX 1 X H33 VAL 7 A H 5.49 
 
3.6523E-05 
 meth XXX 1 X H33 LEU 56 A HD23 5.5 
 
3.61263E-05 















XXX 1 X H33 LYS 5 A HG3 5.67 
 
3.00955E-05 














































meth XXX 1 X H34 VAL 7 A HG22 2.58 3.153333333 0.003390641 0.00101714 
  





















































































meth XXX 1 X H34 LEU 56 A HD12 4.63 5.096666667 0.000101511 5.70535E-05 
 










meth XXX 1 X H34 VAL 7 A HG13 4.79 5.41 8.27917E-05 3.98856E-05 
 













































meth XXX 1 X H34 VAL 7 A HG11 5.51 
 
3.57347E-05 






































































XXX 1 X H34 LEU 6 A HG 5.94 
 
2.27657E-05 



























































































XXX 1 X H35 LEU 56 A HA 4.31 
 
0.000156004 
 exch meth XXX 1 X H35 LYS 5 A HZ3 4.37 4.786666667 0.000143586 8.31383E-05 




































































































XXX 1 X H35 TYR 40 A H 5.53 
 
3.49663E-05 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 meth XXX 1 X H26 VAL 7 B HG22 2.75 3.106666667 
 
0.001112326 



































XXX 1 X H26 LEU 56 B HB3 3.53 
 
0.000516835 








































XXX 1 X H26 GLU 76 B H 4.59 
 
0.000106936 





XXX 1 X H26 VAL 7 B H 4.63 
 
0.000101511 
 meth XXX 1 X H26 LEU 56 B HD22 4.73 5.16 
 
5.29788E-05 






























XXX 1 X H26 LEU 56 B HA 5.11 
 
5.61661E-05 















XXX 1 X H26 LYS 5 B H 5.58 
 
3.3128E-05 
 meth XXX 1 X H26 THR 74 B HG21 5.59 
 
3.2774E-05 





XXX 1 X H26 GLY 77 B H 5.64 
 
3.10689E-05 




















XXX 1 X H26 SER 39 B HB3 5.82 
 
2.57313E-05 










































































































































































































































XXX 1 X H27 TYR 40 B H 5.4 
 
4.03309E-05 
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